<SEC-DOCUMENT>0001193125-25-292015.txt : 20251124
<SEC-HEADER>0001193125-25-292015.hdr.sgml : 20251124
<ACCEPTANCE-DATETIME>20251124072448
ACCESSION NUMBER:		0001193125-25-292015
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20251124
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251124
DATE AS OF CHANGE:		20251124

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Centessa Pharmaceuticals plc
		CENTRAL INDEX KEY:			0001847903
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40445
		FILM NUMBER:		251509573

	BUSINESS ADDRESS:	
		STREET 1:		3RD FLOOR
		STREET 2:		1 ASHLEY ROAD
		CITY:			ALTRINCHAM, CHESHIRE
		STATE:			X0
		ZIP:			WA14 2DT
		BUSINESS PHONE:		44 7391 789784

	MAIL ADDRESS:	
		STREET 1:		3RD FLOOR
		STREET 2:		1 ASHLEY ROAD
		CITY:			ALTRINCHAM, CHESHIRE
		STATE:			X0
		ZIP:			WA14 2DT

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Centessa Pharmaceuticals Ltd
		DATE OF NAME CHANGE:	20210224
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d23843d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cnta="http://www.cnta.com/20251124" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_SecurityExchangeName_duration_2025-11-24_to_2025-11-24_us-gaap-StatementClassOfStockAxis_us-gaap-FairValueMeasuredAtNetAssetValuePerShareMember" name="dei:SecurityExchangeName" contextRef="duration_2025-11-24_to_2025-11-24_us-gaap-StatementClassOfStockAxis_us-gaap-FairValueMeasuredAtNetAssetValuePerShareMember">NASDAQ</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_SecurityExchangeName_duration_2025-11-24_to_2025-11-24_us-gaap-StatementClassOfStockAxis_dei-AdrMember" name="dei:SecurityExchangeName" contextRef="duration_2025-11-24_to_2025-11-24_us-gaap-StatementClassOfStockAxis_dei-AdrMember">NASDAQ</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-275">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-11-24_to_2025-11-24">0001847903</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="cnta-20251124.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-11-24_to_2025-11-24"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847903</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-11-24</xbrli:startDate> <xbrli:endDate>2025-11-24</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2025-11-24_to_2025-11-24_us-gaap-StatementClassOfStockAxis_us-gaap-FairValueMeasuredAtNetAssetValuePerShareMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847903</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-11-24</xbrli:startDate> <xbrli:endDate>2025-11-24</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2025-11-24_to_2025-11-24_us-gaap-StatementClassOfStockAxis_dei-AdrMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847903</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-11-24</xbrli:startDate> <xbrli:endDate>2025-11-24</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-302">8-K</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">PURSUANT TO SECTION 13 OR 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">OF THE SECURITIES EXCHANGE ACT OF 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-11-24_to_2025-11-24" format="ixt:datemonthdayyearen" id="ixv-303">November 24, 2025</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-304">CENTESSA PHARMACEUTICALS PLC</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant, as specified in its charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-11-24_to_2025-11-24" format="ixt-sec:edgarprovcountryen" id="ixv-305">England and Wales</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-306">001-40445</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-307">98-1612294</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(State or other jurisdiction<br/>of incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Mailing address:</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-308">3rd Floor</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-309">1 Ashley Road</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine3" contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-310">Altrincham</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-311">Cheshire</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-312">WA14 2DT</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCountry" contextRef="duration_2025-11-24_to_2025-11-24" format="ixt-sec:countrynameen" id="ixv-313">United Kingdom</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices) (Zip code)</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: +1 (<ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-314">617</ix:nonNumeric>) <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-315">468-5770</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Former name or address, if changed since last report:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-11-24_to_2025-11-24" format="ixt-sec:boolballotbox" id="ixv-316">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-11-24_to_2025-11-24" format="ixt-sec:boolballotbox" id="ixv-317">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-11-24_to_2025-11-24" format="ixt-sec:boolballotbox" id="ixv-318">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-11-24_to_2025-11-24" format="ixt-sec:boolballotbox" id="ixv-319">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br/>on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-11-24_to_2025-11-24_us-gaap-StatementClassOfStockAxis_us-gaap-FairValueMeasuredAtNetAssetValuePerShareMember" id="ixv-320">Ordinary shares, nominal value &#163;0.002 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-11-24_to_2025-11-24_us-gaap-StatementClassOfStockAxis_us-gaap-FairValueMeasuredAtNetAssetValuePerShareMember" id="ixv-321">CNTA</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_SecurityExchangeName_duration_2025-11-24_to_2025-11-24_us-gaap-StatementClassOfStockAxis_us-gaap-FairValueMeasuredAtNetAssetValuePerShareMember"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-11-24_to_2025-11-24" format="ixt-sec:exchnameen" id="ixv-322">Nasdaq Stock Market, LLC</ix:nonNumeric></span> *</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-11-24_to_2025-11-24_us-gaap-StatementClassOfStockAxis_dei-AdrMember" id="ixv-323">American Depositary Shares, each representing one ordinary share, nominal value &#163;0.002 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-11-24_to_2025-11-24_us-gaap-StatementClassOfStockAxis_dei-AdrMember" id="ixv-324">CNTA</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_SecurityExchangeName_duration_2025-11-24_to_2025-11-24_us-gaap-StatementClassOfStockAxis_dei-AdrMember">Nasdaq Stock Market, LLC</span> </td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market, LLC.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-11-24_to_2025-11-24" format="ixt-sec:boolballotbox" id="ixv-325">&#9746;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2025-11-24_to_2025-11-24" format="ixt-sec:boolballotbox" id="ixv-326">&#9744;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;8.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November 24, 2025, Centessa Pharmaceuticals plc (the &#8220;Company&#8221;) entered into an Amended and Restated Sales Agreement (the &#8220;Sales Agreement&#8221;) with Leerink Partners LLC (&#8220;Leerink&#8221;), which amended and restated that certain Sales Agreement, dated as of January&#160;27, 2023, by and between the Company and Leerink (the &#8220;Original Sales Agreement&#8221;). Pursuant to the Sales Agreement, the Company may, from time to time in its sole discretion, issue and sell through Leerink, acting as the Company&#8217;s sales agent, in one or more &#8220;at the market offerings&#8221;, up to $250&#160;million of the Company&#8217;s American Depositary Shares (the &#8220;Placement Shares&#8221;), each representing one ordinary share of the Company, nominal value &#163;0.002 per share. The issuance and sale, if any, of the Placement Shares by the Company under the Sales Agreement will be made pursuant to a prospectus supplement to the Company&#8217;s registration statement on <span style="white-space:nowrap">Form&#160;S-3ASR,&#160;including</span> the prospectus contained therein, originally filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on September&#160;11, 2024 <span style="white-space:nowrap">(Registration&#160;No.&#160;333-282032),</span> which automatically became effective upon filing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Sales Agreement, Leerink may sell the Placement Shares by any method deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Leerink will use commercially reasonable efforts consistent with normal trading and sales practices to sell the Placement Shares from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the Company may impose). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will pay Leerink a commission of up to 3.0% of the gross proceeds from each sale of the Placement Shares sold under the Sales Agreement. In addition, the Company has agreed to reimburse Leerink for the reasonable fees and expenses of their legal counsel incurred in connection with entering into the transactions contemplated by the Sales Agreement in an amount not to exceed $150,000. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is not obligated to make any sales of Placement Shares under the Sales Agreement. No assurance can be given that the Company will sell any Placement Shares under the Sales Agreement, or, if it does, as to the price or amount of Placement Shares that it sells or the dates when such sales will take place. The offering of Placement Shares pursuant to the Sales Agreement will terminate upon the earlier to occur of (i)&#160;the issuance and sale of all Placement Shares subject to the Sales Agreement and (ii)&#160;termination of the Sales Agreement in accordance with its terms. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because there is no minimum offering amount required pursuant to the Sales Agreement, the total number of shares to be sold under the Sales Agreement, if any, and proceeds to the Company, if any, are not determinable at this time. The Company expects to use any net proceeds for working capital, capital expenditures and for general corporate purposes. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sales Agreement contains representations, warranties and covenants that are customary for transactions of this type. In addition, the Company has agreed to indemnify Leerink against certain liabilities, including liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the Sales Agreement is not complete and is qualified in its entirety by reference to the full text of the Sales Agreement, a copy of which is filed herewith as Exhibit 1.1 to this Current Report on <span style="white-space:nowrap">Form&#160;8-K&#160;and</span> is incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The legal opinion of Goodwin Procter (UK) LLP as to the validity of the issuance of the Placement Shares is being filed as Exhibit 5.1 to this Current Report on <span style="white-space:nowrap">Form&#160;8-K.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on <span style="white-space:nowrap">Form&#160;8-K&#160;shall</span> not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation or sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Description</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d23843dex11.htm">Amended and Restated Sales Agreement, dated November 24, 2025, by and between the Company and Leerink Partners LLC </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d23843dex51.htm">Opinion of Goodwin Procter (UK) LLP </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d23843dex51.htm">Consent of Goodwin Procter (UK) LLP (included in Exhibit&#160;5.1) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document and incorporated as Exhibit&#160;101)</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Date: November 24, 2025 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border-spacing:0">


<tr>

<td style="width:14%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:85%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">CENTESSA PHARMACEUTICALS PLC</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">By:</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Saurabh Saha</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">Name:</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Saurabh Saha, M.D., Ph.D.</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">Title:</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d23843dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Execution Version </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CENTESSA PHARMACEUTICALS PLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">$250,000,000 American Depositary Shares </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Representing </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">$250,000,000 Ordinary
Shares, Nominal Value &pound;0.002 Per Share </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>AMENDED AND RESTATED SALES AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">November&nbsp;24, 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LEERINK PARTNERS LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1301 Avenue of the Americas, 5<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10019 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is made to that certain Sales Agreement, entered into as of January&nbsp;27, 2023 (the &#8220;<B><U>Original Sales Agreemen</U></B>t&#8221;) by and
between Centessa Pharmaceuticals plc, a public limited company incorporated under the laws of England and Wales with registered number 12973576&nbsp;(the &#8220;<B><U>Company</U></B>&#8221;), and Leerink Partners LLC (the
&#8220;<B><U>Agent</U></B>&#8221;). The Company and the Agent now intend to enter into this Amended and Restated Sales Agreement (the &#8220;<B><U>Agreement</U></B>&#8221;) to amend and restate the terms of the Original Sales Agreement in its
entirety. Therefore, the Company confirms its agreement with the Agent as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Issuance and Sale of Securities</U>. The Company
agrees that, from time to time during the term of this Agreement, on the terms and subject to the conditions set forth herein, it may issue and sell through the Agent up to $250,000,000 of ordinary shares, nominal value &pound;0.002 per share (the
&#8220;<B><U>Ordinary Shares</U></B>&#8221;), of the Company to be delivered in the form of American Depositary Shares (the &#8220;<B><U>ADSs</U></B>&#8221;), each representing one Ordinary Share, subject to the limitations set forth in
Section&nbsp;5(c) (the &#8220;<B><U>Placement Shares</U></B>&#8221;). Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitation set forth in this Section&nbsp;1 on the aggregate gross
sales price of Placement Shares that may be issued and sold under this Agreement from time to time shall be the sole responsibility of the Company, and that the Agent shall have no obligation in connection with such compliance, and that such
limitation on the aggregate gross sales price excludes the gross sales price of the ADSs sold under the Original Sales Agreement. The issuance and sale of Placement Shares through the Agent will be effected pursuant to the Registration Statement (as
defined below) filed by the Company with the Securities and Exchange Commission (the &#8220;<B><U>Commission</U></B>&#8221;) on September&nbsp;11, 2024 and automatically declared effective by the Commission upon filing, although nothing in this
Agreement shall be construed as requiring the Company to issue any Placement Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has prepared and filed, in accordance
with the provisions of the Securities Act of 1933, as amended, and the rules and regulations thereunder (collectively, the &#8220;<B><U>Securities Act</U></B>&#8221;), with the Commission a registration statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-282032),</FONT> including a base prospectus, relating to certain securities, including the ADSs, to be issued from time to time by the Company, and which
incorporates by reference documents that the Company has filed or will file in accordance with the provisions of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (collectively, the &#8220;<B><U>Exchange
Act</U></B>&#8221;). The Company has prepared a prospectus supplement to the base prospectus included as part of such registration statement at the time the registration statement became effective, which prospectus supplement specifically relates to
the Placement Shares to be issued from time </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">to time pursuant to this Agreement (the &#8220;<B><U>Prospectus Supplement</U></B>&#8221;). The Company will
furnish to the Agent, for use by the Agent, copies of the base prospectus included as part of such registration statement at the time it became effective, as supplemented by the Prospectus Supplement. Except where the context otherwise requires,
such registration statement, including all documents filed as part thereof or incorporated by reference therein, and including any information contained in a Prospectus (as defined below) subsequently filed with the Commission pursuant to Rule
424(b) under the Securities Act or deemed to be a part of such registration statement pursuant to Rule 430B or Rule 462(b) under the Securities Act, is herein called the &#8220;<B><U>Registration Statement</U></B>.&#8221; The base prospectus,
including all documents incorporated therein by reference, included in the Registration Statement, as it may be supplemented by the Prospectus Supplement, in the form in which such prospectus and/or Prospectus Supplement have most recently been
filed by the Company with the Commission pursuant to Rule 424(b) under the Securities Act, together with any &#8220;issuer free writing prospectus&#8221; (as used herein, as defined in Rule 433 under the Securities Act (&#8220;<B><U>Rule
433</U></B>&#8221;)), relating to the Placement Shares that (i)&nbsp;is required to be filed with the Commission by the Company or (ii)&nbsp;is exempt from filing pursuant to Rule&nbsp;433(d)(5)(i), in each case, in the form filed or required to be
filed with the Commission or, if not required to be filed, in the form retained in the Company&#8217;s records pursuant to Rule 433(g), is herein called the &#8220;<B><U>Prospectus</U></B>.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A registration statement on Form <FONT STYLE="white-space:nowrap">F-6</FONT> (File No.&nbsp;333-256385), and any amendments thereto, in
respect of the ADSs has been filed with the Commission; such registration statement in the form heretofore delivered to the Agent and, excluding exhibits, to the Agent, has been declared effective by the Commission; no other document with respect to
such registration statement has heretofore been filed with the Commission; (the various parts of such registration statement, including all exhibits thereto, each as amended at the time such part of the registration statement became effective and
such additional registration statements on Form <FONT STYLE="white-space:nowrap">F-6</FONT> filed after the date hereof, being hereinafter called the &#8220;<B><U>ADS Registration Statement</U></B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any reference herein to the Registration Statement, the ADS Registration Statement, the Prospectus Supplement, the Prospectus or any issuer
free writing prospectus shall be deemed to refer to and include the documents, if any, that are or are deemed to be incorporated by reference therein (the &#8220;<B><U>Incorporated Documents</U></B>&#8221;), including, unless the context otherwise
requires, the documents, if any, filed as exhibits to such Incorporated Documents. Any reference herein to the terms &#8220;amend,&#8221; &#8220;amendment&#8221; or &#8220;supplement&#8221; with respect to the Registration Statement, the ADS
Registration Statement, the Prospectus Supplement, the Prospectus or any issuer free writing prospectus shall be deemed to refer to and include the filing of any document under the Exchange Act on or after the most-recent effective date of the
Registration Statement, the ADS Registration Statement or the respective dates of the Prospectus Supplement, Prospectus or such issuer free writing prospectus, as the case may be, and incorporated therein by reference. For purposes of this
Agreement, all references to the Registration Statement, the ADS Registration Statement, the Prospectus or any amendment or supplement thereto shall be deemed to include the most recent copy filed with the Commission pursuant to its Electronic Data
Gathering Analysis and Retrieval System or, if applicable, the Interactive Data Electronic Application system when used by the Commission (collectively, &#8220;<B><U>EDGAR</U></B>&#8221;). Unless the context otherwise requires, each reference to the
ADSs or the Placement Shares herein also includes the Ordinary Shares underlying the ADSs and Placement Shares (the &#8220;<B><U>Underlying Ordinary Shares</U></B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ADSs may be evidenced by American Depositary Receipts (&#8220;<B>ADRs</B>&#8221;) issued pursuant to a deposit agreement, dated as of
June&nbsp;2, 2021 (the &#8220;<B>Deposit Agreement</B>&#8221;), by and among the Company, Citibank, N.A., as depositary (the &#8220;<B>Depositary</B>&#8221;) and all holders and beneficial owners of the ADSs issued thereunder. The Company shall,
following the sale of Placement Shares through the Agent, deposit or procure the deposit of, on behalf of the Agent, the Underlying Ordinary Shares represented by such Placement Shares with Citibank, N.A. (London), acting as custodian for the
Depositary (the &#8220;<B>Custodian</B>&#8221;), pursuant to which the Depositary (or the Custodian acting on behalf of the Depositary) shall deliver the ADSs (or ADRs evidencing ADSs) to the Agent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">References in this Agreement to (i)&nbsp;the Company issuing and selling ADSs through the
Agent, and similar or analogous expressions, shall be understood to include references to the Company allotting and issuing the new Ordinary Shares underlying those ADSs to the Depositary or its nominee and procuring the issue of ADSs representing
such Ordinary Shares by the Depositary or its nominee to the Agent (acting as agent and/or (if applicable) as principal); and (ii)&nbsp;the purchase of, or payment for, any ADSs, and any similar or analogous expressions, shall be understood to refer
to the subscription for Ordinary Shares underlying those ADSs, as well as the deposit of the Ordinary Shares for ADSs representing such Ordinary Shares, and the payment of the subscription moneys in respect of such Ordinary Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Placements</U>. Each time that the Company wishes to issue and sell any Placement Shares through the Agent hereunder (each, a
&#8220;<B><U>Placement</U></B>&#8221;), it will notify the Agent by email notice (or other method mutually agreed to in writing by the parties) (each such notice, a &#8220;<B><U>Placement Notice</U></B>&#8221;) containing the parameters in
accordance with which it desires such Placement Shares to be sold, which at a minimum shall include the maximum number or dollar amount of Placement Shares to be sold, the time period during which sales are requested to be made, any limitation on
the number or amount of Placement Shares that may be sold in any one Trading Day (as defined in Section&nbsp;3), any minimum price below which sales may not be made and include any other limitations and conditions required by English law, a form of
which containing such minimum sales parameters is attached hereto as <B><U>Schedule 1</U></B>. The Placement Notice must originate from one of the individuals authorized to act on behalf of the Company and set forth on <B><U>Schedule 2</U></B> (with
a copy to each of the other individuals from the Company listed on such <B><U>Schedule 2</U></B>), and shall be addressed to each of the recipients from the Agent set forth on <B><U>Schedule 2</U></B>, as such <B><U>Schedule 2</U></B> may be updated
by either party from time to time by sending a written notice containing a revised <B><U>Schedule 2</U></B> to the other party in the manner provided in Section&nbsp;12 (including by email correspondence to each of the individuals of the Company set
forth on <B><U>Schedule 2</U></B>, if receipt of such correspondence is actually acknowledged by any of the individuals to whom the notice is sent, other than via auto-reply). The Placement Notice shall be effective upon receipt by the Agent unless
and until (i)&nbsp;in accordance with the notice requirements set forth in Section&nbsp;4, the Agent declines to accept the terms contained therein for any reason, in its sole discretion, within two Trading Days of the date the Agent receives the
Placement Notice, (ii)&nbsp;in accordance with the notice requirements set forth in Section&nbsp;4, the Agent suspends sales under the Placement Notice for any reason in its sole discretion, (iii)&nbsp;the entire amount of the Placement Shares has
been sold pursuant to this Agreement, (iv)&nbsp;in accordance with the notice requirements set forth in Section&nbsp;4, the Company suspends sales under or terminates the Placement Notice for any reason in its sole discretion, (v)&nbsp;the Company
issues a subsequent Placement Notice and explicitly indicates that its parameters supersede those contained in the earlier dated Placement Notice or (vi)&nbsp;this Agreement has been terminated pursuant to the provisions of Section&nbsp;11. The
amount of any discount, commission or other compensation to be paid by the Company to the Agent in connection with the sale of the Placement Shares effected through the Agent shall be calculated in accordance with the terms set forth in
<B><U>Schedule 3</U></B>. It is expressly acknowledged and agreed that neither the Company nor the Agent will have any obligation whatsoever with respect to a Placement or any Placement Shares unless and until the Company delivers a Placement Notice
to the Agent and the Agent does not decline such Placement Notice pursuant to the terms set forth above, and then only upon the terms specified therein and herein. In the event of a conflict between the terms of this Agreement and the terms of a
Placement Notice, the terms of the Placement Notice will control with respect to the matters covered thereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Sale of Placement Shares by the Agent</U>. On the basis of the representations and
warranties herein contained and subject to the terms and conditions herein set forth, including Section&nbsp;5(c), upon the Agent&#8217;s acceptance of the terms of a Placement Notice as provided in Section&nbsp;2, and unless the sale of the
Placement Shares described therein has been declined, suspended or otherwise terminated in accordance with the terms of this Agreement, the Agent, for the period specified in the Placement Notice, will use its commercially reasonable efforts
consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations, the laws and regulations of England and Wales and the rules of the Nasdaq Global Select Market (&#8220;<B><U>Nasdaq</U></B>&#8221;)
to sell such Placement Shares up to the number or amount specified in, and otherwise in accordance with the terms of, such Placement Notice. The Agent will provide written confirmation to the Company (including by email correspondence to each of the
individuals of the Company set forth on <B><U>Schedule 2</U></B>, if receipt of such correspondence is actually acknowledged by any of the individuals to whom the notice is sent, other than via auto-reply) no later than the opening of the Trading
Day (as defined below) immediately following the Trading Day on which it has made sales of Placement Shares hereunder setting forth the number or amount of Placement Shares sold on such Trading Day, the volume-weighted average price of the Placement
Shares sold and the Net Proceeds (as defined below) payable to the Company. Unless otherwise specified by the Company in a Placement Notice, the Agent may sell Placement Shares by any method permitted by law deemed to be an &#8220;at the market
offering&#8221; as defined in Rule 415(a)(4) of the Securities Act, including sales made directly on or through Nasdaq, on or through any other existing trading market for the ADSs. If expressly authorized by the Company (including in a Placement
Notice), the Agent may also sell Placement Shares in negotiated transactions. Notwithstanding the provisions of Section&nbsp;6(eee), except as may be otherwise agreed by the Company and the Agent, the Agent shall not purchase Placement Shares on a
principal basis pursuant to this Agreement unless the Company and the Agent enter into a separate written agreement setting forth the terms of such sale. The Company acknowledges and agrees that (i)&nbsp;there can be no assurance that the Agent will
be successful in selling Placement Shares, (ii)&nbsp;the Agent will incur no liability or obligation to the Company or any other person or entity if it does not sell Placement Shares for any reason other than a failure by the Agent to use its
commercially reasonable efforts consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of Nasdaq to sell such Placement Shares as required under this Agreement and
(iii)&nbsp;the Agent shall be under no obligation to purchase Placement Shares on a principal basis pursuant to this Agreement unless the Company and the Agent enter into a separate written agreement setting forth the terms of such sale. For the
purposes hereof, &#8220;<B><U>Trading Day</U></B>&#8221; means any day on which the ADSs are purchased and sold on Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.
<U>Suspension of Sales</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company or the Agent may, upon notice to the other party in writing (including by email
correspondence to each of the individuals of the other party set forth on <B><U>Schedule 2</U></B>, if receipt of such correspondence is actually acknowledged by any of the individuals to whom the notice is sent, other than via auto-reply) or by
telephone (confirmed immediately by email correspondence to each of the individuals of the other party set forth on <B><U>Schedule 2</U></B>), suspend any sale of Placement Shares; <I>provided</I>, <I>however</I>, that such suspension shall not
affect or impair either party&#8217;s obligations with respect to any Placement Shares sold hereunder prior to the receipt of such notice. Each of the parties agrees that no such notice under this Section&nbsp;4 shall be effective against the other
party unless notice is sent by one of the individuals named on <B><U>Schedule 2</U></B> hereto to the other party in writing (including by email correspondence to each of the individuals of the other party set forth on <B><U>Schedule 2</U></B>, if
receipt of such correspondence is actually acknowledged by any of the individuals to whom the notice is sent, other than via auto-reply). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding any other provision of this Agreement, during any period in which the Company is, or could reasonably be deemed to be, in
possession of material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company and the Agent agree that (i)&nbsp;no sale of Placement Shares will take place, (ii)&nbsp;the Company shall not request the sale of any Placement
Shares and shall suspend or cancel any effective Placement Notices instructing the Agent to make any sales and (iii)&nbsp;the Agent shall not be obligated to sell or offer to sell any Placement Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Settlement and Delivery of the Placement Shares</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Settlement of Placement Shares</U>. Unless otherwise specified in the applicable Placement Notice, settlement for sales of Placement
Shares will occur on the first Trading Day (or such earlier day as is industry practice or as is required for <FONT STYLE="white-space:nowrap">regular-way</FONT> trading) following the date on which such sales are made (each, a
&#8220;<B><U>Settlement Date</U></B>&#8221;). The amount of proceeds to be delivered to the Company on a Settlement Date against receipt of the Placement Shares sold (the &#8220;<B><U>Net Proceeds</U></B>&#8221;) will be equal to the aggregate gross
sales price received by the Agent at which such Placement Shares were sold, after deduction of (i)&nbsp;the Agent&#8217;s commission, discount or other compensation for such sales payable by the Company pursuant to Section&nbsp;2 hereof,
(ii)&nbsp;any other amounts due and payable by the Company to the Agent hereunder pursuant to Section&nbsp;7(g) hereof and (iii)&nbsp;any transaction fees imposed by any governmental or self-regulatory organization in respect of such sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Delivery of Placement Shares</U>. On or before each Settlement Date, the Company will issue the Underlying Ordinary Shares to be
represented by the Placement Shares being sold on such date and will, or will cause its transfer agent to, electronically transfer such Placement Shares against the prior deposit with the Custodian of the corresponding number of Underlying Ordinary
Shares necessary for the issue of the Placement Shares by crediting the Agent&#8217;s or its designee&#8217;s account (provided the Agent shall have given the Company written notice of such designee prior to the Settlement Date) at The Depository
Trust Company through its Deposit and Withdrawal at Custodian System (&#8220;<B><U>DWAC</U></B>&#8221;) or by such other means of delivery as may be mutually agreed upon by the parties hereto, which in all cases shall be duly authorized, freely
tradeable, transferable, registered Ordinary Shares and ADSs in good deliverable form. On each Settlement Date, upon receipt of the relevant Placement Shares, the Agent will deliver the related Net Proceeds in same day funds to an account designated
by the Company on or prior to the Settlement Date. The Agent shall be responsible for providing DWAC instructions or other instructions for delivery by other means with regard to the transfer of the Placement Shares being sold. In addition to and in
no way limiting the rights and obligations set forth in Section&nbsp;9(a) hereto, the Company agrees that if the Company or its transfer agent (if applicable), defaults in its obligation to deliver duly authorized, freely tradeable, transferable,
registered Placement Shares in good deliverable form by 2:30 P.M., New York City time, on a Settlement Date (other than as a result of a failure by the Agent to provide instructions for delivery), the Company will (i)&nbsp;take all necessary action
to cause the full amount of any Net Proceeds that were delivered to the Company&#8217;s account with respect to such settlement, together with any costs incurred by the Agent and/or its clearing firm in connection with recovering such Net Proceeds,
to be immediately returned to the Agent or its clearing firm no later than 5:00&nbsp;P.M., New York City time, on such Settlement Date, by wire transfer of immediately available funds to an account designated by the Agent or its clearing firm,
(ii)&nbsp;indemnify and hold the Agent and its clearing firm harmless against any loss, claim, damage, or expense (including reasonable and documented legal fees and expenses), as incurred, arising out of or in connection with such default by the
Company or its transfer agent (if applicable) and (iii)&nbsp;pay to the Agent (without duplication) any commission, discount or other compensation to which it would otherwise have been entitled absent such default. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Limitations on Offering Size</U>. Under no circumstances shall the Company cause or request the offer or sale of any Placement Shares
if, after giving effect to the sale of such Placement Shares, the aggregate number or gross sales proceeds of Placement Shares sold pursuant to this Agreement would exceed the lesser of: (i)&nbsp;the number or dollar amount of Ordinary Shares and
ADSs registered pursuant to, and available for offer and sale under, the Registration Statement and the ADS Registration Statement pursuant to which the offering of Placement Shares is being made, (ii)&nbsp;the number of Ordinary Shares representing
the pound sterling nominal amount of Ordinary Shares that the Company&#8217;s board of directors is authorized to allot on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">non-pre-emptive</FONT></FONT> basis from time to time, in
accordance with the Company&#8217;s articles of association and pursuant to a valid authority under section 551 of the U.K. Companies Act 2006 (the &#8220;<B><U>Companies Act</U></B>&#8221;) and a valid power under section 570 or 571 of the
Companies Act (less any Ordinary Shares issued or rights to subscribe for, or to convert any security into, Ordinary Shares granted pursuant to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such authorities), (iii) the number or dollar amount of Ordinary Shares and Underlying Ordinary Shares in the form of ADSs permitted to be offered and sold by the Company under Form <FONT
STYLE="white-space:nowrap">S-3</FONT> (including General Instruction I.B.6. thereof, if such instruction is applicable), or (iv)&nbsp;the number or dollar amount of Ordinary Shares and Underlying Ordinary Shares in the form of ADSs for which the
Company has filed the Prospectus Supplement. Under no circumstances shall the Company cause or request the offer or sale of any Placement Shares pursuant to this Agreement at a price lower than the minimum price (if any) authorized from time to time
by the Company&#8217;s board of directors or a duly authorized committee thereof, and notified to the Agent in writing. Notwithstanding anything to the contrary contained herein, the parties hereto acknowledge and agree that compliance with the
limitations set forth in this Section&nbsp;5(c) on the number or dollar amount of Placement Shares that may be issued and sold under this Agreement from time to time shall be the sole responsibility of the Company, and that the Agent shall have no
obligation in connection with such compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Representations and Warranties of the Company</U>. The Company represents and
warrants to, and agrees with, the Agent that as of the date of this Agreement, and as of (i)&nbsp;each Representation Date (as defined in Section&nbsp;7(m)), (ii) each date on which a Placement Notice is given, (iii)&nbsp;the date and time of each
sale of any Placement Shares pursuant to this Agreement and (iv)&nbsp;each Settlement Date (each such time or date referred to in clauses (i)&nbsp;through (iv), an &#8220;<B><U>Applicable Time</U></B>&#8221;): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company and the transactions contemplated by this Agreement meet the requirements for and comply with the conditions for the use of
Form <FONT STYLE="white-space:nowrap">S-3</FONT> (including General Instructions I.A and I.B.1.) under the Securities Act. The Registration Statement and the ADS Registration Statement have been filed or will be filed with the Commission and have
been or will be declared effective by the Commission under the Securities Act prior to the issuance of any Placement Notices by the Company. At the time the Registration Statement and the ADS Registration Statement were originally declared effective
and at the time the Company&#8217;s most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> was filed with the Commission, the Company met the then-applicable requirements for use of Form
<FONT STYLE="white-space:nowrap">S-3</FONT> (including General Instructions I.A and I.B.1.) under the Securities Act. The Registration Statement and the ADS Registration Statement meet, and the offering and sale of Placement Shares as contemplated
hereby comply with, the requirements of Rule 415(a)(1)(x) under the Securities Act. The Agent is named as the agent engaged by the Company in the section entitled &#8220;Plan of Distribution&#8221; in the Prospectus Supplement. The Company has not
received, and has no notice from the Commission of, any notice pursuant to Rule&nbsp;401(g)(1) under the Securities Act objecting to the use of the shelf registration statement form. No stop order of the Commission preventing or suspending the use
of the base prospectus, the Prospectus Supplement or the Prospectus, or the effectiveness of the Registration Statement or the ADS Registration Statement, has been issued, and no proceedings for such purpose are pending before or, to the knowledge
of the Company, threatened by the Commission. At the time of the initial filing of the Registration Statement, the Company deferred payment of the required Commission filing fees relating to the securities covered by the Registration Statement in
accordance with Rules&nbsp;456(b)&nbsp;and 457(r)&nbsp;under the Securities Act. At the time of the filing of the Prospectus Supplement, the Company has paid, or will pay, the required Commission filing fees related to the securities covered by the
Prospectus Supplement, including the Placement Shares that may be sold pursuant to this Agreement, in accordance with Rules 457(o) and 457(r) under the Securities Act. Copies of the Registration Statement, the ADS Registration Statement, the
Prospectus, any such amendments or supplements to any of the foregoing and all Incorporated Documents that were filed with the Commission on or prior to the date of this Agreement have been delivered, or are available through EDGAR, to the Agent and
its counsel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Each of the Registration Statement and the ADS Registration Statement and any post-effective amendment thereto, at the
time it became or becomes effective, at each deemed effective date with respect to the Agent pursuant to Rule&nbsp;430B(f)(2) under the Securities Act and as of each Applicable Time, complied, complies and will comply in all material respects with
the requirements of the Securities Act and did not, does not and will not contain any untrue statement of a material fact or omit to state a material fact </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
required to be stated therein or necessary to make the statements therein not misleading, except that the representations and warranties set forth in this sentence do not apply to Agent&#8217;s
Information (as defined below). The Prospectus and any amendment or supplement thereto, when so filed with the Commission under Rule 424(b) under the Securities Act, complied, complies and as of each Applicable Time will comply in all material
respects with the requirements of the Securities Act, and each Prospectus Supplement, Prospectus or issuer free writing prospectus (or any amendments or supplements to any of the foregoing) furnished to the Agent for use in connection with the
offering of the Placement Shares was identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation <FONT STYLE="white-space:nowrap">S-T.</FONT> Neither the
Prospectus nor any amendment or supplement thereto, as of its date and as of each Applicable Time, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order
to make the statements therein, in the light of the circumstances under which they were made, not misleading, except that the representations and warranties set forth in this sentence do not apply to Agent&#8217;s Information. Each Incorporated
Document heretofore filed, when it was filed (or, if any amendment with respect to any such document was filed, when such amendment was filed), conformed in all material respects with the requirements of the Exchange Act and were filed on a timely
basis with the Commission, and any further Incorporated Documents so filed and incorporated after the date of this Agreement will be filed on a timely basis and, when so filed, will conform in all material respects with the requirements of the
Exchange Act; no such Incorporated Document when it was filed (or, if an amendment with respect to any such document was filed, when such amendment was filed), contained an untrue statement of a material fact or omitted to state a material fact
required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; and no such Incorporated Document, when it is filed, will contain an untrue statement
of a material fact or will omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Each issuer free writing prospectus, as of its issue date and as of each Applicable Time, did not, does not and will not include any
information that conflicted, conflicts or will conflict in any material respect with the information contained in the Registration Statement or the Prospectus, including any Incorporated Document deemed to be a part thereof that has not been
superseded or modified. Each issuer free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433 or that was prepared by or on behalf of or used by the Company complies or will comply in all material respects with
the requirements of the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Company is not an &#8220;ineligible issuer&#8221; in connection with the offering
pursuant to Rules 164, 405 and 433 under the Securities Act. Any free writing prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the
requirements of the Securities Act and the applicable rules and regulations of the Commission thereunder. Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that was
prepared by or on behalf of or used or referred to by the Company complies, or will comply, as of the date of each filing, in all material respects with the applicable requirements of the Securities Act and the applicable rules and regulations of
the Commission thereunder. The Company has paid the registration fee for this offering pursuant to Rule 456(b)(1) under the Securities Act or will pay such fee within the time period required by such rule (without giving effect to the proviso
therein). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Company has been duly incorporated, is validly existing as a public limited company in good standing under the laws of
the jurisdiction of its incorporation, has the corporate power and authority to own or lease its property, to conduct its business as described in each of the Registration Statement and the Prospectus and to enter into this Agreement and perform its
obligations hereunder and is duly qualified to transact business and is in good standing in each jurisdiction (to the extent the concept of good standing is applicable in such jurisdiction) in which the conduct of its business or its ownership or
leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not, singly or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a
whole. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Each subsidiary of the Company has been duly incorporated, organized or formed, is
validly existing as a corporation or other business entity in good standing (to the extent the concept of good standing is applicable in such jurisdiction) under the laws of the jurisdiction of its incorporation, organization or formation, has the
corporate or other business entity power and authority to own or lease its property and to conduct its business as described in each of the Registration Statement and the Prospectus and is duly qualified to transact business and is in good standing
(to the extent the concept of good standing is applicable in such jurisdiction) in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to
be so qualified or be in good standing would not, singly or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a whole; all of the issued shares of share capital or other equity interests of each
subsidiary of the Company have been duly and validly authorized and issued, are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> (to the extent such concepts are applicable under relevant law) and are owned directly or
indirectly by the Company, free and clear of all liens (other than the first priority security interest granted to Oxford Finance LLC, as the collateral agent, pursuant to that certain Loan and Security Agreement dated December&nbsp;30, 2024 (as the
same may from time to time be amended, modified, supplemented, or restated)), encumbrances, equities or claims. Except as disclosed in the Registration Statement and Prospectus, the Company does not own or control, directly or indirectly, any
corporation, association or other entity, other than the subsidiaries listed in <B><U>Schedule 4</U></B> to this Agreement. No subsidiary is prohibited or restricted, directly or indirectly, from paying dividends to the Company, from making any
other distribution with respect to such subsidiary&#8217;s equity securities to the Company or from transferring any property or assets to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Each of this Agreement and the Deposit Agreement have been duly authorized, executed and delivered by the Company and constitute a valid
and legally binding obligation of the Company, enforceable against the Company in accordance with its terms, except as enforceability, including rights of indemnification, may be limited by bankruptcy, insolvency, fraudulent conveyance,
reorganization, moratorium and other similar laws relating to or affecting creditors&#8217; rights generally and by general principles of equity. Each of this Agreement and the Deposit Agreement conform in all material respects to the descriptions
thereof in the Registration Statement, the ADS Registration Statement and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Upon due and authorized issuance by the
Depositary of ADSs against deposit of the Ordinary Shares in accordance with the provisions of the Deposit Agreement, the Placement Shares will be duly and validly issued and persons in whose names the ADSs are registered will be entitled to the
rights specified in the Deposit Agreement and the ADRs (if applicable); and upon issuance and sale of the Placement Shares, and payment therefor, pursuant to this Agreement, the Agent or the purchases thereof, as the case may be, will acquire good,
marketable and valid title to such Placement Shares, free and clear of all pledges, liens, security interests, charges, claims or encumbrances of any kind. The ADSs conform in all material respects to the descriptions thereof contained in the
Registration Statement, the ADS Registration Statement and the Prospectus. The Placement Shares, when issued and delivered against payment therefor, will be freely transferable by the Agent to or for the account of the purchasers thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The issued and outstanding share capital and authorized share capital of the Company conforms to the description thereof contained in each
of the Registration Statement and the Prospectus. All of the issued and outstanding share capital or other equity or ownership interest of the Company (including the Ordinary Shares and ADSs) has been duly authorized and validly issued and is fully
paid and <FONT STYLE="white-space:nowrap">non-assessable,</FONT> has been issued in compliance with all federal, state and local securities laws and is free and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clear of any security interest, mortgage, pledge, lien, encumbrance or adverse claim. None of the outstanding shares in the capital of the Company were issued in violation of any preemptive
rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company. Other than as disclosed in the Registration Statement and Prospectus and as granted in the ordinary course of business pursuant to the
Stock Plans (defined below), there are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase or subscribe for, or equity or debt securities convertible into or exchangeable or
exercisable for, any share capital of the Company or any of its subsidiaries or to which the Company or any of its subsidiaries is a party or by which any of them may be bound. The descriptions of the Company&#8217;s equity incentive plans, stock
option plans and other stock plans or arrangements described in the Prospectus and in effect as of the date hereof (collectively, the &#8220;<B><U>Stock Plans</U></B>&#8221;) and the options or other rights granted thereunder, set forth in the
Registration Statement and the Prospectus accurately and fairly present in all material respects the information required to be shown with respect to such Stock Plans and the options or other rights granted thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) The Underlying Ordinary Shares underlying the Placement Shares have been duly and validly authorized for allotment and issue pursuant to
this Agreement (including pursuant to section 551 of the Companies Act) and, when the Underlying Ordinary Shares are allotted and issued by the Company to the Custodian (or its nominee) and the Placement Shares are issued and delivered against
payment therefor pursuant to this Agreement and the Deposit Agreement, such Placement Shares (and the relevant Underlying Ordinary Shares) will be validly allotted and issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable,</FONT>
and the issuance of such Placement Shares (and the allotment and issue of the relevant Underlying Ordinary Shares) will not be subject to any preemptive or similar rights (including those provided by section 561 of the Companies Act. The Underlying
Ordinary Shares and Placement Shares will conform to the description of such Ordinary Shares and ADSs in the Registration Statement, the ADS Registration Statement and the Prospectus. The Underlying Ordinary Shares, when issued and delivered against
payment therefor, may be freely deposited by the Company with the Depositary or its nominee against issuance of the Placement Shares. The Underlying Ordinary Shares will rank equally in all respects with the existing Ordinary Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) The execution and delivery by the Company of, and the performance by the Company of its obligations under, this Agreement and the Deposit
Agreement, and the issuance and sale of the Placement Shares and the deposit of the Underlying Ordinary Shares after the execution, delivery and performance of this Agreement and the Deposit Agreement, will not contravene any provision of
(i)&nbsp;applicable law or regulation, (ii)&nbsp;the articles of association, the certificate of incorporation or memorandum or bylaws of the Company or any of its subsidiaries, (iii)&nbsp;any agreement or other instrument binding upon the Company
or any of its subsidiaries that is material to the Company and its subsidiaries, taken as a whole, or (iv)&nbsp;any judgment, order or decree of any governmental body, agency or court having jurisdiction over the Company or any subsidiary, and no
consent, approval, authorization or order of, or qualification with, any governmental body, agency or court is required for the issue and sale of the Placement Shares, the allotment and issue of the Underlying Ordinary Shares and registration of the
ADSs under the Securities Act, the performance by the Company of its obligations under this Agreement and the Deposit Agreement, except (i)&nbsp;registration of the Placement Shares under the Securities Act, which has been effected (or, with respect
to any such Rule 462 Registration Statement, will be effected in accordance herewith) and (ii)&nbsp;the approval by the Financial Industry Regulatory Authority (&#8220;<B><U>FINRA</U></B>&#8221;) of the terms and arrangements and such consents,
approvals, authorizations, registrations or qualifications as may be required by the securities or Blue Sky laws of the various states in connection with the offer and sale of the Placement Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) There has been no material adverse change, or any development that could reasonably be expected to result in a material adverse change, in
the condition (financial or otherwise), earnings, results of operations, business, properties, operations, assets, liabilities or prospects of the Company and its subsidiaries, taken as a whole (&#8220;<B><U>Material Adverse Change</U></B>&#8221;),
whether or not arising from transactions in the ordinary course of business, from that set forth in the Registration Statement and the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) There are no legal or governmental proceedings pending or, to the Company&#8217;s
knowledge, threatened to which the Company or any of its subsidiaries is a party or to which any of the properties of the Company or any of its subsidiaries is subject (i)&nbsp;other than proceedings accurately described in all material respects in
each of the Registration Statement and the Prospectus and proceedings that would not singly or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a whole, or on the power or ability of the Company to
perform its obligations under this Agreement or to consummate the transactions contemplated by each of the Registration Statement and the Prospectus or (ii)&nbsp;that are required to be described in the Registration Statement or the Prospectus and
are not so described; and there are no statutes, regulations, contracts or other documents that are required to be described in the Registration Statement or the Prospectus or to be filed as exhibits to the Registration Statement that are not
described or filed as required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) The Company is not, and after giving effect to the offering and sale of the Placement Shares, the
allotment and issue of the Underlying Ordinary Shares and the application of the proceeds thereof as described in each of the Registration Statement and the Prospectus will not be, required to register as an &#8220;investment company&#8221; as such
term is defined in the Investment Company Act of 1940, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) The Company and each of its subsidiaries (i)&nbsp;are in
compliance with any and all applicable foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants
(&#8220;<B><U>Environmental Laws</U></B>&#8221;), (ii) have received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii)&nbsp;are in compliance with all terms
and conditions of any such permit, license or approval, except where such noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits,
licenses or approvals would not, singly or in the aggregate, reasonably expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) There are no costs or liabilities associated with Environmental Laws (including, without limitation, any capital or operating expenditures
required for <FONT STYLE="white-space:nowrap">clean-up,</FONT> closure of properties or compliance with Environmental Laws or any permit, license or approval, any related constraints on operating activities and, to the Company&#8217;s knowledge, any
potential liabilities to third parties) which would, singly or in the aggregate, reasonably expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) There are no contracts, agreements or understandings between the Company and any person granting such person the right to require the
Company to file a registration statement under the Securities Act (or the equivalent thereof in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions) with respect to any securities of the Company or to require the Company to include such
securities with the Placement Shares registered pursuant to the Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) (i) None of the Company or any of its
subsidiaries or affiliates, or any director, officer or employee thereof, or, to the Company&#8217;s knowledge, any agent or representative of the Company or of any of its subsidiaries or affiliates, has taken or will take any action in furtherance
of an offer, payment, promise to pay, or authorization or approval of the payment, giving or receipt of money, property, gifts or anything else of value, directly or indirectly, to any government official (including any officer or employee of a
government or government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political
office) (&#8220;<B><U>Government Official</U></B>&#8221;) in order to influence official action, or to any person in violation of any applicable anti-corruption laws; (ii)&nbsp;the Company and each of its subsidiaries and affiliates have conducted
their businesses in compliance with applicable anti-corruption laws and have instituted and maintained and will continue to maintain policies and procedures reasonably </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
designed to promote and achieve compliance with such laws and with the representations and warranties contained herein; and (iii)&nbsp;neither the Company nor any of its subsidiaries will use,
directly or indirectly, the proceeds of the offering in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any person in violation of any applicable anti-corruption
laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) The operations of the Company and each of its subsidiaries are and have been conducted at all times in material compliance with
all applicable financial recordkeeping and reporting requirements, including those of the Bank Secrecy Act, as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism
Act of 2001 (USA PATRIOT Act), the Currency and Foreign Transactions Reporting Act of 1970, as amended, the Proceeds of Crime Act 2002, the Terrorism Act 2000, the Terrorism Act 2006 and the Money Laundering, Terrorist Financing and Transfer of
Funds (Information on the Payer) Regulations 2017 (in each case as amended) and the applicable anti-money laundering statutes of jurisdictions where the Company and each of its subsidiaries conduct business, the rules and regulations thereunder and
any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &#8220;<B><U>Anti-Money Laundering Laws</U></B>&#8221;), and no action, suit or proceeding by or before any court
or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the best knowledge of the Company, threatened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) (i) None of the Company, any of its subsidiaries, or any director, officer, or employee thereof, or to the Company&#8217;s knowledge, any
agent, affiliate or representative of the Company or any of its subsidiaries, is an individual or entity (&#8220;<B><U>Person</U></B>&#8221;) that is, or is owned or controlled by one or more Persons that are: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the subject of any sanctions administered or enforced by the U.S. Department of the Treasury&#8217;s Office of
Foreign Assets Control, the United Nations Security Council, the European Union, His Majesty&#8217;s Treasury, or other relevant sanctions authority (collectively, &#8220;<B><U>Sanctions</U></B>&#8221;), or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">located, organized or resident in a country or territory that is the subject of Sanctions (including, without
limitation, the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#8217;s Republic, Iran, the <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#8217;s Republic, Crimea, Cuba, Iran, North Korea and Syria).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company will not, directly or indirectly, use the proceeds of the offering, or lend, contribute or
otherwise make available such proceeds to any subsidiary, joint venture partner or other Person: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fund or facilitate any activities or business of or with any Person or in any country or territory that, at
the time of such funding or facilitation, is the subject of Sanctions, except to the extent permitted for a Person required to comply with Sanctions; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other manner that will result in a violation of Sanctions by any Person (including any Person
participating in the offering, whether as underwriter, advisor, investor or otherwise). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company and each of its subsidiaries have not knowingly engaged in, are not now knowingly engaged in, and
will not engage in, any dealings or transactions with any Person, or in any country or territory that at the time of the dealing or transaction is or was the subject of Sanctions. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) Subsequent to the respective dates as of which information is given in each of the
Registration Statement and the Prospectus, (i)&nbsp;the Company and its subsidiaries, taken as a whole, have not incurred any material liability or obligation, direct or contingent, nor entered into any material transaction; (ii)&nbsp;the Company
has not purchased any of its outstanding share capital, nor declared, paid or otherwise made any dividend or distribution of any kind on its share capital other than ordinary and customary dividends; and (iii)&nbsp;there has not been any material
change in the share capital, <FONT STYLE="white-space:nowrap">short-term</FONT> debt or <FONT STYLE="white-space:nowrap">long-term</FONT> debt of the Company and its subsidiaries, taken as a whole, except in each case as described in each of the
Registration Statement and the Prospectus, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) Neither the Company nor any of its subsidiaries own real property. The
Company and each of its subsidiaries have good and marketable title to all personal property (other than intellectual property which is addressed exclusively in Section&nbsp;6(w) below) owned by them which is material to the business of the Company
and its subsidiaries, in each case free and clear of all liens (other than the liens disclosed in the Registration Statement and Prospectus), encumbrances and defects except such as do not materially affect the value of such property and do not
materially interfere with the use made and proposed to be made of such property by the Company and its subsidiaries and except as disclosed in the Registration Statement and Prospectus; and any real property and buildings held under lease by the
Company and its subsidiaries are held by them under valid, subsisting and enforceable leases with such exceptions as are not material and would not reasonably be expected to materially interfere with the use made and proposed to be made of such
property and buildings by the Company and its subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) The Company and its subsidiaries own or have valid licenses to all
patents, inventions, copyrights, know how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks and trade names reasonably necessary to the
conduct of their businesses, as currently conducted on the date hereof or as proposed to be conducted or to the development, manufacture, operation and sale of any products and services sold or proposed to be sold by any of the Company or its
subsidiary as described in the Registration Statement or the Prospectus as being owned by or licensed to the Company or its subsidiaries (collectively, &#8220;<B><U>Intellectual Property Rights</U></B>&#8221;). To the Company&#8217;s knowledge, each
issued patent of the Intellectual Property Rights is being diligently maintained, and is enforceable and each patent application in the Intellectual Property Rights is subsisting and has not been abandoned, save issued patents of the Intellectual
Property Rights that the Company has determined are not material to its business as currently conducted, including such patents pertaining to Company discontinued programs. Except as disclosed in the Registration Statement and the Prospectus, to the
Company&#8217;s knowledge, there is no pending or threatened action, suit, proceeding or claim by others (i)&nbsp;challenging the validity, scope or enforceability of any such Intellectual Property Rights or (ii)&nbsp;challenging the Company&#8217;s
rights in or to any Intellectual Property Rights; and there is no pending action, suit, proceeding or claim by others asserting that the Company infringes, misappropriates, or otherwise violates any patent, trademark, trade name, service name,
copyright, trade secret, or other proprietary right of another which, if the subject of an unfavorable decision, ruling or finding by a court of competent jurisdiction, would reasonably be expected to have a material adverse effect on the Company
and its subsidiaries, taken as a whole. Neither the Company nor any of its subsidiaries has received any notice alleging any infringement, misappropriation or other violation of Intellectual Property Rights which, if the subject of an unfavorable
decision, ruling or finding by a court of competent jurisdiction, would reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. To the Company&#8217;s knowledge, no third party is infringing,
misappropriating or otherwise violating, or has infringed, misappropriated or otherwise violated, any Intellectual Property Rights. To the Company&#8217;s knowledge, the Company and its subsidiaries have taken reasonable steps necessary to secure
its respective interests in Intellectual Property Rights, by the execution of appropriate confidentiality agreements and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
invention assignment agreements, from the Company&#8217;s and its subsidiaries&#8217; employees or contractors engaged in the development of Intellectual Property Rights on behalf of the Company
or any subsidiary of the Company. Except as disclosed in the Registration Statement and the Prospectus, to the Company&#8217;s knowledge, there are no third parties who have rights to any Intellectual Property disclosed in the Registration Statement
and the Prospectus as being owned or exclusively licensed by the Company, including no liens, security interests, or other encumbrances except such rights and licenses as is granted to third parties (including CROs and other vendors) in the ordinary
course of business, and excluding, for the avoidance of doubt, any Intellectual Property comprised in any commercially available off the shelf software packages or &#8220;click through&#8221; licenses. To the Company&#8217;s knowledge, the Company
and its subsidiaries have complied in all material respects with the terms of each agreement pursuant to which Intellectual Property has been exclusively licensed to the Company and its subsidiaries, and all such agreements are in full force and
effect. To the Company&#8217;s knowledge, the Company and its Subsidiaries have complied with the duty of disclosure to the USPTO prior to the issuance of a material patent. To the Company&#8217;s knowledge, there are no material defects in any of
the patents or patent applications within the Intellectual Property. To the Company&#8217;s knowledge, no employee of the Company or any of the subsidiaries is in or has been in violation of any terms of any employment contract, patent disclosure
agreement, invention assignment agreement, <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, nondisclosure agreement or any restrictive covenant to or with a former
employer where the basis of such violation relates to such employee&#8217;s employment with the Company or any of its subsidiaries. None of the Intellectual Property Rights <FONT STYLE="white-space:nowrap">in-licensed</FONT> by the Company have been
obtained or, so far as the Company is aware, are being used by the Company in violation of any contractual obligation owed by the Company to the licensor of such Intellectual Property Right, except where such violations would not reasonably be
expected, individually or in the aggregate, to have a Material Adverse Change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) (i) In all material respects, the Company and each of
its subsidiaries have complied, at all relevant times, and are presently in compliance with the Company&#8217;s and/or, as applicable, relevant subsidiaries&#8217; privacy and information security policies, contractual obligations and all applicable
laws (including, without limitation, the Privacy Laws as defined below), statutes, judgments, orders, rules and regulations of any court or arbitrator or other governmental or regulatory authority and any other legal obligations, in each case,
relating to the collection, use, transfer, import, export, storage, protection, disposal disclosure and/or other processing by the Company or any of its subsidiaries of personal, personally identifiable, household, sensitive, confidential or
regulated data (&#8220;<B><U>Data Security Obligations</U></B>&#8221;, and such data, &#8220;<B><U>Data</U></B>&#8221;) including, to the extent applicable but without limitation, (A)&nbsp;the Health Insurance Portability and Accountability Act of
1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, &#8220;<B><U>HIPAA</U></B>&#8221;), (B) the California Consumer Privacy Act (&#8220;<B><U>CCPA</U></B>&#8221;), (C) the European Union General
Data Protection Regulation (EU 2016/679) &#8220;(<B><U>GDPR</U></B>&#8221;), together with any applicable implementing or supplementary legislation in any member state of the European Economic Area, and (D)&nbsp;the GDPR as it forms part United
Kingdom law by virtue of section 3 of the European Union (Withdrawal) Act 2018 and as amended (including, without limitation, by the Data Protection, Privacy and Electronic Communications (Amendments etc.) (EU Exit) Regulations 2019), together with
the United Kingdom Data Protection Act (collectively, (A)&nbsp;through (D) the &#8220;<B><U>Privacy Laws</U></B>&#8221;); (ii) the Company has not, nor has any subsidiary, received any notification of or complaint regarding, and is unaware of any
other facts that, individually or in the aggregate, would reasonably indicate, <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any Data Security Obligation by the Company or any of its subsidiaries; and (iii)&nbsp;there has not been, and
there is no pending or, to the Company&#8217;s knowledge, threatened action, suit or proceeding by or before any court or governmental agency, authority or body alleging <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any Data Security
Obligation by the Company or any of its subsidiaries, or any person acting jointly with, or on behalf of, the Company or any of its subsidiaries, and the Company is unaware of any facts that would be reasonably likely to give rise to any such
action, suit or proceeding. The execution, delivery and performance of this Agreement or any other agreement referred to in this Agreement will not result in a material breach or violation of any Data Security Obligations. The Company and each of
its subsidiaries have taken all reasonably necessary actions to be in material compliance (by the applicable effective date) with any anticipated applicable laws and regulations with respect to Data that have been announced as of the date hereof.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) The Company has implemented and maintained technical, administrative, physical and
organizational measures designed to protect the information technology systems and Data used in connection with the operation of the Company&#8217;s and its subsidiaries&#8217; businesses. Without limiting the foregoing the Company has established,
maintained, implemented and complied with, and shall continue to establish, maintain, implement and comply with, reasonable information technology, information security, cyber security and data protection controls, policies and procedures, including
reasonable oversight, access controls, encryption (to the extent deemed appropriate by the Company), technological and physical safeguards that are designed to protect against and prevent breach, destruction, loss, unauthorized distribution, use,
access, disablement, misappropriation or modification, or other compromise or misuse of or relating to any Company information technology system or Data used or otherwise processed in connection with the operation of the Company&#8217;s and its
subsidiaries&#8217; businesses (&#8220;<B><U>Breach</U></B>&#8221;). Except as otherwise conveyed to counsel for agent prior to the date of this Agreement or as set forth in the Registration Statement and Prospectus, to the Company&#8217;s
knowledge, there has been no such Breach, and the Company and its subsidiaries have not been notified of and have no knowledge of any event or condition that would reasonably be expected to result in, any such Breach. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) No material labor dispute with the employees of the Company or any of its subsidiaries exists, or, to the knowledge of the Company, is
imminent; and the Company is not aware of any existing, threatened or imminent labor disturbance by the employees of any of its principal suppliers, manufacturers or contractors that could, singly or in the aggregate, have a material adverse effect
on the Company and its subsidiaries, taken as a whole. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) The Company and each of its subsidiaries are insured by insurers of
recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which they are engaged; neither the Company nor any of its subsidiaries has been refused any insurance coverage
sought or applied for; and neither the Company nor any of its subsidiaries has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar
insurers as may be necessary to continue its business at a cost that would not, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) The Company and each of its subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state or
foreign regulatory authorities necessary to conduct their respective businesses, except where any failure to possess the same would not reasonably be expected to have a material adverse effect on the Company or any subsidiary singly, and neither the
Company nor any of its subsidiaries has received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit which, singly or in the aggregate, if the subject of an unfavorable decision,
ruling or finding, would have a material adverse effect on the Company and its subsidiaries, taken as a whole. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) The financial
statements (including the related notes thereto) included and incorporated by reference in the Registration Statement and the Prospectus, together with the related schedules and notes thereto, comply as to form in all material respects with the
applicable accounting requirements of the Securities Act and present fairly the consolidated financial position of the Company and its subsidiaries as of the dates shown and its results of operations and cash flows for the periods shown, and such
financial statements have been prepared in conformity with generally accepted accounting principles in the United States (&#8220;<B><U>U.S. GAAP</U></B>&#8221;) applied on a consistent basis throughout the periods covered thereby except for any
normal <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments in the Company&#8217;s quarterly financial statements. The other financial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
information included and incorporated by reference in each of the Registration Statement and the Prospectus has been derived from the accounting records of the Company and its consolidated
subsidiaries and presents fairly in all material respects the information shown thereby. There are no financial statements (historical or pro forma) that are required to be included in the Registration Statement or the Prospectus that are not
included as required. The Company and each of its subsidiaries do not have any material liabilities or obligations, direct or contingent (including any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet obligations), not disclosed in the
Registration Statement and the Prospectus. All disclosures contained in the Registration Statement or the Prospectus that contain <FONT STYLE="white-space:nowrap">&#8220;non-GAAP</FONT> financial measures&#8221; (as such term is defined by the rules
and regulations of the Commission) comply, in all material respects, with Regulation G under the Exchange Act and Item 10 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act, to the extent applicable. To the
Company&#8217;s knowledge, no person who has been suspended or barred from being associated with a registered public accounting firm, or who has failed to comply with any sanction pursuant to Rule 5300 promulgated by the Public Company Accounting
Oversight Board (&#8220;<B><U>PCAOB</U></B>&#8221;), has participated in or otherwise aided the preparation of, or audited, the financial statements, supporting schedules or other financial data filed with the Commission as a part of the
Registration Statement and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) The statistical, industry-related and market-related data included in each of the
Registration Statement and the Prospectus are based on or derived from sources which the Company reasonably and in good faith believes are reliable and accurate and such data is consistent with the sources from which they are derived, in each case
in all material respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) KPMG LLP, whose report on the consolidated financial statements of the Company is filed with the
Commission as part of the Company&#8217;s most recent annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed with the Commission and incorporated by reference in the Registration Statement and the Prospectus, is an independent
registered public accounting firm with respect to the Company within the meaning of the Securities Act and the applicable rules and regulations thereunder adopted by the Commission and the PCAOB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) The Company and each of its subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance
that (i)&nbsp;transactions are executed in accordance with management&#8217;s general or specific authorizations; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with U.S. GAAP and to
maintain asset accountability (except as disclosed in each of the Registration Statement and the Prospectus); (iii) access to assets is permitted only in accordance with management&#8217;s general or specific authorization; (iv)&nbsp;the recorded
accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v)&nbsp;the interactive data in eXtensible Business Reporting Language included or
incorporated by reference in the Registration Statement and the Prospectus fairly presents the information called for in all material respects and is prepared in accordance with the Commission&#8217;s rules and guidelines applicable thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) The Company and each of its subsidiaries have established and maintain disclosure controls and procedures (as defined in Rules <FONT
STYLE="white-space:nowrap">13a-15</FONT> and <FONT STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act), which (i)&nbsp;are designed to ensure that information relating to the Company, including its consolidated subsidiaries, is made
known to the Company&#8217;s principal executive officer and its principal financial officer by others within those entities, particularly during the periods in which the periodic reports required under the Exchange Act are being prepared;
(ii)&nbsp;have been evaluated by management of the Company for effectiveness as of the end of the Company&#8217;s most recent fiscal quarter; and (iii)&nbsp;are effective in all material respects to perform the functions for which they were
established. Except as disclosed in the Registration Statement and the Prospectus, since the end of the Company&#8217;s most recent audited fiscal year, there has been (i)&nbsp;no material weakness in the Company&#8217;s internal control over
financial reporting (whether or not remediated) and (ii) no change in the Company&#8217;s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over
financial reporting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) The Company and each of its subsidiaries have filed all tax returns required to be
filed or have requested extensions thereof (except where the failure to file would not, singly or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a whole) and have paid all taxes for which they are
liable and any related or similar assessment, fine or penalty levied against them (except for cases in which the failure to pay would not, singly or in the aggregate, have a material adverse effect on the Company and its subsidiaries or as currently
being contested in good faith by appropriate proceedings and for which adequate reserves required by U.S. GAAP have been created and maintained in the most recent financial statements of the Company), and no tax deficiency has been asserted, or
determined adversely, to or against the Company or any of its subsidiaries which, singly or in the aggregate, has had or would have (nor does the Company nor any of its subsidiaries have any notice or knowledge of any tax deficiency or tax audit
which could reasonably be expected to be determined adversely to the Company or its subsidiaries and which could reasonably be expected to have) a material adverse effect on the Company and its subsidiaries, taken as a whole. The Company has made
adequate charges, accruals and reserves in the most recent financial statements of the Company in respect of any federal, state, local and <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> taxes for any periods not finally determined. All taxes which
the Company and its subsidiaries are required by law to withhold or to collect for payment have been duly withheld and collected and have been paid to the appropriate governmental authority or agency (except for cases in which the failure to so
withhold would not, singly or in the aggregate, have a material adverse effect on the Company and its subsidiaries or as currently being contested in good faith by appropriate proceedings and for which adequate reserves required by U.S. GAAP have
been created and maintained in the most recent financial statements of the Company). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The Company is an &#8220;emerging growth
company,&#8221; as defined in Section&nbsp;2(a) of the Securities Act (an &#8220;<B><U>Emerging Growth Company</U></B>&#8221;) unless that the Company has notified the Agent that the Company ceases to be an Emerging Growth Company in accordance with
Section&nbsp;7(y). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) The Company and each subsidiary has in all material respects operated, at all times and is currently in
compliance in all material respects with all applicable statutes, rules and regulations of the U.S. Food and Drug Administration (the &#8220;<B><U>FDA</U></B>&#8221;), other applicable regulatory authorities, including the European Medicines Agency
and the UK Medicines&nbsp;&amp; Healthcare products Regulatory Agency (collectively, the &#8220;<B><U>Regulatory Authorities</U></B>&#8221;), including, without limitation (but, in each case, to the extent applicable): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(i) the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167;&#167; 301 et seq.), the Public Health Service Act (42 U.S.C. &#167;&#167; 201 et
seq.), and the regulations promulgated pursuant to such statutes; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(ii) all applicable federal, state, local and foreign health care laws,
including, without limitation, the U.S. Anti-Kickback Statute (42 <FONT STYLE="white-space:nowrap">U.S.C.&nbsp;Section&nbsp;1320a-7b(b)),&nbsp;the</FONT> Civil Monetary Penalties Law (42 U.S.C.
<FONT STYLE="white-space:nowrap">&#167;&nbsp;1320a-7a),&nbsp;the</FONT> U.S. Civil False Claims Act (31 U.S.C. Section&nbsp;3729 et seq.), all applicable federal, state, local and all foreign criminal laws relating to health care fraud and abuse,
including but not limited to the U.S. False Statements Law (42 <FONT STYLE="white-space:nowrap">U.S.C.&nbsp;Section&nbsp;1320a-7b(a)),&nbsp;18</FONT> U.S.C. Sections 286 and 287, and the health care fraud criminal provisions under HIPAA (42 U.S.C.
Section&nbsp;1320d et seq.), the U.S. Physician Payments Sunshine Act (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7h),</FONT> the exclusion law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7),</FONT> the
statutes, regulations and directives of applicable government funded or sponsored healthcare programs, and the regulations promulgated pursuant to such statutes; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(iii) HIPAA, as amended by the Health Information Technology for Economic and Clinical
Health Act (42 U.S.C. Section&nbsp;17921 et seq.), and the regulations promulgated thereunder and any state <FONT STYLE="white-space:nowrap">or&nbsp;non-U.S.&nbsp;counterpart</FONT> thereof or any other law or regulation the purpose of which is to
protect the privacy of individuals or prescribers; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(iv) the Patient Protection and Affordable Care Act of 2010, as amended by the Health
Care and Education Reconciliation Act of 2010, the regulations promulgated thereunder; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(v) licensure, quality, safety and accreditation
requirements under applicable federal, state, local or foreign laws or Regulatory Authorities; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(vi) those foreign laws that are analogous
to each of the aforementioned laws; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(vii) all other local, state, federal, national, supranational and foreign laws, relating to the
regulation of the Company and/or any subsidiary and the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product
under development, manufactured or distributed by the Company and/or any subsidiary, to the extent applicable to the Company&#8217;s operations; (clauses (i)&nbsp;through (vii), collectively, &#8220;<B><U>Health Care Laws</U></B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) (i) The tests, preclinical studies and clinical trials conducted by or on behalf of or sponsored by the Company or any subsidiary or in
which the Company or any subsidiary has participated, were, and if still pending are, being conducted in accordance in all material respects with applicable standard medical and experimental protocols, procedures and controls pursuant to applicable
and generally accepted professional scientific research standards and procedures, and all applicable Health Care Laws, the rules and regulations of the Regulatory Authorities and current good clinical practices and good laboratory practices;
(ii)&nbsp;the descriptions of the results of such studies and trials contained in the Registration Statement or the Prospectus are accurate in all material respects and fairly present the data derived from such trials and studies; (iii)&nbsp;neither
the Company nor any subsidiary has undertaken any other studies or trials not described in the Registration Statement and the Prospectus, the results of which are materially inconsistent with or call into question in a material respect the results
described or referred to in the Registration Statement and the Prospectus; and (iv)&nbsp;neither the Company nor any subsidiary has received any written notices, correspondence or other communications from any Regulatory Authority or any other
governmental entity requiring or threatening the termination, material modification or suspension of any studies or trials that are described in the Registration Statement and the Prospectus or the results of which are referred to in the
Registration Statement and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) Except in each case as would not be reasonably expected to have a material adverse effect
on the Company and its subsidiaries, taken as a whole, (i)&nbsp;the Company and each subsidiary has filed, obtained, maintained or submitted all applicable mandatory reports, documents, forms, notices, applications, records, claims, submissions and
supplements or amendments as required by any applicable Health Care Laws, and, all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were, to the best knowledge of the Company, timely,
complete, accurate and not misleading on the date filed (or were corrected or supplemented by a subsequent submission); and (ii)&nbsp;neither the Company nor any subsidiary has received written notice of any claim, action, suit, proceeding, hearing,
enforcement, investigation, arbitration or other action from any court or arbitrator or Regulatory Authority, other governmental entity or third party alleging that any Company, subsidiary, or product operation or activity is in material violation
of any applicable Health Care Laws, including, without limitation, but only to the extent applicable, any Form FDA 483, notice of adverse finding, warning letter, untitled letter or other written correspondence or notice from the FDA or any other
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Regulatory Authority or governmental entity, nor is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action threatened in writing. Further,
(i)&nbsp;neither the Company nor any subsidiary is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any Regulatory Authority or other governmental
entity; and (ii)&nbsp;neither the Company nor any subsidiary or any of their respective employees, officers, directors or agents has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical
research or, to the knowledge of the Company, is subject to an inquiry, investigation, proceeding or other similar action by a Regulatory Authority or other governmental entity that could reasonably be expected to result in debarment, suspension, or
exclusion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) Neither the Company nor any of its subsidiaries has any securities rated by any &#8220;nationally recognized statistical
rating organization,&#8221; as such term is defined in Section&nbsp;3(a)(62) of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn) Under the current laws and
regulations of the United Kingdom, all dividends and other distributions declared and payable on the Ordinary Shares in cash may be freely remitted out of the United Kingdom and may be paid in, or freely converted into, United States dollars, in
each case without there being required any consent, approval, authorization or order of, or qualification with, any court or governmental agency or body in the United Kingdom; and except as disclosed in each of the Registration Statement and the
Prospectus, all such dividends and other distributions paid by the Company will not be subject to withholding under the current laws and regulations of the United Kingdom. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo) No stamp, documentary, issuance, registration, transfer, or other similar taxes or duties (including any United Kingdom stamp duty or
stamp duty reserve tax) are payable by or on behalf of the Agent, the Company or any of its subsidiaries in the United Kingdom or the United States or to any taxing authority of either of them or therein in connection with (i)&nbsp;the execution or
delivery of this Agreement or the Deposit Agreement, (ii)&nbsp;the creation, allotment, issuance and delivery of the Ordinary Shares by the Company to the Depositary and the creation, allotment, issuance and delivery of the ADSs (and any
corresponding ADRs evidencing such ADSs), in each case, in the manner contemplated by this Agreement or the Deposit Agreement, (iii)&nbsp;the sale and delivery of the ADSs (and any corresponding ADRs evidencing such ADSs) to the Agent in the manner
contemplated by this Agreement, or (iv)&nbsp;the initial sale and delivery of the ADSs (and any corresponding ADRs evidencing such ADSs) by the Agent in the manner contemplated herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp) The Company is resident for tax purposes solely in the United Kingdom and has no permanent establishment (and is not subject to income
taxation) in any other jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq) The statements contained in the Registration Statement and the Prospectus, as of the dates
thereof, under the headings (i) &#8220;Material Income Tax Considerations&#8212;Certain Material United States Federal Income Tax Considerations for U.S. Holders&#8221; and (ii) &#8220;Material Income Tax Considerations&#8212;U.K. Taxation,&#8221;
insofar as they purport to describe the provisions of the laws and documents referred to therein, are accurate and complete in all material respects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr) Neither the Company nor any of its subsidiaries was a &#8220;passive foreign investment company&#8221; (&#8220;<B><U>PFIC</U></B>&#8221;)
as defined in Section&nbsp;1297 of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;<B><U>Code</U></B>&#8221;) for U.S. federal income tax purposes for its most recent taxable year ending December&nbsp;31, 2024 and neither the Company
nor any of its subsidiaries expects, after consultation with its tax advisors, to be a PFIC for its current taxable year or in the foreseeable future. The Company expects that it will make available the information necessary for U.S. persons to make
a &#8220;qualified electing fund&#8221; election if the Company determines that it or any of its subsidiaries is a PFIC for the current taxable year or any future taxable year. The Company believes it is not currently a &#8220;controlled foreign
corporation&#8221; (&#8220;<B><U>CFC</U></B>&#8221;) within the meaning of Section&nbsp;957 of the Code, and does not expect to become a CFC in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss) Each of this Agreement and the Deposit Agreement is in proper form under the laws of
England and Wales for the enforcement thereof against the Company, and to ensure the legality, validity, enforceability or admissibility into evidence in England and Wales of each of this Agreement and the Deposit Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt) Under the laws of England and Wales, each holder of ADSs issued pursuant to the Deposit Agreement shall be entitled, subject to the
Deposit Agreement, to seek enforcement of its rights through the Depositary or its nominee registered as representative of the holders of the ADSs in a direct suit, action or proceeding against the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu) Neither the Company nor any of its subsidiaries nor any of its or their properties or assets has any immunity from the jurisdiction of
any court or from any legal process (whether through service or notice, attachment prior to judgment, attachment in aid of execution or otherwise) under the laws of England and Wales. The irrevocable and unconditional waiver and agreement of the
Company contained in Section&nbsp;17 not to plead or claim any such immunity in any legal action, suit or proceeding based on this Agreement is valid and binding under the laws of England and Wales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv) The courts of England and Wales would recognize as a valid judgment any final monetary judgment obtained against the Company in the
courts of the State of New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ww) The choice of law of the State of New York as the governing law of this Agreement is a valid choice
of law under the laws of England and Wales and will be honored by the courts of England and Wales. The Company has the power to submit, and pursuant to Section&nbsp;17 has, to the extent permitted by law, legally, validly, effectively and
irrevocably submitted, to the jurisdiction of the Specified Courts (as defined in Section&nbsp;17, and has the power to designate, appoint and empower, and pursuant to Section&nbsp;17, has legally, validly and effectively designated, appointed and
empowered an agent for service of process in any suit or proceeding based on or arising under this Agreement in any of the Specified Courts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xx) The Company has not distributed and, prior to the later to occur of each Settlement Date and completion of the Agent&#8217;s distribution
of the Placement Shares under this Agreement, will not distribute any offering material in connection with the offering and sale of the Placement Shares other than the Registration Statement, the ADS Registration Statement the Prospectus or any
Permitted Free Writing Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(yy) The interactive data in eXtensible Business Reporting Language included or incorporated by
reference in the Registration Statement and the Prospectus fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#8217;s rules and guidelines applicable thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(zz) The Company is subject to and in compliance in all material respects with the reporting requirements of Section&nbsp;13 or
Section&nbsp;15(d) of the Exchange Act. The ADSs and the Ordinary Shares are registered pursuant to Section&nbsp;12(b) or 12(g) of the Exchange Act, the ADSs listed on Nasdaq, and the Company has taken no action designed to, or reasonably likely to
have the effect of, terminating the registration of the ADSs or Ordinary Shares under the Exchange Act, delisting the ADSs from Nasdaq, nor has the Company received any notification that the Commission or Nasdaq is contemplating terminating such
registration or listing. The Company is in compliance with the current listing standards of Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aaa) Neither the Company, nor any of
its subsidiaries, nor to the knowledge of the Company, any of its or their respective directors, officers or controlling persons has taken, directly or indirectly, without giving effect to any actions taken by the Agent, (i)&nbsp;any action designed
to or that might constitute or reasonably be expected to cause or result in, under the Exchange Act or otherwise, stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Placement Shares or
(ii)&nbsp;any action designed to or that might constitute or reasonably be expected to cause or result in a violation of Regulation M under the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bbb) No person (as such term is defined in Rule
<FONT STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> promulgated under the Securities Act) has the right to act as an underwriter or as a financial advisor to the Company in connection with the offer
and sale of the Placement Shares hereunder, whether as a result of the filing or effectiveness of the Registration Statement or the ADS Registration Statement or the sale of the Placement Shares as contemplated hereby or otherwise. Except for the
Agent, there is no broker, finder or other party that is entitled to receive from the Company or any of its subsidiaries (as defined below) any brokerage or finder&#8217;s fee or other fee or commission as a result of any transactions contemplated
by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ccc) There are no persons (as such term is defined in Rule <FONT STYLE="white-space:nowrap">1-02</FONT> of Regulation
<FONT STYLE="white-space:nowrap">S-X</FONT> promulgated under the Securities Act) with registration or other similar rights to have any equity or debt securities of the Company registered for sale under the Registration Statement or included in the
offering contemplated by this Agreement, except for such rights as have been duly waived in a writing previously furnished to the Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ddd) The Company is in compliance with, and there is and has been no failure on the part of the Company and, to the Company&#8217;s
knowledge, any of the Company&#8217;s directors or officers, in their capacities as such, to comply with, any provision of the Sarbanes-Oxley Act of 2002 and all rules and regulations promulgated thereunder or implementing the provisions thereof
(the &#8220;<B><U>Sarbanes-Oxley Act</U></B>&#8221;) and the rules and regulations promulgated in connection therewith, including Section&nbsp;402 relating to loans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(eee) The Company acknowledges and agrees that the Agent has informed the Company that the Agent may, to the extent permitted under the
Securities Act and the Exchange Act, purchase and sell shares of Ordinary Shares and ADSs for its own account while this Agreement is in effect; <I>provided</I>, that (i)&nbsp;no such purchase or sales shall take place while a Placement Notice is in
effect (except to the extent the Agent may engage in sales of Placement Shares purchased or deemed purchased from the Company as a &#8220;riskless principal&#8221; or in a similar capacity) and (ii)&nbsp;the Company shall not be deemed to have
authorized or consented to any such purchases or sales by the Agent, except as may be otherwise agreed by the Company and the Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(fff) The Company is not a party to any agreement with an agent or underwriter for any other &#8220;at the market&#8221; or continuous equity
transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ggg) The Company is not required to register as a &#8220;broker&#8221; or &#8220;dealer&#8221; in accordance with the
provisions of the Exchange Act and does not, directly or indirectly through one or more intermediaries, control or have any other association with (within the meaning of Article I of the <FONT STYLE="white-space:nowrap">By-laws</FONT> of FINRA) any
member firm of FINRA. To the Company&#8217;s knowledge, no relationship, direct or indirect, exists between or among the Company, on the one hand, and the directors, officers or shareholders of the Company, on the other hand, which is required by
the rules of FINRA to be described in the Registration Statement and the Prospectus, which is not so described. All of the information (including, but not limited to, information regarding affiliations, security ownership and trading activity)
provided to the Agent or its counsel by the Company in connection with the filing to be made and other supplemental information to be provided to FINRA pursuant to FINRA Rule 5110 in connection with the transactions contemplated by this Agreement is
true, complete and correct. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hhh) As of the close of trading on Nasdaq on September&nbsp;30, 2025, the aggregate market
value of the outstanding voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common equity (as defined in Rule 405) of the Company held by persons other than affiliates of the Company (pursuant to Rule 144 of the Securities Act, those that
directly, or indirectly through one or more intermediaries, control, or are controlled by, or are under common control with, the Company) (the &#8220;<B><U><FONT STYLE="white-space:nowrap">Non-Affiliate</FONT> Shares</U></B>&#8221;), was
approximately $2.8&nbsp;billion (calculated by multiplying (x)&nbsp;the price at which the common equity of the Company was last sold on Nasdaq on September&nbsp;30, 2025 by (y)&nbsp;the number of
<FONT STYLE="white-space:nowrap">Non-Affiliate</FONT> Shares outstanding on September&nbsp;30, 2025). The Company is not a shell company (as defined in Rule 405) and has not been a shell company for at least 12 calendar months previously. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Neither the issuance, sale and delivery of the Placement Shares nor the application of the proceeds thereof by the Company as described
in the Registration Statement and the Prospectus will violate Regulation T, U or X of the Board of Governors of the Federal Reserve System or any other regulation of such Board of Governors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jjj) Each of the independent directors (or independent director nominees, once appointed, if applicable) named in the Registration Statement
and Prospectus satisfies the independence standards established by Nasdaq and, with respect to members of the Company&#8217;s audit committee, the enhanced independence standards contained in Rule <FONT STYLE="white-space:nowrap">10A-3(b)(1)</FONT>
promulgated by the Commission under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kkk) Neither the Company nor, to the Company&#8217;s knowledge, any of its
affiliates (within the meaning of Rule 144 under the Securities Act) has, prior to the date hereof, made any offer or sale of any securities which could be &#8220;integrated&#8221; (within the meaning of the Securities Act) with the offer and sale
of the Placement Shares hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(lll) Neither the Company nor any of its subsidiaries has (i)&nbsp;failed to pay any dividend or
sinking fund installment on preferred stock or (ii)&nbsp;defaulted on any installment or payment due on indebtedness for borrowed money or any rental on one or more long-term leases, which defaults, individually or in the aggregate, could reasonably
be expected to result in a Material Adverse Change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mmm) Each financial or operational projection or other &#8220;forward-looking
statement&#8221; (as defined by Section&nbsp;27A of the Securities Act or Section&nbsp;21E of the Exchange Act) contained in the Registration Statement or the Prospectus (i)&nbsp;was so included by the Company in good faith and with reasonable basis
after due consideration by the Company of the underlying assumptions, estimates and other applicable facts and circumstances and (ii)&nbsp;as required, is accompanied by meaningful cautionary statements identifying those factors that could cause
actual results to differ materially from those in such forward-looking statement. No such statement was made with the knowledge of a director or senior manager of the Company that was false or misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nnn) There are no relationships, direct or indirect, or related party transactions involving the Company or any of its subsidiaries or any
other person (including any director, officer, stockholder, customer or supplier of the Company or any of its subsidiaries) required to be described in the Registration Statement or the Prospectus that have not been described as required. There are
no material outstanding loans, advances (except normal advances for business expenses in the ordinary course of business) or guarantees of indebtedness by the Company or any of its subsidiaries to or for the benefit of any of the officers or
directors of the Company or any of its subsidiaries, or any of the family members of any of such persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ooo) The Company is not in or
subject to a bankruptcy or insolvency proceeding in any jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ppp) No director or officer of the Company or any of its
subsidiaries is subject to any <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement or <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement with any employer or prior employer which could materially affect each
director&#8217;s or officer&#8217;s ability to be and act in the capacity of a director or officer of the Company or a subsidiary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qqq) The Company has not and will not make an offer to the public of the ADSs in any member
state of the European Economic Area or the United Kingdom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rrr) (A) At the original effectiveness of the Registration Statement,
(B)&nbsp;at the time of the most recent amendment thereto for purposes of complying with Section&nbsp;10(a)(3) of the Securities Act (whether such amendment was by post-effective amendment or incorporated report filed pursuant to Section&nbsp;13 or
15(d) of the Exchange Act or in the form of a prospectus), and (C)&nbsp;at the time the Company or any person acting on its behalf (within the meaning, for this clause only, of Rule 163(c) under the Securities Act) made any offer relating to the
Placement Shares in reliance on the exemption of Rule 163 under the Securities Act, the Company was and is a &#8220;well-known seasoned issuer&#8221; (as defined in Rule 405). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(sss) Neither the Company nor any of its subsidiaries is a &#8220;covered foreign person&#8221;, as that term is defined in 31 C.F.R. &#167;
850.209. Neither the Company nor any of its subsidiaries currently engages, or has plans to engage, directly or indirectly, in a &#8220;covered activity&#8221;, as that term is defined in 31 C.F.R. &#167; 850.208 (&#8220;<B><U>Covered
Activity</U></B>&#8221;). The Company does not have any joint ventures that engage in or plan to engage in any Covered Activity. The Company also does not, directly or indirectly, hold a board seat on, have a voting or equity interest in, or have
any contractual power to direct or cause the direction of the management or policies of any person or persons that engages or plans to engage in any Covered Activity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any certificate signed by any officer of the Company and delivered to the Agent or its counsel in connection with the offering of the
Placement Shares shall be deemed a representation and warranty by the Company, as to matters covered thereby, to the Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.
<U>Covenants of the Company</U>. The Company covenants and agrees with the Agent that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Registration Statement Amendments</U>.
After the date of this Agreement and during any period in which the Prospectus relating to any Placement Shares is required to be delivered by the Agent under the Securities Act (including in circumstances where such requirement may be satisfied
pursuant to Rule 172 under the Securities Act or a similar rule); (i) the Company will notify the Agent promptly of the time when any subsequent amendment to the Registration Statement or ADS Registration Statement, other than Incorporated
Documents, has been filed with the Commission and/or has become effective or any subsequent supplement to the Prospectus, other than Incorporated Documents, has been filed and of any request by the Commission for any amendment or supplement to the
Registration Statement, ADS Registration Statement or Prospectus or for additional information (in each case, insofar as it relates to the transactions contemplated hereby); (ii) the Company will prepare and file with the Commission, promptly upon
the Agent&#8217;s request, any amendments or supplements to the Registration Statement, the ADS Registration Statement or Prospectus that, in the Agent&#8217;s reasonable opinion, may be necessary in connection with the distribution of the Placement
Shares by the Agent (provided, however, that the failure of the Agent to make such request shall not relieve the Company of any obligation or liability hereunder, or affect the Agent&#8217;s right to rely on the representations and warranties made
by the Company in this Agreement and provided, further, that the only remedy the Agent shall have with respect to the failure by the Company to make such filing (but without limiting the Agent&#8217;s rights under Section&nbsp;9 hereof) will be to
cease making sales under this Agreement until such amendment or supplement is filed); (iii) the Company will not file any amendment or supplement to the Registration Statement, the ADS Registration Statement or Prospectus, other than Incorporated
Documents, relating to the Placement Shares or a security convertible into or exchangeable or exercisable for the Placement Shares unless a copy thereof has been submitted to the Agent within a reasonable period of time before the filing and the
Agent has not reasonably objected thereto (provided, however, that (A)&nbsp;the failure of the Agent to make such objection shall not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
relieve the Company of any obligation or liability hereunder, or affect the Agent&#8217;s right to rely on the representations and warranties made by the Company in this Agreement and
(B)&nbsp;the Company has no obligation to provide the Agent any advance copy of such filing or to provide the Agent an opportunity to object to such filing if the filing does not name the Agent and does not relate to the transaction herein,
provided, further, that the only remedy the Agent shall have with respect to the failure by the Company to provide the Agent with such copy or the filing of such amendment or supplement despite the Agent&#8217;s objection (but without limiting the
Agent&#8217;s rights under Section&nbsp;9 hereof) will be to cease making sales under this Agreement) and the Company will furnish to the Agent at the time of filing thereof a copy of any Incorporated Document, except for those documents available
via EDGAR; and (iv)&nbsp;the Company will cause each amendment or supplement to the Prospectus, other than Incorporated Documents, to be filed with the Commission as required pursuant to the applicable paragraph of Rule 424(b) of the Securities Act
and, in the case of any Incorporated Document, to be filed with the Commission as required pursuant to the Exchange Act, within the time period prescribed (the determination to file or not file any amendment or supplement with the Commission under
this Section&nbsp;7(a), based on the Company&#8217;s reasonable opinion or reasonable objections, shall be made exclusively by the Company). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Notice of Commission Stop Orders</U>. The Company will advise the Agent, promptly after it receives notice or obtains knowledge
thereof, of the issuance or threatened issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or ADS Registration Statement, of the suspension of the qualification of the Placement Shares for offering
or sale in any jurisdiction or of the initiation or threatening of any proceeding for any such purpose; and it will promptly use its commercially reasonable efforts to prevent the issuance of any stop order or to obtain its withdrawal if such a stop
order should be issued. The Company will advise the Agent promptly after it receives any request by the Commission for any amendments to the Registration Statement, the ADS Registration Statement or any amendment or supplements to the Prospectus or
for additional information related to the offering of the Placement Shares or for additional information related to the Registration Statement, the ADS Registration Statement or the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Delivery of Prospectus; Subsequent Changes</U>. During any period in which the Prospectus relating to the Placement Shares is required
to be delivered by the Agent under the Securities Act with respect to the offer and sale of the Placement Shares (including in circumstances where such requirement may be satisfied pursuant to Rule 172 under the Securities Act or a similar rule),
the Company will comply in with all requirements imposed upon it by the Securities Act, as from time to time in force, and will file on or before their respective due dates (taking into account any extensions available under the Exchange Act) all
reports and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14, 15(d) or any other provision of or under the Exchange Act. If during such period any event
occurs as a result of which the Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances then
existing, not misleading, or if during such period it is necessary to amend or supplement the Registration Statement, the ADS Registration Statement or Prospectus to comply with the Securities Act, the Company will promptly notify the Agent to
suspend the offering of Placement Shares during such period and the Company will promptly amend or supplement the Registration Statement, the ADS Registration Statement or Prospectus (at the expense of the Company) so as to correct such statement or
omission or effect such compliance; provided that the Company may delay the filing of any amendment or supplement if, in the judgment of the Company, it is in the best interest of the Company. If the Company has omitted any information from the
Registration Statement or ADS Registration Statement pursuant to Rule 430B under the Securities Act, it will use its best efforts to comply with the provisions thereof and make all requisite filings with the Commission pursuant to said Rule 430B and
to notify the Agent promptly of all such filings if not available on EDGAR. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Listing of Placement Shares</U>. During any period in which the Prospectus relating
to the Placement Shares is required to be delivered by the Agent under the Securities Act with respect to the offer and sale of the Placement Shares (including in circumstances where such requirement may be satisfied pursuant to Rule 172 under the
Securities Act or a similar rule), the Company will use its commercially reasonable efforts to cause the Placement Shares to be listed on Nasdaq. The Company will timely file with Nasdaq all material documents and notices required by Nasdaq of
companies that have or will issue securities that are traded on Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Delivery of Registration Statement, the ADS Registration
Statement and Prospectus</U>. The Company will furnish to the Agent and its counsel (at the reasonable expense of the Company) copies of the Registration Statement, the ADS Registration Statement, the Prospectus (including all Incorporated
Documents) and all amendments and supplements to the Registration Statement, the ADS Registration Statement or Prospectus that are filed with the Commission during any period in which the Prospectus relating to the Placement Shares is required to be
delivered under the Securities Act with respect to the offer and sale of the Placement Shares (including all Incorporated Documents filed with the Commission during such period), in each case as soon as reasonably practicable and in such quantities
as the Agent may from time to time reasonably request and, at the Agent&#8217;s request, will also furnish copies of the Prospectus to each exchange or market on which sales of the Placement Shares may be made; <I>provided</I>, <I>however</I>, that
the Company shall not be required to furnish any document (other than the Prospectus) to the Agent to the extent such document is available on EDGAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Earnings Statement</U>. The Company will make generally available to its security holders and to the Agent as soon as practicable, but
in any event not later than 15 months after the end of the Company&#8217;s current fiscal quarter, an earnings statement covering a <FONT STYLE="white-space:nowrap">12-month</FONT> period that satisfies the provisions of Section&nbsp;11(a) of and
Rule 158 under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Expenses</U>. The Company, whether or not the transactions contemplated hereunder are
consummated or this Agreement is terminated in accordance with the provisions of Section&nbsp;11 hereunder, will pay all expenses incident to the performance of its obligations hereunder, including expenses relating to (i)&nbsp;the preparation,
printing and filing of the Registration Statement, the ADS Registration Statement and each amendment and supplement thereto, of the Prospectus and of each amendment and supplement thereto and of this Agreement and such other documents as may be
required in connection with the offering, purchase, sale, issuance or delivery of the Placement Shares, (ii)&nbsp;the preparation, issuance, sale and delivery of the Placement Shares and any taxes due or payable in connection therewith,
(iii)&nbsp;the qualification of the Placement Shares under securities laws in accordance with the provisions of Section&nbsp;7(w) of this Agreement, including filing fees (provided, however, that any fees or disbursements of counsel for the Agent in
connection therewith shall be paid by the Agent except as set forth in clauses (vii)&nbsp;and (viii) below), (iv) the printing and delivery to the Agent and its counsel of copies of the Prospectus and any amendments or supplements thereto, and of
this Agreement, (v)&nbsp;the fees and expenses incurred in connection with the listing or qualification of the Placement Shares for trading on Nasdaq, (vi)&nbsp;the filing fees and expenses, if any, owed to the Commission or FINRA and the fees and
expenses of any transfer agent or registrar for the Placement Shares, (vii)&nbsp;the fees and associated expenses of the Agent&#8217;s outside legal counsel for filings with the FINRA Corporate Financing Department in an amount not to exceed $15,000
(excluding FINRA filing fees referred to in clause (vi)&nbsp;above and in addition to the fees and disbursements referred to in clause (viii)&nbsp;below), and (viii)&nbsp;the reasonable fees and disbursements of the Agent&#8217;s outside legal
counsel (A)&nbsp;in an amount not to exceed $150,000 arising out of executing this Agreement and the Company&#8217;s delivery of the initial certificate and other deliverables pursuant to Section&nbsp;7(m) and (B)&nbsp;in an amount not to exceed
$25,000 in connection with each Representation Date (as defined below) on which the Company is required to provide a certificate pursuant to Section&nbsp;7(m) (in addition to the fees and associated expenses referred to in clause (vii)&nbsp;above).
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Use of Proceeds</U>. The Company will use the Net Proceeds as described in the
Prospectus in the section entitled &#8220;Use of Proceeds.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Notice of Other Sales</U>. Without the prior written consent of
the Agent, the Company will not, directly or indirectly, offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Ordinary Shares or ADSs (other than the Placement Shares offered pursuant to this Agreement) or
securities convertible into or exchangeable or exercisable for Ordinary Shares, ADSs, warrants or any rights to purchase or acquire Ordinary Shares or ADSs during the period beginning on the fifth Trading Day immediately prior to the date on which
any Placement Notice is delivered to Agent hereunder and ending on the second Trading Day immediately following the final Settlement Date with respect to Placement Shares sold pursuant to such Placement Notice (or, if the Placement Notice has been
terminated or suspended prior to the sale of all Placement Shares covered by a Placement Notice, the date of such suspension or termination); and will not directly or indirectly in any other &#8220;at the market offering&#8221; or continuous equity
transaction offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Ordinary Shares or ADSs (other than the Placement Shares offered pursuant to this Agreement) or securities convertible into or exchangeable or
exercisable for Ordinary Shares, ADSs, warrants or any rights to purchase or acquire, Ordinary Shares or ADSs prior to the later of the termination of this Agreement and the sixtieth day immediately following the final Settlement Date with respect
to Placement Shares sold pursuant to such Placement Notice; <I>provided</I>, <I>however</I>, that such restrictions will not be required in connection with the Company&#8217;s issuance or sale of (i)&nbsp;Ordinary Shares, ADSs, options to purchase
Ordinary Shares, options to purchase ADSs, other securities under the Company&#8217;s existing equity incentive plans, or Ordinary Shares or ADSs issuable upon the exercise of options or vesting of RSUs or other securities, pursuant to any employee
or director stock option or benefits plan, stock ownership plan or dividend reinvestment plan (but not Ordinary Shares or ADSs subject to a waiver to exceed plan limits in its dividend reinvestment plan) of the Company whether now in effect or
hereafter implemented, (ii)&nbsp;Ordinary Shares or ADSs issuable upon conversion of securities or the exercise of warrants, options, RSUs or other rights in effect or outstanding, and disclosed in filings by the Company available on EDGAR or
otherwise made available to the Agent, (iii)&nbsp;Ordinary Shares or ADSs or securities convertible into or exchangeable for Ordinary Shares or ADSs as consideration for mergers, acquisitions, joint ventures, collaborations, licensing agreements,
other business combinations or strategic alliances occurring after the date of this Agreement which are not issued for capital raising purposes and (iv)&nbsp;modification of any outstanding options, warrants, RSUs and/or other security interests of
any rights to purchase or acquire Ordinary Shares or ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>Change of Circumstances</U>. The Company will, at any time during a
fiscal quarter in which the Company intends to tender a Placement Notice or sell Placement Shares, advise the Agent promptly after it shall have received notice or obtained knowledge of any information or fact that would alter or affect in any
material respect any opinion, certificate, letter or other document provided or required to be provided to the Agent pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <U>Due Diligence Cooperation</U>. During the term of this Agreement, the Company will cooperate with any reasonable due diligence review
conducted by the Agent, its affiliates agents and counsel from time to time in connection with the transactions contemplated hereby, including providing information and making available documents and senior corporate officers, during regular
business hours and at the Company&#8217;s principal offices, as the Agent may reasonably and properly request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <U>Required Filings
Relating to Placement of Placement Shares</U>. The Company agrees that on or prior to such dates as the Securities Act shall require with respect to the Placement Shares, the Company will (i)&nbsp;file a prospectus supplement with the Commission
under the applicable paragraph of Rule 424(b) under the Securities Act, which prospectus supplement will set forth, within the relevant period, the number or amount of Placement Shares sold through the Agent, the Net Proceeds to the Company and the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
compensation payable by the Company to the Agent with respect to such Placement Shares, and (ii)&nbsp;deliver such number of copies of each such prospectus supplement to each exchange or market
on which such sales were effected as may be required by the rules or regulations of such exchange or market; <I>provided</I>, that, unless a prospectus supplement containing such information is required to be filed under the Securities Act, the
requirement of this Section&nbsp;7(l) may be satisfied by Company&#8217;s inclusion in the Company&#8217;s annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> or quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT>
as applicable, of the number or amount of Placement Shares sold through the Agent, the Net Proceeds to the Company and the compensation payable by the Company to the Agent with respect to such Placement Shares during the relevant period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <U>Representation Dates; Certificate</U>. On or prior to the date on which the Company first delivers a Placement Notice pursuant to this
agreement (the &#8220;<B><U>First Placement Notice Date</U></B>&#8221;) and each time the Company: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) amends or supplements the
Registration Statement, the ADS Registration Statement or the Prospectus relating to the Placement Shares (other than a prospectus supplement filed in accordance with Section&nbsp;7(l) of this Agreement or a prospectus supplement relating solely to
an offering of securities other than the Placement Shares) by means of a post-effective amendment, sticker or supplement but not by means of incorporation of document(s) by reference into the Registration Statement, the ADS Registration Statement or
the Prospectus relating to the Placement Shares; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) files an annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> under
the Exchange Act (including any Form <FONT STYLE="white-space:nowrap">10-K/A</FONT> containing amended financial information or a material amendment to the previously filed Form <FONT STYLE="white-space:nowrap">10-K);</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) files a quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> under the Exchange Act; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) files a current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> containing amended financial information (other than
information that is &#8220;furnished&#8221; pursuant to Item 2.02 or Item 7.01 of Form <FONT STYLE="white-space:nowrap">8-K)</FONT> under the Exchange Act (each date of filing of one or more of the documents referred to in clauses (i)&nbsp;through
(iv) shall be a &#8220;<B><U>Representation Date</U></B>&#8221;), </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the Company shall furnish the Agent (but in the case of clause (iv)&nbsp;above only if
(1)&nbsp;a Placement Notice is pending or in effect and (2)&nbsp;the Agent requests such certificate within three Business Days after the filing of such Form <FONT STYLE="white-space:nowrap">8-K</FONT> with the Commission) with a certificate, in the
form attached hereto as <B><U>Exhibit 7(m)</U></B><B> </B>(modified, as necessary, to relate to the Registration Statement, the ADS Registration Statement and the Prospectus as then amended or supplemented), within two Trading Days of any
Representation Date. The requirement to provide a certificate under this Section&nbsp;7(m) shall be waived for any Representation Date occurring at a time at which no Placement Notice is pending or in effect or if a suspension is in effect with
respect to any Placement Notice, which waiver shall continue until the earlier to occur of (1)&nbsp;the date the Company delivers a Placement Notice hereunder (which for such calendar quarter shall be considered a Representation Date) and
(2)&nbsp;the next occurring Representation Date. Notwithstanding the foregoing, if the Company subsequently decides to sell Placement Shares following a Representation Date on which the Company relied on the waiver referred to in the previous
sentence and did not provide the Agent with a certificate under this Section&nbsp;7(m), then before the Company delivers a Placement Notice or the Agent sells any Placement Shares pursuant thereto, the Company shall provide the Agent with a
certificate, in the form attached hereto as <B><U>Exhibit</U></B><B><U></U></B><B><U>&nbsp;7(m)</U></B>, dated the date of such Placement Notice. Within two Trading Days of each Representation Date, the Company shall have furnished to the Agent such
further information, certificates and documents as the Agent may reasonably request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <U>Legal Opinions</U>. On or prior to the First Placement Notice Date and on any date
which the Company is obligated to deliver a certificate pursuant to Section&nbsp;7(m) for which no suspension or waiver is applicable, the Company shall cause to be furnished to the Agent the written opinion and negative assurance letter of Goodwin
Procter LLP, counsel to the Company, and the written legal opinion of Goodwin Procter (UK) LLP, English counsel for the Company, or such other counsel satisfactory to the Agent (&#8220;<B><U>Company Counsel</U></B>&#8221;), in form and substance
satisfactory to the Agent and its counsel, dated the date that the opinion and negative assurance letter are required to be delivered, modified, as necessary, to relate to the Registration Statement, the ADS Registration Statement and the Prospectus
as then amended or supplemented; <I>provided</I>, <I>however</I>, that in lieu of such opinion and negative assurance letter for subsequent Representation Dates, Company Counsel may furnish the Agent with a letter to the effect that the Agent may
rely on a prior opinion or negative assurance letter delivered by such counsel under this Section&nbsp;7(n) to the same extent as if it were dated the date of such letter (except that statements in such prior opinion or negative assurance letter
shall be deemed to relate to the Registration Statement, the ADS Registration Statement and the Prospectus as amended or supplemented at such Representation Date). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <U>Intellectual Property Opinion</U>. On or prior to the First Placement Notice Date and on any date which the Company is obligated to
deliver a certificate pursuant to Section&nbsp;7(m) for which no waiver is applicable, the Company shall cause to be furnished to the Agent the written opinion of Wilson Sonsini Goodrich&nbsp;&amp; Rosati P.C., counsel for the Company with respect
to intellectual property matters, or such other intellectual property counsel reasonably satisfactory to the Agent (&#8220;<B><U>Intellectual Property Counsel</U></B>&#8221;), in form and substance reasonably satisfactory to the Agent, dated the
date that the opinion letter is required to be delivered, modified, as necessary, to relate to the Registration Statement, the ADS Registration Statement and the Prospectus as then amended or supplemented; <I>provided</I>, <I>however</I>, that in
lieu of such written opinion for subsequent Representation Dates, Intellectual Property Counsel may furnish the Agent with a letter to the effect that the Agent may rely on a prior opinion letter delivered by such counsel under this
Section&nbsp;7(o) to the same extent as if it were dated the date of such opinion letter (except that statements in such prior opinion letter shall be deemed to relate to the Registration Statement, the ADS Registration Statement and the Prospectus
as amended or supplemented at such Representation Date). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <U>Comfort Letter and CFO Certificate</U>. On or prior to the First
Placement Notice Date and on any date which the Company is obligated to deliver a certificate pursuant to Section&nbsp;7(m) for which no waiver is applicable, the Company shall cause its independent registered public accounting firm (and any other
independent accountants whose report is included in the Registration Statement, the ADS Registration Statement or the Prospectus) to furnish the Agent letters (the &#8220;<B><U>Comfort Letters</U></B>&#8221;), dated the date the Comfort Letter is
delivered, which shall meet the requirements set forth in this Section&nbsp;7(p); <I>provided</I>, that if requested by the Agent, the Company shall cause a Comfort Letter to be furnished to the Agent within 10 Trading Days of the occurrence of any
material transaction or event that necessitates the filing of additional, pro forma, amended or revised financial statements (including any restatement of previously issued financial statements). Each Comfort Letter shall be in form and substance
reasonably satisfactory to the Agent and each Comfort Letter from the Company&#8217;s independent registered public accounting firm shall (i)&nbsp;confirm that they are an independent registered public accounting firm within the meaning of the
Securities Act and the PCAOB, (ii)&nbsp;state, as of such date, the conclusions and findings of such firm with respect to the financial information and other matters ordinarily covered by accountants&#8217; &#8220;comfort letters&#8221; to
underwriters in connection with registered public offerings (the first such letter, the &#8220;<B><U>Initial Comfort Letter</U></B>&#8221;) and (iii)&nbsp;update the Initial Comfort Letter with any information that would have been included in the
Initial Comfort Letter had it been given on such date and modified as necessary to relate to the Registration Statement, the ADS Registration Statement and the Prospectus, as amended and supplemented to the date of such letter. In addition, in
certain cases, the Agent may request a certificate of the Chief Financial Officer of the Company with respect to certain financial data providing &#8220;management comfort&#8221; with respect to such information, in form and substance reasonably
satisfactory to the Agent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <U>Market Activities</U>. The Company will not, directly or indirectly, and will cause
its officers, directors and subsidiaries not to (i)&nbsp;take any action designed to cause or result in, or that constitutes or might reasonably be expected to constitute, the stabilization or manipulation of the price of any security of the Company
to facilitate the sale or resale of Ordinary Shares or (ii)&nbsp;sell, bid for, or purchase Ordinary Shares in violation of Regulation M, or pay anyone any compensation for soliciting purchases of the Placement Shares other than the Agent;
<I>provided</I>, <I>however</I>, that the Company may bid for and purchase Ordinary Shares in accordance with Rule <FONT STYLE="white-space:nowrap">10b-18</FONT> under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <U>Insurance</U>. The Company and its subsidiaries shall maintain, or cause to be maintained, insurance in such amounts and covering such
risks as is reasonable and customary for the business for which it is engaged. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) <U>Compliance with Laws</U>. The Company and each of
its subsidiaries shall maintain, or cause to be maintained, all material environmental certificates, authorizations or permits required by federal, state and local law in order to conduct their businesses as described in the Prospectus
(collectively, &#8220;<B>Permits</B>&#8221;), and the Company and each of its subsidiaries shall conduct their businesses, or cause their businesses to be conducted, in substantial compliance with such Permits and with applicable Environmental Laws,
except where the failure to maintain or be in compliance with such Permits could not reasonably be expected to result in a material adverse effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <U>Investment Company Act</U>. The Company will conduct its affairs in such a manner so as to reasonably ensure that neither it nor any of
its subsidiaries will be or become, at any time prior to the termination of this Agreement, an &#8220;investment company,&#8221; as such term is defined in the Investment Company Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) <U>Securities Act and Exchange Act</U>. The Company will use its best efforts to comply with all requirements imposed upon it by the
Securities Act and the Exchange Act as from time to time in force, so far as necessary to permit the sales of, or dealings in, the Placement Shares as contemplated by the provisions hereof and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <U>No Offer to Sell</U>. Other than a free writing prospectus (as defined in Rule 405 under the Securities Act) approved in advance by the
Company and the Agent in its capacity as agent hereunder (such approval by the Agent not to be unreasonably conditioned, delayed or withheld), neither the Agent nor the Company (including its agents and representatives, other than the Agent in its
capacity as agent) will make, use, prepare, authorize, approve or refer to any written communication (as defined in Rule 405 under the Securities Act), required to be filed with the Commission, that constitutes an offer to sell or solicitation of an
offer to buy Placement Shares hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) <U>Blue Sky and Other Qualifications</U>. The Company will use its commercially reasonable
efforts, in cooperation with the Agent, to qualify the Placement Shares for offering and sale, or to obtain an exemption for the Placement Shares to be offered and sold, under the applicable securities laws of such states and other jurisdictions
(domestic or foreign) as the Agent may designate and to maintain such qualifications and exemptions in effect for so long as required for the distribution of the Placement Shares (but in no event for less than one year from the date of this
Agreement); <I>provided, however</I>, that the Company shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified
or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject. In each jurisdiction in which the Placement Shares have been so qualified or exempt, the Company will file such statements and
reports as may be required by the laws of such jurisdiction to continue such qualification or exemption, as the case may be, in effect for so long as required for the distribution of the Placement Shares (but in no event for less than one year from
the date of this Agreement). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) <U>Sarbanes-Oxley Act</U>. The Company will maintain and keep accurate books and records
reflecting its assets and maintain internal accounting controls in a manner designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with GAAP and including those policies and procedures that (i)&nbsp;pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company, (ii)&nbsp;provide
reasonable assurance that transactions are recorded as necessary to permit the preparation of the Company&#8217;s financial statements in accordance with GAAP, (iii)&nbsp;that receipts and expenditures of the Company are being made only in
accordance with management&#8217;s and the Company&#8217;s directors&#8217; authorization, and (iv)&nbsp;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&#8217;s
assets that could have a material effect on its financial statements. The Company will maintain such controls and other procedures, including, without limitation, those required by Sections 302 and 906 of the Sarbanes-Oxley Act, and the applicable
regulations thereunder that are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods
specified in the Commission&#8217;s rules and forms, including, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is
accumulated and communicated to the Company&#8217;s management, including its principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required
disclosure and to ensure that material information relating to the Company is made known to it by others within the Company, particularly during the period in which such periodic reports are being prepared. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) <U>Emerging Growth Company</U>. The Company will promptly notify the Agent if the company ceases to be an Emerging Growth Company at any
time prior to the completion of the Agent&#8217;s distribution of the Placement Shares pursuant to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) <U>Renewal of
Registration Statement.</U> If, immediately prior to the third anniversary of the initial effective date of the Registration Statement (the &#8220;<B><U>Renewal Date</U></B>&#8221;), any of the Placement Shares remain unsold and this Agreement has
not been terminated, the Company may (but without obligation to do so), at its sole discretion, prior to the Renewal Date, file a new shelf registration statement or, if applicable, an automatic shelf registration statement relating to the Ordinary
Shares that may be offered and sold pursuant to this Agreement (which shall include a prospectus reflecting the number or amount of Placement Shares that may be offered and sold pursuant to this Agreement), in a form reasonably satisfactory to the
Agent and its counsel, and, if such registration statement is not an automatic shelf registration statement, will use its commercially reasonable efforts to cause such registration statement to be declared effective within 180 days after the Renewal
Date. The Company will take all other reasonable actions necessary or appropriate to permit the public offer and sale of the Placement Shares to continue as contemplated in the expired registration statement and this Agreement. From and after the
effective date thereof, references herein to the &#8220;Registration Statement&#8221; shall include such new shelf registration statement or such new automatic shelf registration statement, as the case may be. For the avoidance of doubt, the Company
may, at its sole discretion, file a new shelf registration statement but shall not be obligated to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) <U>General Instruction
I.B.6. of Form <FONT STYLE="white-space:nowrap">S-3</FONT></U>. If, from and after the date of this Agreement, the Company is no longer eligible to use Form <FONT STYLE="white-space:nowrap">S-3</FONT> (including pursuant to General Instruction
I.B.6.) at the time it files with the Commission an annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> or any post-effective amendment to the Registration Statement, then it shall promptly notify the Agent and, within two Business
Days after the date of filing of such annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> or amendment to the Registration Statement, the Company shall file a new prospectus supplement with the Commission reflecting the number of
Ordinary Shares available to be offered and sold by the Company under this Agreement pursuant to General Instruction I.B.6. of Form <FONT STYLE="white-space:nowrap">S-3;</FONT> <I>provided</I>, <I>however</I>, that the Company may delay the filing
of any such prospectus supplement, provided that no Placement Notice is in effect or pending during such time, and until such time as the Company intends to resume sales of the Placement Shares. Until such time as the Company shall have corrected
such misstatement or omission or effected such compliance, the Company shall not notify the Agent to resume the offering of Placement Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) <U>Tax Indemnity</U>. The Company shall pay, and shall indemnify and hold the Agent
harmless against, any stamp, issuance, registration, documentary, transfer or other similar taxes or duties (including any United Kingdom stamp duty or stamp duty reserve tax), and any interest and penalties, that is payable in connection with
(i)&nbsp;the execution or delivery of this Agreement or the Deposit Agreement, (ii)&nbsp;the creation, allotment, issuance and delivery of the Ordinary Shares by the Company to the Depositary and the allotment, issuance and delivery of the ADSs (and
any corresponding ADRs evidencing such ADSs), in each case, in the manner contemplated by this Agreement or the Deposit Agreement, (iii)&nbsp;the sale and delivery of the ADSs (and any corresponding ADRs evidencing such ADSs) to the Agent in the
manner contemplated by this Agreement, or (iv)&nbsp;the initial sale and delivery of the ADSs (and any corresponding ADRs evidencing such ADSs) by the Agent in the manner contemplated herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) <U>Transfer Agent</U>. The Company has engaged and will maintain, at its sole expense, a transfer agent and registrar for the Ordinary
Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) <U>Value Added Tax</U>. All sums payable to the Agent shall be considered exclusive of any value added tax chargeable
pursuant to the Value Added Tax Act 1994, or any equivalent value added or sales tax whether imposed in the United Kingdom (instead of or in addition to value added tax) or elsewhere from time to time (&#8220;<B><U>VAT</U></B>&#8221;). Where the
Company is obliged to pay VAT on any amount payable hereunder to the Agent, the Company shall in addition to the sum payable hereunder pay an amount equal to any applicable VAT subject to receipt of a valid VAT invoice (or equivalent documentation
in any jurisdiction other than the United Kingdom (to the extent required)) from the Agent. Where the Company is required by the terms of this Agreement to reimburse or indemnify the Agent for any cost or expense related to or arising out of VAT,
the Company shall reimburse or indemnify the Agent for such cost or expense, save to the extent that the Agent (or any member of the Agent&#8217;s group for VAT purposes) is entitled to credit or repayment in respect of such VAT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) <U>Deductions and Withholdings</U>. All sums payable by the Company under this Agreement shall be paid free and clear of and without
deductions or withholdings of any present or future taxes or duties, unless the deduction or withholding is required by law, in which case the Company shall pay such additional amount so that after such deduction or withholding has been made
(including such deductions and withholdings applicable to additional amounts payable under this clause) the Agent receives the full amount that would have been received had no deduction or withholding been made, other than to the extent that any
deductions or withholdings of any present or future taxes or duties are imposed by a jurisdiction as a result of any present or former connection (other than any connection resulting from the transactions contemplated by this Agreement) between the
Agent and such jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Conditions to the Agent&#8217;s Obligations</U>. The obligations of the Agent hereunder with respect
to a Placement will be subject to the continuing accuracy and completeness of the representations and warranties made by the Company herein, to the due performance by the Company of its obligations hereunder, to the completion by the Agent of a due
diligence review satisfactory to the Agent in its reasonable judgment, and to the continuing satisfaction (or waiver by the Agent in its sole discretion) of the following additional conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Registration Statement Effective</U>. The Registration Statement and the ADS Registration Statement shall be effective and shall be
available for all offers and sales of Placement Shares (i)&nbsp;that have been issued pursuant to all prior Placement Notices and (ii)&nbsp;that will be issued pursuant to any Placement Notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Prospectus Supplement</U>. The Company shall have filed with the Commission the
Prospectus Supplement pursuant to Rule 424(b) under the Securities Act not later than the Commission&#8217;s close of business on the second Business Day following the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>No Material Notices</U>. None of the following events shall have occurred and be continuing: (i)&nbsp;receipt by the Company or any of
its subsidiaries of any request for additional information from the Commission or any other federal or state governmental authority during the period of effectiveness of the Registration Statement and the ADS Registration Statement, the response to
which would require any post-effective amendments or supplements to the Registration Statement, the ADS Registration Statement or the Prospectus; (ii)&nbsp;the issuance by the Commission or any other federal or state governmental authority of any
stop order suspending the effectiveness of the Registration Statement, the ADS Registration Statement or the initiation of any proceedings for that purpose; (iii)&nbsp;receipt by the Company or any of its subsidiaries of any notification with
respect to the suspension of the qualification or exemption from qualification of any of the Placement Shares for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; or (iv)&nbsp;the occurrence of any event
that makes any material statement made in the Registration Statement, the ADS Registration Statement or the Prospectus or any material Incorporated Document untrue in any material respect or that requires the making of any changes in the
Registration Statement, the ADS Registration Statement, the Prospectus or Incorporated Documents so that, in the case of the Registration Statement and the ADS Registration Statement, it will not contain any untrue statement of a material fact or
omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading and, in the case of the Prospectus, so that it will not contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>No Misstatement or Material Omission</U>. The Agent shall not have advised the Company that the Registration Statement, the ADS
Registration Statement or Prospectus, or any amendment or supplement thereto, contains an untrue statement of fact that in the Agent&#8217;s opinion is material, or omits to state a fact that in the Agent&#8217;s opinion is material and is required
to be stated therein or is necessary to make the statements therein not misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Material Changes</U>. Except as contemplated
in the Prospectus, or disclosed in the Company&#8217;s reports filed with the Commission, there shall not have been any Material Adverse Change, on a consolidated basis, in the issued share capital of the Company or any Material Adverse Change or
any development that could reasonably be expected to result in a Material Adverse Change, or any downgrading in or withdrawal of the rating assigned to any of the Company&#8217;s securities (other than asset backed securities), if any, by any rating
organization or a public announcement by any rating organization that it has under surveillance or review its rating of any of the Company&#8217;s securities (other than asset backed securities), if any, the effect of which, in the judgment of the
Agent (without relieving the Company of any obligation or liability it may otherwise have), is so material as to make it impracticable or inadvisable to proceed with the offering of the Placement Shares on the terms and in the manner contemplated in
the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Company Counsel Legal Opinions</U>. The Agent shall have received the opinions and negative assurance letters, as
applicable, of Company Counsel and Intellectual Property Counsel required to be delivered pursuant to Section&nbsp;7(n) and Section&nbsp;7(o), as applicable, on or before the date on which such delivery of such opinions and negative assurance
letters are required pursuant to Section&nbsp;7(n) and Section&nbsp;7(o), as applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Agent&#8217;s Counsel Legal Opinion</U>. The Agent shall have received from Cooley
LLP, counsel for the Agent, such opinion or opinions, on or before the date on which the delivery of the Company Counsel legal opinion is required pursuant to Section&nbsp;7(n), with respect to such matters as the Agent may reasonably require, and
the Company shall have furnished to such counsel such documents as they may request to enable them to pass upon such matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)
<U>Comfort Letter and CFO Certificate</U>. The Agent shall have received the Comfort Letter required to be delivered pursuant to Section&nbsp;7(p) on or before the date on which such delivery of such Comfort Letter is required pursuant to
Section&nbsp;7(p). The Agent also shall have received the certificate of the Chief Financial Officer on or before the date on which such delivery of such certificate is required pursuant to Section&nbsp;7(p) if so requested by the Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Representation Certificate</U>. The Agent shall have received the certificate required to be delivered pursuant to Section&nbsp;7(m) on
or before the date on which delivery of such certificate is required pursuant to Section&nbsp;7(m). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>Secretary&#8217;s
Certificate</U>. On or prior to the First Placement Notice Date, the Agent shall have received a certificate, signed on behalf of the Company by the Secretary of the Company and attested to by an executive officer of the Company, dated as of such
date and in form and substance reasonably satisfactory to the Agent and its counsel, certifying as to (i)&nbsp;the amended and restated certificate of incorporation of the Company, (ii)&nbsp;the amended and restated bylaws of the Company,
(iii)&nbsp;the resolutions of the board of directors of the Company or duly authorized committee thereof authorizing the execution, delivery and performance of this Agreement and the issuance and sale of the Placement Shares and (iv)&nbsp;the
incumbency of the officers of the Company duly authorized to execute this Agreement and the other documents contemplated by this Agreement (including each of the officers set forth on <B><U>Schedule 2</U></B>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <U>No Suspension</U>. The ADSs shall be duly listed, and admitted and authorized for trading, subject to official notice of issuance, on
Nasdaq. Trading in the ADSs shall not have been suspended on, and the ADSs shall not have been delisted from, Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <U>Other
Materials</U>. On each date on which the Company is required to deliver a certificate pursuant to Section&nbsp;7(m), the Company shall have furnished to the Agent such appropriate further information, opinions, certificates, letters and other
documents as the Agent may have reasonably requested in its capacity as agent hereunder (such approval by the Agent not to be unreasonably conditioned, delayed or withheld). All such information, opinions, certificates, letters and other documents
shall have been in compliance with the provisions hereof. The Company shall have furnished the Agent with conformed copies of such opinions, certificates, letters and other documents as the Agent may have reasonably requested. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <U>Securities Act Filings Made</U>. All filings with the Commission required by Rule 424(b) or Rule 433 under the Securities Act to have
been filed prior to the issuance of any Placement Notice hereunder shall have been made within the applicable time period prescribed for such filing by Rule 424(b) (without reliance on Rule 424(b)(8) of the Securities Act) or Rule 433, as
applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <U>Approval for Listing</U>. Either (i)&nbsp;the Placement Shares shall have been approved for listing on Nasdaq, subject
only to notice of issuance, or (ii)&nbsp;the Company shall have filed an application for listing of the Placement Shares on Nasdaq at, or prior to, the First Placement Notice Date and Nasdaq shall have reviewed such application and not provided any
objections thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <U>FINRA</U>. FINRA shall have raised no objection to the terms of the offering contemplated hereby and the
amount of compensation allowable or payable to the Agent as described in the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <U>No Termination Event</U>. There shall not have occurred any event that would permit
the Agent to terminate this Agreement pursuant to Section&nbsp;11(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <U>Depositary&#8217;s Counsel Opinion</U>. The Agent shall have
received an opinion of Patterson Belknap Webb&nbsp;&amp; Tyler LLP, counsel for the Depositary, in form and substance reasonably satisfactory to counsel for the Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) <U>Approval for Listing</U>. On each relevant Settlement Date, the ADSs shall be approved for listing, and not subject to any notice of
delisting, on Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Indemnification and Contribution</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Company Indemnification</U>. The Company agrees to indemnify and hold harmless the Agent, its affiliates and their respective partners,
members, directors, officers, employees and agents, and each person, if any, who (i)&nbsp;controls the Agent within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act or (ii)&nbsp;is controlled by or is under
common control with the Agent, in each case from and against any and all losses, claims, liabilities, expenses and damages (including any and all investigative, legal and other expenses reasonably incurred in connection with, and any and all amounts
paid in settlement (in accordance with this Section&nbsp;9), any action, suit, investigation or proceeding between any of the indemnified parties and any indemnifying parties or between any indemnified party and any third party (including any
governmental or self-regulatory authority, or otherwise, or any claim asserted or threatened), as and when incurred, to which the Agent, or any such other person may become subject under the Securities Act, the Exchange Act or other federal or state
statutory law or regulation, at common law or otherwise, insofar as such losses, claims, liabilities, expenses or damages arise out of or are based, directly or indirectly, on (x)&nbsp;any untrue statement or alleged untrue statement of a material
fact contained in the Registration Statement, the ADS Registration Statement or the Prospectus (or any amendment or supplement to the Registration Statement, the ADS Registration Statement or the Prospectus) or in any free writing prospectus or in
any application or other document executed by or on behalf of the Company or based on written information furnished by or on behalf of the Company filed in any jurisdiction in order to qualify the Ordinary Shares under the securities laws thereof or
filed with the Commission, (y)&nbsp;the omission or alleged omission to state in any such document a material fact required to be stated therein or necessary to make the statements therein (solely with respect to the Prospectus, in light of the
circumstances under which they were made) not misleading or (z)&nbsp;any breach by any of the indemnifying parties of any of their respective representations, warranties or agreements contained in this Agreement; <I>provided</I>, <I>however</I>,
that this indemnity agreement shall not apply to the extent that such loss, claim, liability, expense or damage arises from the sale of the Placement Shares pursuant to this Agreement and is caused, directly or indirectly, by an untrue statement or
omission, or alleged untrue statement or omission, made in reliance upon and in conformity with the Agent&#8217;s Information. This indemnity agreement will be in addition to any liability that the Company might otherwise have. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Agent Indemnification</U>. The Agent agrees to indemnify and hold harmless the Company and its directors and each officer of the
Company who signed the Registration Statement, and each person, if any, who (i)&nbsp;controls the Company within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act or (ii)&nbsp;is controlled by or is under
common control with the Company against any and all loss, liability, claim, damage and expense described in the indemnity contained in Section&nbsp;9(a), as incurred, but only with respect to untrue statements or omissions, or alleged untrue
statements or omissions, made in the Registration Statement (or any amendments thereto) or the Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with the Agent&#8217;s Information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Procedure</U>. Any party that proposes to assert the right to be indemnified under
this Section&nbsp;9 will, promptly after receipt of notice of commencement of any action against such party in respect of which a claim is to be made against an indemnifying party or parties under this Section&nbsp;9, notify each such indemnifying
party of the commencement of such action, enclosing a copy of all papers served, but the omission so to notify such indemnifying party will not relieve the indemnifying party from (i)&nbsp;any liability that it might have to any indemnified party
otherwise than under this Section&nbsp;9 and (ii)&nbsp;any liability that it may have to any indemnified party under the foregoing provision of this Section&nbsp;9 unless, and only to the extent that, such omission results in the forfeiture of
substantive rights or defenses by the indemnifying party. If any such action is brought against any indemnified party and it notifies the indemnifying party of its commencement, the indemnifying party will be entitled to participate in and, to the
extent that it elects by delivering written notice to the indemnified party promptly after receiving notice of the commencement of the action from the indemnified party, jointly with any other indemnifying party similarly notified, to assume the
defense of the action, with counsel reasonably satisfactory to the indemnified party, and after notice from the indemnifying party to the indemnified party of its election to assume the defense, the indemnifying party will not be liable to the
indemnified party for any other legal expenses except as provided below and except for the reasonable costs of investigation subsequently incurred by the indemnified party in connection with the defense. The indemnified party will have the right to
employ its own counsel in any such action, but the fees, expenses and other charges of such counsel will be at the expense of such indemnified party unless (1)&nbsp;the employment of counsel by the indemnified party has been authorized in writing by
the indemnifying party, (2)&nbsp;the indemnified party has reasonably concluded (based on advice of counsel) that there may be legal defenses available to it or other indemnified parties that are different from or in addition to those available to
the indemnifying party, (3)&nbsp;a conflict or potential conflict exists (based on advice of counsel to the indemnified party) between the indemnified party and the indemnifying party (in which case the indemnifying party will not have the right to
direct the defense of such action on behalf of the indemnified party) or (4)&nbsp;the indemnifying party has not in fact employed counsel reasonably satisfactory to the indemnified party to assume the defense of such action within a reasonable time
after receiving notice of the commencement of the action, in each of which cases the reasonable and documented fees, disbursements and other charges of counsel will be at the expense of the indemnifying party or parties. It is understood that the
indemnifying party or parties shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the reasonable and documented fees, disbursements and other charges of more than one separate firm (plus local
counsel) admitted to practice in such jurisdiction at any one time for all such indemnified party or parties. All such documented fees, disbursements and other charges will be reimbursed by the indemnifying party promptly after the indemnifying
party receives a written invoice relating to such documented fees, disbursements and other charges in reasonable detail. An indemnifying party will not, in any event, be liable for any settlement of any action or claim effected without its written
consent. No indemnifying party shall, without the prior written consent of each indemnified party, settle or compromise or consent to the entry of any judgment in any pending or threatened claim, action or proceeding relating to the matters
contemplated by this Section&nbsp;9 (whether or not any indemnified party is a party thereto), unless such settlement, compromise or consent (1)&nbsp;includes an unconditional release of each indemnified party, in form and substance reasonably
satisfactory to such indemnified party, from all liability arising out of such claim, action or proceeding and (2)&nbsp;does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified
party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Settlement Without Consent if Failure to Reimburse</U><I>. </I>If an indemnified party shall have requested an indemnifying
party to reimburse the indemnified party for reasonable fees and expenses of counsel for which it is entitled to be reimbursed under this Section&nbsp;9, such indemnifying party agrees that it shall be liable for any settlement of the nature
contemplated by Section&nbsp;9(a) effected without its written consent if (i)&nbsp;such settlement is entered into more than 45 days after receipt by such indemnifying party of the aforesaid request, (ii)&nbsp;such indemnifying party shall have
received notice of the terms of such settlement at least 30 days prior to such settlement being entered into and (iii)&nbsp;such indemnifying party shall not have reimbursed such indemnified party in accordance with such request prior to the date of
such settlement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Contribution</U>. In order to provide for just and equitable contribution in
circumstances in which the indemnification provided for in the foregoing paragraphs of this Section&nbsp;9 is applicable in accordance with its terms but for any reason is held to be unavailable or insufficient from the Company or the Agent, the
Company and the Agent will contribute to the total losses, claims, liabilities, expenses and damages (including any documented investigative, legal and other expenses reasonably incurred in connection with, and any amount paid in settlement of, any
action, suit, investigation or proceeding or any claim asserted, but after deducting any contribution received by the Company from persons other than the Agent, such as persons who control the Company within the meaning of the Securities Act,
officers of the Company who signed the Registration Statement and directors of the Company, who also may be liable for contribution) to which the Company and the Agent may be subject in such proportion as shall be appropriate to reflect the relative
benefits received by the Company on the one hand and the Agent on the other hand. The relative benefits received by the Company on the one hand and the Agent on the other hand shall be deemed to be in the same proportion as the total Net Proceeds
from the sale of the Placement Shares (before deducting expenses) received by the Company bear to the total compensation received by the Agent from the sale of Placement Shares on behalf of the Company. If, but only if, the allocation provided by
the foregoing sentence is not permitted by applicable law, the allocation of contribution shall be made in such proportion as is appropriate to reflect not only the relative benefits referred to in the foregoing sentence but also the relative fault
of the Company, on the one hand, and the Agent, on the other hand, with respect to the statements or omission that resulted in such loss, claim, liability, expense or damage, or action, suit, investigation or proceeding in respect thereof, as well
as any other relevant equitable considerations with respect to such offering. Such relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or omission or alleged
omission to state a material fact relates to information supplied by the Company or the Agent, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such statement or omission. The
Company and the Agent agree that it would not be just and equitable if contributions pursuant to this Section&nbsp;9(e) were to be determined by<I> pro rata</I> allocation or by any other method of allocation that does not take into account the
equitable considerations referred to herein. The amount paid or payable by an indemnified party as a result of the loss, claim, liability, expense or damage, or action, suit, investigation or proceeding in respect thereof, referred to above in this
Section&nbsp;9(e) shall be deemed to include, for the purpose of this Section&nbsp;9(e), any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action, suit, investigation,
proceeding or claim to the extent consistent with this Section&nbsp;9. Notwithstanding the foregoing provisions of this Section&nbsp;9(e), the Agent shall not be required to contribute any amount in excess of the commissions received by it under
this Agreement and no person found guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) will be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. For
purposes of this Section&nbsp;9(e), any person who controls a party to this Agreement within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act, any affiliates of the Agent, any partners, members, directors,
officers, employees and agents of the Agent and each person that is controlled by or under common control with the Agent will have the same rights to contribution as that party, and each director of the Company and each officer of the Company who
signed the Registration Statement will have the same rights to contribution as the Company, subject in each case to the provisions hereof. Any party entitled to contribution, promptly after receipt of notice of commencement of any action against
such party in respect of which a claim for contribution may be made under this Section&nbsp;9(e), will notify any such party or parties from whom contribution may be sought, but the omission to so notify will not relieve that party or parties from
whom contribution may be sought from any other obligation it or they may have under this Section&nbsp;9(e) except to the extent that the failure to so notify such other party materially prejudiced the substantive rights or defenses of the party from
whom contribution is sought. Except for a settlement entered into pursuant to the last sentence of Section&nbsp;9(c) hereof or pursuant to Section&nbsp;9(d) hereof, no party will be liable for contribution with respect to any action or claim settled
without its written consent if such consent is required pursuant to Section&nbsp;9(c) hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Representations and Agreements to Survive Delivery</U>. The indemnity and
contribution agreements contained in Section&nbsp;9 of this Agreement and all representations and warranties of the Company herein or in certificates delivered pursuant hereto shall survive, as of their respective dates, regardless of (i)&nbsp;any
investigation made by or on behalf of the Agent, any controlling persons, or the Company (or any of their respective officers, directors, employees or controlling persons), (ii) delivery and acceptance of the Placement Shares and payment therefor or
(iii)&nbsp;any termination of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Termination</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Agent shall have the right, by giving notice as hereinafter specified, at any time to terminate this Agreement if (i)&nbsp;any
Material Adverse Change, or any development that could reasonably be expected to result in a Material Adverse Change, has occurred that, in the judgment of the Agent, may materially impair the ability of the Agent to sell the Placement Shares
hereunder, (ii)&nbsp;the Company shall have failed, refused or been unable to perform any material agreement on its part to be performed hereunder; <I>provided</I>, <I>however</I>, in the case of any failure of the Company to deliver (or cause
another person to deliver) any certification, opinion or letter required under Section&nbsp;7(m), Section&nbsp;7(n), Section&nbsp;7(o) or Section&nbsp;7(p), the Agent&#8217;s right to terminate shall not arise unless such failure to deliver (or
cause to be delivered) continues for more than 15 calendar days from the date such delivery was required, (iii)&nbsp;any other condition of the Agent&#8217;s obligations hereunder is not fulfilled due to the actions or inactions of the Company,
(iv)&nbsp;any suspension or limitation of trading in the ADSs or in securities generally on Nasdaq shall have occurred, (v)&nbsp;a general banking moratorium shall have been declared by any of United States federal or New York authorities or United
Kingdom authorities, or (vi)&nbsp;there shall have occurred any outbreak or escalation of national or international hostilities or any crisis or calamity, or any change in the United States or the United Kingdom or international financial markets,
or any substantial change or development involving a prospective substantial change in United States or international political, financial or economic conditions that, in the judgment of the Agent, may materially impair the ability of the Agent to
sell the Placement Shares hereunder or to enforce contracts for the sale of securities. Any such termination shall be without liability of any party to any other party except that the provisions of Section&nbsp;7(g), Section&nbsp;9, Section&nbsp;10,
Section&nbsp;16 and Section&nbsp;17 hereof shall remain in full force and effect notwithstanding such termination. If the Agent elects to terminate this Agreement as provided in this Section&nbsp;11(a), the Agent shall provide the required notice as
specified in Section&nbsp;12. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company shall have the right, by giving 10 days&#8217; prior notice as hereinafter specified, to
terminate this Agreement in its sole discretion at any time after the date of this Agreement. Any such termination shall be without liability of any party to any other party except that the provisions of Section&nbsp;7(g), Section&nbsp;9,
Section&nbsp;10, Section&nbsp;11(f), Section&nbsp;16 and Section&nbsp;17 hereof shall remain in full force and effect notwithstanding such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Agent shall have the right, by giving 10 days&#8217; prior notice as hereinafter specified, to terminate this Agreement in its sole
discretion at any time after the date of this Agreement. Any such termination shall be without liability of any party to any other party except that the provisions of Section&nbsp;7(g), Section&nbsp;9, Section&nbsp;10, Section&nbsp;11(f),
Section&nbsp;16 and Section&nbsp;17 hereof shall remain in full force and effect notwithstanding such termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Unless earlier
terminated pursuant to this Section&nbsp;11, this Agreement shall automatically terminate upon the earlier to occur of (i)&nbsp;the Renewal Date, or (ii)&nbsp;the issuance and sale of all of the Placement Shares through the Agent on the terms and
subject to the conditions set forth herein; <I>provided</I> that the provisions of Section&nbsp;7(g), Section&nbsp;9, Section&nbsp;10, Section&nbsp;11(f), Section&nbsp;16 and Section&nbsp;17 hereof shall remain in full force and effect
notwithstanding such termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) This Agreement shall remain in full force and effect unless terminated pursuant to
Sections 11(a), (b), (c), or (d)&nbsp;above or otherwise by mutual agreement of the parties; <I>provided</I>, <I>however</I>, that any such termination by mutual agreement shall in all cases be deemed to provide that Section&nbsp;7(g),
Section&nbsp;9, Section&nbsp;10, Section&nbsp;11(f), Section&nbsp;16 and Section&nbsp;17 shall remain in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Any
termination of this Agreement shall be effective on the date specified in such notice of termination; <I>provided, however</I>, that such termination shall not be effective until the close of business on the date of receipt of such notice by the
Agent or the Company, as the case may be. If such termination shall occur prior to the Settlement Date for any sale of Placement Shares, such Placement Shares shall settle in accordance with the provisions of this Agreement. Upon termination of this
Agreement, the Company shall not be required to pay to the Agent any discount or commission with respect to any Placement Shares not otherwise sold by the Agent under this Agreement; <I>provided</I>, <I>however</I>, that the Company shall remain
obligated to reimburse the Agent&#8217;s expenses pursuant to Section&nbsp;7(g). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Notices</U>. All notices or other communications
required or permitted to be given by any party to any other party pursuant to the terms of this Agreement shall be in writing, unless otherwise specified in this Agreement, and if sent to the Agent, shall be delivered to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1301
Avenue of the Americas, 5<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New York, New York 10019 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention: Peter M. Fry </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">E-mail:</FONT> peter.fry@leerink.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1301
Avenue of the Americas, 5<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New York, New York 10019 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention: Stuart R. Nayman, Esq. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> stuart.nayman@leerink.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">And </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cooley LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">55 Hudson Yards 10001 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention:
Daniel I. Goldberg, Esq. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> dgoldberg@cooley.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and if to the Company, shall be delivered to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Centessa Pharmaceuticals Plc </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1
Ashley Road, 3<SUP STYLE="font-size:75%; vertical-align:top">rd</SUP> Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Altrincham, Cheshire </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">United Kingdom, WA14 2DT </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention: Iqbal Hussain </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">E-mail:</FONT> iqbal.hussain@centessa.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">with copies (which shall not constitute notice) to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Goodwin Procter LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">100
Northern Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts 02210 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention: Mitchell S. Bloom, Esq. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> mbloom@goodwinlaw.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each party to this Agreement may change such address for notices by sending to the parties to this Agreement written notice of a new address for such purpose.
Each such notice or other communication shall be deemed given (i)&nbsp;when delivered personally on or before 4:30 P.M., New York City time, on a Business Day, or, if such day is not a Business Day, on the next succeeding Business Day, (ii)&nbsp;by
Electronic Notice as set forth in the next paragraph, (iii)&nbsp;on the next Business Day after timely delivery to a nationally-recognized overnight courier or (iv)&nbsp;on the Business Day actually received if deposited in the U.S. mail (certified
or registered mail, return receipt requested, postage prepaid). For purposes of this Agreement, &#8220;<B><U>Business Day</U></B>&#8221; shall mean any day on which the Nasdaq and commercial banks in the City of New York are open for business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An electronic communication (&#8220;<B><U>Electronic Notice</U></B>&#8221;) shall be deemed written notice for purposes of this Section&nbsp;12 if sent to the
electronic mail address specified by the receiving party in Section&nbsp;12. Electronic Notice shall be deemed received at the time the party sending Electronic Notice receives actual acknowledgment of receipt from the person whom the notice is
sent, other than via auto-reply. Any party receiving Electronic Notice may request and shall be entitled to receive the notice on paper, in a nonelectronic form (&#8220;<B><U>Nonelectronic Notice</U></B>&#8221;), which shall be sent to the
requesting party within 10 days of receipt of the written request for Nonelectronic Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Successors and Assigns</U>. This
Agreement shall inure to the benefit of and be binding upon the Company and the Agent and their respective successors and the affiliates, controlling persons, officers, directors and other persons referred to in Section&nbsp;9 hereof. References to
any of the parties contained in this Agreement shall be deemed to include the successors and permitted assigns of each such party. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto, the
persons referred to in the preceding sentence and their respective successors and permitted assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. Neither party
may assign its rights or obligations under this Agreement without the prior written consent of the other party; <I>provided, however</I>, that the Agent may assign its rights and obligations hereunder to an affiliate of the Agent without obtaining
the Company&#8217;s consent, so long as such affiliate is a registered broker-dealer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Adjustments for Share Splits (etc.)</U>. The
parties acknowledge and agree that all share-related numbers contained in this Agreement shall be adjusted to take into account any share split <FONT STYLE="white-space:nowrap">(sub-division),</FONT> share consolidation share dividend or similar
event effected with respect to the Ordinary Shares or a change in ratio of Ordinary Share to ADS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Entire Agreement; Amendment;
Severability; Waiver</U>. This Agreement (including all schedules (as amended pursuant to this Agreement) and exhibits attached hereto and Placement Notices issued pursuant hereto) constitutes the entire agreement and supersedes all other prior and
contemporaneous agreements and undertakings, both written and oral, among the parties hereto with regard to the subject matter hereof, including but not limited to the Original Sales Agreement. Neither this Agreement nor any term hereof may be
amended except pursuant to a written instrument executed by the Company and the Agent; <I>provided</I>, <I>however</I>, that <B><U>Schedule 2</U></B> of this Agreement may be amended by either party from time
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to time by sending a notice containing a revised <B><U>Schedule 2</U></B> to the other party in the manner provided in Section&nbsp;12 and, upon such amendment, all references herein to
<B><U>Schedule 2</U></B> shall automatically be deemed to refer to such amended <B><U>Schedule 2</U></B>. In the event that any one or more of the provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal
or unenforceable as written by a court of competent jurisdiction, then such provision shall be given full force and effect to the fullest possible extent that it is valid, legal and enforceable, and the remainder of the terms and provisions herein
shall be construed as if such invalid, illegal or unenforceable term or provision was not contained herein, but only to the extent that giving effect to such provision and the remainder of the terms and provisions hereof shall be in accordance with
the intent of the parties as reflected in this Agreement. No implied waiver by a party shall arise in the absence of a waiver in writing signed by such party. No failure or delay in exercising any right, power, or privilege hereunder shall operate
as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any right, power, or privilege hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <B><U>GOVERNING LAW AND TIME; WAIVER OF JURY TRIAL</U></B><B>. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE
LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAWS. SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME. EACH PARTY HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO
TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.
<U>Consent to Jurisdiction</U>. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan,<B> </B>for the adjudication of any dispute hereunder or in
connection with any of the transactions contemplated hereby, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such
suit, action or proceeding is brought in an inconvenient forum, or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit,
action or proceeding by mailing a copy (certified or registered mail, return receipt requested) to such party at the address in effect for notices under Section&nbsp;12 of this Agreement and agrees that such service shall constitute good and
sufficient notice of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. The Company hereby irrevocably appoints Centessa Pharmaceuticals, Inc., One
Federal Street, 38<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor, Boston, MA 02110, Attention: Saurabh Saha, as its agent for service of process in any Related Proceeding and agrees that service of process in any dispute hereunder may
be made upon it at the office of such agent. The Company waives, to the fullest extent permitted by law, any other requirements of or objections to personal jurisdiction with respect thereto. The Company represents and warrants that such agent has
agreed to act as the Company&#8217;s agent for service of process, and the Company agrees to take any and all action, including the filing of any and all documents and instruments, that may be necessary to continue such appointment in full force and
effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <U>Judgment Currency</U>. If for the purposes of obtaining judgment in any court it is necessary to convert a sum due
hereunder into any currency other than United States dollars, the parties hereto agree, to the fullest extent permitted by law, that the rate of exchange used shall be the rate at which in accordance with normal banking procedures the Agent could
purchase United States dollars with such other currency in the City of New York on the business day preceding that on which final judgment is given. The obligation of the Company with respect to any sum due from it to the Agent or any person
controlling the Agent shall, notwithstanding any judgment in a currency other than United States dollars, not be discharged until the first business day following receipt by the Agent or controlling person of any sum in such other
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
currency, and only to the extent that the Agent or controlling person may in accordance with normal banking procedures purchase United States dollars with such other currency. If the United
States dollars so purchased are less than the sum originally due to the Agent or controlling person hereunder, the Company agrees as a separate obligation and notwithstanding any such judgment, to indemnify the Agent or controlling person against
such loss. If the United States dollars so purchased are greater than the sum originally due to the Agent or controlling person hereunder, the Agent or controlling person agrees to pay to the Company an amount equal to the excess of the dollars so
purchased over the sum originally due to the Agent or controlling person hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. <U>Construction</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The section and exhibit headings herein are for convenience only and shall not affect the construction hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Words defined in the singular shall have a comparable meaning when used in the plural, and vice versa. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The words &#8220;hereof,&#8221; &#8220;hereto,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of similar import, when
used in this Agreement, shall refer to this Agreement as a whole and not to any particular provision of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Wherever the
word &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; is used in this Agreement, it shall be deemed to be followed by the words &#8220;without limitation.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) References herein to any gender shall include each other gender. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) References herein to any law, statute, ordinance, code, regulation, rule or other requirement of any governmental authority shall be
deemed to refer to such law, statute, ordinance, code, regulation, rule or other requirement of any governmental authority as amended, reenacted, supplemented or superseded in whole or in part and in effect from time to time and also to all rules
and regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. <U>Permitted Free Writing Prospectuses</U>. Each of the Company and the Agent represents,
warrants and agrees that, unless it obtains the prior written consent of the other party, which consent shall not be unreasonably withheld, conditioned or delayed, it has not made and will not make any offer relating to the Placement Shares that
would constitute an issuer free writing prospectus, or that would otherwise constitute a free writing prospectus (as defined in Rule 405), required to be filed with the Commission. Any such free writing prospectus consented to by the Agent or by the
Company, as the case may be, is hereinafter referred to as a &#8220;<B><U>Permitted Free Writing Prospectus</U></B>.&#8221; The Company represents and warrants that it has treated and agrees that it will treat each Permitted Free Writing Prospectus
as an issuer free writing prospectus, and that it has complied and will comply with the requirements of Rule 433 applicable to any Permitted Free Writing Prospectus, including timely filing with the Commission where required, legending and record
keeping. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. <U>Absence of Fiduciary Relationship</U>. The Company acknowledges and agrees that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the Agent has been retained to act as sales agent in connection with the sale of the Placement Shares, the Agent has acted at arms&#8217;
length and no fiduciary or advisory relationship between the Company or any of its respective affiliates, stockholders (or other equity holders), creditors or employees or any other party, on the one hand, and the Agent, on the other hand, has been
or will be created in respect of any of the transactions contemplated by this Agreement, irrespective of whether the Agent has advised or is advising the Company on other matters and the Agent has no duties or obligations to the Company with respect
to the transactions contemplated by this Agreement except the obligations expressly set forth herein; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the Company is capable of evaluating, and understanding and understands and accepts, the
terms, risks and conditions of the transactions contemplated by this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) neither the Agent nor its affiliates have provided
any legal, accounting, regulatory or tax advice with respect to the transactions contemplated by this Agreement and it has consulted its own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) the Company has been advised and is aware that the Agent and its affiliates are engaged in a broad range of transactions which may involve
interests that differ from those of the Company and that the Agent and its affiliates have no obligation to disclose such interests and transactions to the Company by virtue of any fiduciary, advisory or agency relationship or otherwise; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) the Company waives, to the fullest extent permitted by law, any claims it may have against the Agent or its affiliates for breach of
fiduciary duty or alleged breach of fiduciary duty in connection with the transactions contemplated by this Agreement and agrees that the Agent and its affiliates shall have no liability (whether direct or indirect) to the Company in respect of such
a fiduciary claim or to any person asserting a fiduciary duty claim on behalf of or in right of the Company, including stockholders (or other equity holders), creditors or employees of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22. <U>Recognition of the U.S. Special Resolution Regimes</U>. In the event that the Agent is a Covered Entity and becomes subject to a
proceeding under a U.S. Special Resolution Regime, the transfer from the Agent of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S.
Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the Agent is a Covered Entity and the Agent or a BHC Act Affiliate of the Agent becomes subject to a proceeding under a U.S.
Special Resolution Regime, Default Rights under this Agreement that may be exercised against the Agent are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this
Agreement were governed by the laws of the United States or a state of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, (A) &#8220;BHC
Act Affiliate&#8221; has the meaning assigned to the term &#8220;affiliate&#8221; in, and shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k); (B) &#8220;Covered Entity&#8221; means any of the following: (i)&nbsp;a &#8220;covered
entity&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); (ii) a &#8220;covered bank&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or (iii)&nbsp;a
&#8220;covered FSI&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b); (C) &#8220;Default Right&#8221; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R.
&#167;&#167; 252.81, 47.2 or 382.1, as applicable; and (D) &#8220;U.S. Special Resolution Regime&#8221; means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall
Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23. <U>Counterparts</U>. This Agreement may be executed in two or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute one and the same instrument. Delivery of an executed Agreement by one party to the other may be made by facsimile or electronic transmission. Counterparts may be delivered
via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or
other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24. <U>Use of Information</U>. The Agent may not provide any information gained in connection with this Agreement and the transactions
contemplated by this Agreement, including due diligence, to any third party other than its legal counsel advising it on this Agreement and the transactions contemplated by this Agreement unless expressly approved by the Company in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">25. <U>Agent&#8217;s Information</U>. As used in this Agreement, &#8220;<B><U>Agent&#8217;s Information</U></B>&#8221; means solely the
following information in the Registration Statement and the Prospectus: the ninth paragraph under the heading &#8220;Plan of Distribution&#8221; in the Prospectus Supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All references in this Agreement to the Registration Statement, the ADS Registration Statement, the Prospectus or any amendment or supplement
to any of the foregoing shall be deemed to include the copy filed with the Commission pursuant to EDGAR. All references in this Agreement to financial statements and schedules and other information that is &#8220;contained,&#8221;
&#8220;included&#8221; or &#8220;stated&#8221; in the Registration Statement, the ADS Registration Statement or the Prospectus (and all other references of like import) shall be deemed to mean and include all such financial statements and schedules
and other information that is incorporated by reference in the Registration Statement, the ADS Registration Statement or the Prospectus, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All references in this Agreement to &#8220;supplements&#8221; to the Prospectus shall include any supplements, &#8220;wrappers&#8221; or
similar materials prepared in connection with any offering, sale or private placement of any Placement Shares by the Agent outside of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[Remainder of Page Intentionally Blank] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing correctly sets forth the understanding between the Company and the Agent,
please so indicate in the space provided below for that purpose, whereupon this letter shall constitute a binding agreement between the Company and the Agent. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CENTESSA PHARMACEUTICALS PLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Saurabh Saha</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Saurabh Saha</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ACCEPTED as of the date first-above written:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LEERINK PARTNERS LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter M. Fry</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Peter M. Fry</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Head of Alternative Equities</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>SCHEDULE 1 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>FORM OF PLACEMENT NOTICE </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195; ]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[TITLE]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Centessa Pharmaceuticals plc</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cc:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195; ]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">To:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Leerink Partners LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Subject:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Leerink Partners&#8212;At the Market Offering&#8212;Placement Notice</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant
to the terms and subject to the conditions contained in the Amended and Restated Sales Agreement, dated November&nbsp;24, 2025 (the &#8220;<B><U>Agreement</U></B>&#8221;), by and between Centessa Pharmaceuticals plc, a public limited company
incorporated under the laws of England and Wales&nbsp;(the &#8220;<B><U>Company</U></B>&#8221;), and Leerink Partners LLC (&#8220;<B><U>Leerink Partners</U></B>&#8221;), I hereby request on behalf of the Company that Leerink Partners sell up to $[ ]
of ordinary shares, nominal value &pound;0.002 per share (the &#8220;<B><U>Ordinary Shares</U></B>&#8221;), of the Company to be delivered in the form of American Depositary Shares (the &#8220;<B><U>ADSs</U></B>&#8221;), each representing one
Ordinary Share of the Company (the &#8220;<B><U>Placement Shares</U></B>&#8221;), at a minimum market price of $&#8195; per Placement Share [; <I>provided</I> that no more than [ ] Shares shall be sold in any one Trading Day (as such term is defined
in Section&nbsp;3 of the Agreement)]. Sales should begin [on the date of this Placement Notice] and end on [DATE] [until all Placement Shares that are the subject of this Placement Notice are sold]. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>SCHEDULE 2 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>The Company </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Saurabh Saha, M.D., Ph.D. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gregory Weinhoff, M.D., M.B.A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">John Crowley, CPA </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">with copies to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Iqbal Hussain </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Raphael Deferiere </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Leerink Partners </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gabriel Cavazos </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brian Swanson </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">atm@leerink.com </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>SCHEDULE 3 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Compensation </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company shall
pay Leerink Partners compensation in cash up to 3.0% of the gross proceeds from the sales of Placement Shares pursuant to the terms of the Sales Agreement of which this <B><U>Schedule 3</U></B> forms a part. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>SCHEDULE 4 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Company&#8217;s Subsidiaries </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Subsidiary</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Jurisdiction of Incorporation</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Centessa Pharmaceuticals (UK) Limited</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">England and Wales</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Centessa Pharmaceuticals Holdings, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Centessa Biosciences, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Centessa Pharmaceuticals, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ApcinteX Limited</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">England and Wales</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d23843dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g23843g1120224650146.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwin Procter (UK) LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sancroft</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">10-15</FONT> Newgate Street</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">London EC1A 7AZ</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+44 (0) 20 7447 4200</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">24 November 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Centessa
Pharmaceuticals plc </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3rd Floor 1 Ashley Road </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Altrincham,
Cheshire, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United Kingdom, WA14 2DT </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Centessa Pharmaceuticals plc &#8211; Prospectus Supplement &#8211; Exhibit 5.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as English legal advisers to Centessa Pharmaceuticals plc, a public limited company incorporated in England and Wales (the
&#8220;<B>Company</B>&#8221;) in connection with the preparation and filing on the date hereof with the U.S. Securities and Exchange Commission (the &#8220;<B>SEC</B>&#8221;) of a prospectus supplement (the &#8220;<B>Prospectus
Supplement</B>&#8221;) to the Company&#8217;s prospectus dated 11&nbsp;September 2024 (the &#8220;<B>Prospectus</B>&#8221;), pursuant to the U.S. Securities Act of 1933, as amended (the &#8220;<B>Securities Act</B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Prospectus Supplement relates to the registration for the issue and sale by the Company of American depositary shares (&#8220;<B>ADSs</B>&#8221;), each
ADS representing one ordinary share at a nominal value of &pound;0.002 per share (the &#8220;<B>Ordinary Shares</B>&#8221;) (the &#8220;<B>Offering</B>&#8221; and the Ordinary Shares allotted and issued in connection therewith to Citibank N.A. as
the custodian and represented by ADSs, being the &#8220;<B>Shares</B>&#8221;). The Company has entered into a sales agreement with Leerink Partners LLC (&#8220;<B>Leerink</B>&#8221;) dated 24 November 2025 (the &#8220;<B>Sales Agreement</B>&#8221;),
pursuant to which the Company may offer and sell its ADSs having an aggregate offering price of up to US$250,000,000 from time to time through Leerink acting as its sales agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The sale of any ADSs by the Company pursuant to the Prospectus Supplement will constitute an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4)
promulgated under the Securities Act. The Company&#8217;s ADSs are listed on The Nasdaq Global Select Market under the symbol &#8220;CNTA&#8221;.<B> </B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INTRODUCTION </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Purpose </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the preparation and filing of the Prospectus Supplement with the SEC pursuant to the Securities Act we have been asked to provide opinions
on certain matters, as set out below. We have taken instruction in this regard solely from the Company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Defined terms and headings</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In this letter: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">capitalised terms used without definition in this letter or the schedules hereto have the meanings assigned to
them in the Prospectus Supplement unless a contrary indication appears; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">headings are for ease of reference only and shall not affect interpretation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Goodwin Procter (UK) LLP is a limited liability partnership registered in England and Wales with registered number OC362294. Its registered
office is at Sancroft, <FONT STYLE="white-space:nowrap">10-15</FONT> Newgate Street London EC1A 7AZ. A list of the names of the members of Goodwin Procter (UK) LLP is available for inspection at the registered office. Goodwin Procter (UK) LLP is
authorised and regulated by the Solicitors Regulation Authority. Goodwin Procter (UK) LLP is affiliated with Goodwin Procter LLP, which operates in the United States of America. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g23843g1120224650146.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Centessa Pharmaceuticals plc </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">24 November 2025 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.3 <B>Legal review</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purpose of issuing this letter, we have examined such questions of law as we have considered appropriate to give the opinions set forth in this letter.
We have reviewed such documents and conducted such enquiries and searches as we have considered appropriate to give the opinions set forth in this letter, including the following documents and the following enquiries and searches: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an online search at Companies House in respect of information available for inspection on the Company&#8217;s
file conducted on 24 November 2025 at 10:46&nbsp;am (London time); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an enquiry of the Central Index of Winding Up Petitions, London on 24 November 2025 at 11:06&nbsp;am (London
time) ((a) and (b)&nbsp;together, the &#8220;<B>Searches</B>&#8221;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a certificate dated 24 November 2025 signed by the Chief Executive Officer of the Company (the
&#8220;<B>Certificate</B>&#8221;) relating to certain factual matters as at the date of the Certificate and having annexed thereto copies (certified by the Chief Executive Officer of the Company as being true, complete, accurate and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">up-to-date</FONT></FONT> in each case) of the following documents: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an executed copy of the print of the resolutions passed by the shareholders of the Company at the
Company&#8217;s annual general meeting on 20&nbsp;June 2025 approving, <I>inter alia</I>, the allotment of shares by the directors, or the granting of rights to subscribe for, or to convert any security into, shares on a non-preemptive basis up to
an aggregate nominal amount of &pound;133,184 (the &#8220;<B>Shareholder Resolutions</B>&#8221;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an executed copy of the written resolutions of the board of directors of the Company (the
&#8220;<B>Board</B>&#8221;) dated 22 November 2025 (the &#8220;<B>Board Resolutions</B>&#8221;) at which it was resolved, <I>inter alia</I>: (i)&nbsp;that the Offering be approved in principle; (ii)&nbsp;that the Company be authorised to issue for
sale the offered ADSs in accordance with the offer terms set out in the Prospectus Supplement; and (iii)&nbsp;to appoint a committee of the Board with delegated authority to effect the Offering; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a PDF copy of the current articles of association of the Company adopted on 2&nbsp;June 2021 pursuant to a
special resolution dated 20&nbsp;May 2021 (the &#8220;<B>Articles</B>&#8221;), the certificate of incorporation of the Company dated 26&nbsp;October 2020 and the certificate of incorporation on <FONT STYLE="white-space:nowrap">re-registration</FONT>
of the Company as a public company dated 14&nbsp;May 2021; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a copy of the Prospectus Supplement filed with the SEC on 24 November 2025. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Applicable law</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This letter, the opinions given in it, and any <FONT STYLE="white-space:nowrap">non-contractual</FONT> obligations arising out of or in connection with this
letter and/or the opinions given in it, are governed by, and to be construed in accordance with, English law as in force on the date of this letter and relate only to English law as applied by the English courts as at today&#8217;s date. In
particular: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">we have not investigated the laws of any country other than England and we express no opinion in this letter on
the laws of any jurisdiction other than England and we assume that no foreign law affects any of the opinions given below. It is assumed that no foreign law which may apply to the matters contemplated by the Prospectus Supplement, the Company, any
document or any other matter contemplated by any document would or might affect this letter and/or the opinions given in it; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">we do not undertake or accept any obligation to update this letter and/or the opinions given in it to reflect
subsequent changes in English law or factual matters; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">we express no opinion in this letter on the laws of any jurisdiction other than England. It is assumed that no
foreign law which may apply to the matters contemplated by the Prospectus Supplement, the Company, any document or any other matter contemplated by any document would or might affect this letter and/or the opinions given in it.
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g23843g1120224650146.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Centessa Pharmaceuticals plc </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">24 November 2025 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 3
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Assumptions and reservations</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The opinions given in this letter are given on the basis of each of the assumptions set out in schedule 1 (<I>Assumptions</I>) to this letter and are subject
to each of the reservations set out in schedule 2 (<I>Reservations</I>) to this letter. The opinions given in this letter are strictly limited to the matters stated in paragraph 2 (<I>Opinions</I>) below and do not extend, and should not be read as
extending, by implication or otherwise, to any other matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It should be understood that we have not been responsible for investigating or verifying
the accuracy of any facts or the reasonableness of any statement of opinion or intention contained in or relevant to any Document. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>OPINIONS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to paragraph 1 (<I>Introduction</I>) and the other matters set out in this letter and its schedules, we are of the opinion that as at today&#8217;s
date: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company is a public limited company duly incorporated under English law, noting the Searches revealed no
order or resolution for the <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company and no notice of the appointment of a receiver or administrator in respect of it or any of its assets; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Shares, when issued and sold as contemplated in the Prospectus Supplement, the Prospectus and any related
Prospectus supplement(s), will be duly and validly authorised and issued, fully paid or credited as fully paid and will not be subject to any call for payment of further capital. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EXTENT OF OPINIONS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We express no opinion as to any agreement, instrument or other document other than as specified in this letter or as to any liability to tax or duty which may
arise or be suffered as a result of or in connection with the transactions contemplated thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This letter only applies to those facts and
circumstances which exist as at today&#8217;s date and we assume no obligation or responsibility to update or supplement this letter to reflect any facts or circumstances which may subsequently come to our attention, any changes in laws which may
occur after today, or to inform the addressee of any change in circumstances happening after the date of this letter which would alter our opinion. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DISCLOSURE AND RELIANCE </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This letter is addressed to you in connection with the Prospectus Supplement. We consent to the filing of this letter as an exhibit to the Company&#8217;s
Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> relating to the Shares, which is incorporated by reference in the Prospectus Supplement. In giving such consent, we do not thereby admit that we are in the category of persons whose
consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations thereunder. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g23843g1120224650146.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Centessa Pharmaceuticals plc </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">24 November 2025 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 4
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than for the purpose set out in the prior paragraph, this letter may not be relied upon, or assigned,
for any purpose, without our prior written consent, which may be granted or withheld in our discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yours faithfully </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Goodwin Procter (UK) LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Goodwin Procter (UK) LLP
</B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g23843g1120224650146.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Centessa Pharmaceuticals plc </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">24 November 2025 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 5
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ASSUMPTIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The opinions in this letter
have been given on the basis of the following assumptions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the genuineness of all signatures (including electronic signatures), stamps and seals on all documents, the
authenticity and completeness of all documents submitted to us as originals, and the conformity to original documents of all documents submitted to us as copies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that each of the individuals who signs as, or otherwise claims to be, an officer of the Company is the
individual whom they claim to be and holds the office they claim to hold; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the accuracy as to factual matters of each document we have reviewed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that, where a document has been examined by us in draft or specimen form, it will be or has been duly executed
in the form of that draft or specimen, and that each of the signed documents examined by us has been duly executed and, where applicable, delivered on behalf of the Company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the Articles remain in full force and effect and no alteration has been made or will be made to such
articles of association, in each case prior to the date of the allotment and issue of the Shares (the &#8220;<B>Allotment Date</B>&#8221;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on the Allotment Date, the Company will comply with all applicable laws, and will have all necessary corporate
and other power, authority and capacity, in order to allot and issue the Shares and the Company will receive such amounts as are necessary to fully pay the nominal value of the Shares and any applicable share premium; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that all documents, forms and notices which should have been delivered to the Registrar of Companies in respect
of the Company have been so delivered, that information revealed by the Searches was complete and accurate in all respects and has not, since the time of the Searches, been altered and that the results of the Searches will remain complete and
accurate as at the date of the Prospectus Supplement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the Prospectus Supplement, as finally amended, has become effective under the Securities Act;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an appropriate prospectus supplement with respect to the Shares has been prepared, delivered and filed in
compliance with the Securities Act and the rules and regulations thereunder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Shares will be sold or issued in accordance with a duly authorised, executed and delivered purchase,
underwriting or similar agreement as may be required from time to time by Leerink acting as the Company&#8217;s sales agent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the Shares when issued will be accurately and properly completed, duly authorised, executed and delivered
on behalf of the Company and authenticated, issued and paid for and registered in the register of holders of Shares maintained for this purpose, in accordance with the then operative Articles and all applicable laws (for the avoidance of doubt, as
in force at all relevant times); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that any issuance of securities, or any allotment of Shares, which occurs after the date of this letter is done
in accordance with any terms and limits prescribed by the Shareholder Resolutions or such other shareholder resolutions relating to the Company in force at the time of such allotment; </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g23843g1120224650146.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Centessa Pharmaceuticals plc </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">24 November 2025 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 6
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(m)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the contents of the Certificate were true and not misleading when given and remain true and not misleading
as at the date of this letter and there is no fact or matter not referred to in the Certificate which could make any of the information in the Certificate inaccurate or misleading; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(n)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that any minutes of the meetings of the Board or the written resolutions of the Board provided to us in
connection with the giving of this letter or otherwise contemplated in connection with the matters referred to herein were and/or will be duly passed as resolutions of the Board, all constitutional, statutory and other formalities were and/or will
be observed and such resolutions have not been, and will not be, revoked or varied and remain in full force and effect as at the Allotment Date or the date on which the securities (other than Shares) are issued or granted; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(o)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the resolutions set out in the Shareholder Resolutions were validly passed and have not been and will not
be revoked or varied and remain in full force and effect and will remain so as at the Allotment Date or the date on which securities (other than Shares) are issued or granted and that, prior to the Allotment Date or the date on which securities
(other than Shares) are issued or granted, the Company has not allotted shares or granted rights to subscribe for, or to convert any security into, shares pursuant to the Shareholder Resolutions which would, when aggregated with the allotment of the
Shares in connection with the Offering, result in the directors exceeding the limits set out in the Shareholder Resolutions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(p)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that if the number of Shares, or other securities capable of being converted into Shares, to be allotted and
issued in connection with the Offering, exceeds the limits set out in the Shareholder Resolutions, such new Shares shall be allotted and issued pursuant to an authority and power granted to the directors pursuant to section 551 and section 570 or
571 of the Companies Act 2006 at a general meeting of the Company duly convened and held at which all constitutional, statutory and other formalities will be duly observed, a quorum of shareholders will be present throughout and the relevant
resolutions will have been duly passed and will not have been revoked or varied and will remain in full force and effect, and that all filings required to be made with Companies House in connection therewith will have been made within the relevant
time limits; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(q)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that in relation to the allotment and issue of the Shares, the Board has acted and will act in the manner
required by section 172 of the Companies Act 2006 (Duty to promote the success of the Company), and there has not been and will not be any bad faith, breach of trust, fraud, coercion, duress or undue influence on the part of any of the directors of
the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(r)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the directors of the Company, including any pricing committee or other appropriate committee appointed thereby,
and appropriate officers of the Company have taken all necessary corporate action to approve the allotment and issue of the Shares and related matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(s)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the directors of the Company acted or will act in accordance with sections 171 to 174 of the UK Companies
Act 2006 in approving the resolutions recorded in the Board Resolutions and that all actions to be carried out by the Company are or will be in its commercial interests; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(t)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that there are no facts or circumstances (and no documents, agreements, instruments or correspondence) which
are not apparent from the face of the documents listed in paragraph 1.3 or which have not been disclosed to us that may affect the validity or enforceability of the documents listed in paragraph 1.3 or any obligation therein or otherwise affect the
opinions expressed in this letter; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(u)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the Company has not taken any corporate or other action nor have any steps been taken or legal proceedings
been started against the Company for the liquidation, winding up, dissolution, reorganisation or bankruptcy of, or for the appointment of a liquidator, receiver, trustee, administrator, administrative receiver or similar officer of, the Company or
all or any of its assets (or any analogous proceedings in any jurisdiction) and the Company is not unable to pay its debts as they fall due within </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g23843g1120224650146.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Centessa Pharmaceuticals plc </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">24 November 2025 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 7
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
the meaning of section 123 of the Insolvency Act 1986, as amended, and will not become unable to pay its debts within the meaning of that section as a result of any of the transactions
contemplated herein, is not insolvent and has not been dissolved or declared bankrupt (although the Searches gave no indication that any <FONT STYLE="white-space:nowrap">winding-up,</FONT> dissolution or administration order or appointment of a
receiver, administrator, administrative receiver or similar officer has been made with respect to the Company); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">following the date of this letter and prior to the issue of the Shares, the Company will validly enter into the
Sales Agreement (as defined above); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(w)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">hat no Shares or rights to subscribe for Shares have been or shall be offered to the public in the United
Kingdom in breach of the Financial Services and Markets Act 2000, as amended (&#8220;<B>FSMA</B>&#8221;) or of any other United Kingdom laws or regulations concerning offers of securities to the public, and no communication has been or shall be made
in relation to the Shares in breach of section 21 of FSMA or any other United Kingdom laws or regulations relating to offers or invitations to subscribe for, or to acquire rights to subscribe for or otherwise acquire, shares or other securities; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(x)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company is not, nor will be, engaging in criminal, misleading, deceptive or unconscionable conduct or
seeking to conduct any relevant transaction or any associated activity in a manner or for a purpose which might render any transaction contemplated under any corporate approvals or any associated activity illegal, void or voidable.
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g23843g1120224650146.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Centessa Pharmaceuticals plc </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">24 November 2025 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 8
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESERVATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The opinions in this letter
are subject to the following reservations: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Searches are not capable of revealing conclusively whether or not a
<FONT STYLE="white-space:nowrap">winding-up</FONT> or administration petition or order has been presented or made, a receiver appointed, a company voluntary arrangement proposed or approved or any other insolvency proceeding commenced, and the
available records may not be complete or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">up-to-date.</FONT></FONT> In particular, the Central Registry of <FONT STYLE="white-space:nowrap">Winding-Up</FONT> Petitions in England may
not contain details of administration applications filed, or appointments recorded in or orders made by, district registries and county courts outside London. Searches at Companies House and at the Central Registry of Winding Up Petitions in England
are not capable of revealing whether or not a winding up petition or a petition for the making of an administration order has been presented and, further, notice of a winding up order or resolution, notice of an administration order and notice of
the appointment of a receiver may not be filed at Companies House immediately and there may be a delay in the relevant notice appearing on the file of the company concerned. Further, not all security interests are registrable, such security
interests have not in fact been registered or such security interests have been created by an individual or an entity which is not registered in England. We have not made enquiries of any District Registry or County Court in England;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the opinions set out in this letter are subject to: (i)&nbsp;any limitations arising from applicable laws
relating to insolvency, bankruptcy, administration, reorganisation, liquidation, moratoria, schemes or analogous circumstances; and (ii)&nbsp;an English court exercising its discretion under section 426 of the Insolvency Act 1986 (<I><FONT
STYLE="white-space:nowrap">co-operation</FONT> between courts exercising jurisdiction in relation to insolvency</I>) to assist the courts having the corresponding jurisdiction in any part of the United Kingdom or any relevant country or territory;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if any agreement is entered into for a purpose prohibited by sections 678 and 679 of the Companies Act 2006, it
will be void; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">we express no opinion as to matters of fact; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">we express no opinion as to taxation matters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">save for the matters set out in the Certificate, we have made no enquiries of any individual connected with the
Company and have relied entirely on the facts, statements and confirmations contained in the Certificate and we have not undertaken any independent investigation or verification of the matters referred to in the Certificate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a certificate, documentation, notification, opinion or the like might be held by the English courts not to be
conclusive if it can be shown to have an unreasonable or arbitrary basis or in the event of a manifest error; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it should be understood that we have not been responsible for investigating or verifying (i)&nbsp;the accuracy
of the facts, including statements of foreign law, or the reasonableness of any statements of opinion, contained in the Prospectus Supplement; or (ii)&nbsp;that no material facts have been omitted from it. </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>cnta-20251124.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 11/24/2025 5:05:30 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2025"
  xmlns:cnta="http://www.cnta.com/20251124"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.cnta.com/20251124"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" namespace="http://xbrl.sec.gov/naics/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" namespace="http://fasb.org/us-gaap/2025" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" namespace="http://fasb.org/us-types/2025" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cnta-20251124_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cnta-20251124_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cnta-20251124_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="cnta_DocumentAndEntityInformationTable" name="DocumentAndEntityInformationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cnta_DocumentAndEntityInformationLineItems" name="DocumentAndEntityInformationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>cnta-20251124_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 11/24/2025 5:05:30 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef roleURI="http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="cnta-20251124.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="cnta-20251124.xsd#cnta_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="cnta_DocumentAndEntityInformationTable" />
    <link:loc xlink:href="cnta-20251124.xsd#cnta_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="cnta_DocumentAndEntityInformationLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AdrMember" xlink:type="locator" xlink:label="dei_AdrMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="cnta_DocumentAndEntityInformationTable" order="1" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cnta_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="23.0001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" order="24" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dei_AdrMember" order="25" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="27.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="28.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="29.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="34.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="35.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="36.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="37.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="38.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="39.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="40.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="41.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine3" order="42.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="43.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="44.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCountry" order="45.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="46.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="47.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="48.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="49.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="50.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="51.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="52.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="53.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="54.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="55.001" priority="2" use="optional" />
  </link:definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>cnta-20251124_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 11/24/2025 5:05:30 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Three</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Three</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Country</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Country</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="cnta-20251124.xsd#cnta_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="cnta_DocumentAndEntityInformationTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cnta_DocumentAndEntityInformationTable" xlink:to="cnta_DocumentAndEntityInformationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="cnta_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="cnta_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Table]</link:label>
    <link:loc xlink:href="cnta-20251124.xsd#cnta_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="cnta_DocumentAndEntityInformationLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="cnta_DocumentAndEntityInformationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="cnta_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cnta_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:to="us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measured at Net Asset Value Per Share [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measured at Net Asset Value Per Share [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AdrMember" xlink:type="locator" xlink:label="dei_AdrMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AdrMember" xlink:to="dei_AdrMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AdrMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adr [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AdrMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adr [Member]</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>cnta-20251124_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 11/24/2025 5:05:30 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="cnta-20251124.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="cnta-20251124.xsd#cnta_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="cnta_DocumentAndEntityInformationTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="cnta_DocumentAndEntityInformationTable" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="cnta-20251124.xsd#cnta_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="cnta_DocumentAndEntityInformationLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cnta_DocumentAndEntityInformationTable" xlink:to="cnta_DocumentAndEntityInformationLineItems" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cnta_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AdrMember" xlink:type="locator" xlink:label="dei_AdrMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dei_AdrMember" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine3" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCountry" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="47.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="48.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="49.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="50.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="51.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="52.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="53.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="54.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cnta_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="55.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g23843g1120224650146.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23843g1120224650146.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  W -\# 2(  A$! Q$!_\0
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M@2,>U $^:!4;.B(68A57DDG %,BGBF#>3-')C&=K X_*@1R'Q ;:=._[:?\
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M5V,ZW&A!/L4%LTDY;J"N2<?AB@1L>%TU+3/"T/\ ;MR'N(HR\C'^!0,X)[X
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M**8!Q1Q110 <4444 '%'%%% !Q1Q110 <4<444 '%'%%% !1Q110 <4<444
.'%'%%% !Q2\444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 24, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cnta_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001847903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 24,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CENTESSA PHARMACEUTICALS PLC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">X0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1612294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3rd Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">1 Ashley Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Altrincham<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cheshire<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">WA14 2DT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">468-5770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Fair Value Measured at Net Asset Value Per Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cnta_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Ordinary shares, nominal value &#163;0.002 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CNTA<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember', window );">Adr [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cnta_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">American Depositary Shares, each representing one ordinary share, nominal value &#163;0.002 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CNTA<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cnta_DocumentAndEntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cnta_DocumentAndEntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cnta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dei_AdrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>25</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d23843d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cnta-20251124.xsd</File>
    <File>cnta-20251124_def.xml</File>
    <File>cnta-20251124_lab.xml</File>
    <File>cnta-20251124_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="d23843d8k.htm">d23843d8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d23843d8k.htm": {
   "nsprefix": "cnta",
   "nsuri": "http://www.cnta.com/20251124",
   "dts": {
    "schema": {
     "local": [
      "cnta-20251124.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "cnta-20251124_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cnta-20251124_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cnta-20251124_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "d23843d8k.htm"
     ]
    }
   },
   "keyStandard": 25,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 2,
   "memberCustom": 0,
   "hidden": {
    "total": 4,
    "http://xbrl.sec.gov/dei/2025": 4
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 32,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 29
   },
   "report": {
    "R1": {
     "role": "http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-11-24_to_2025-11-24",
      "name": "dei:SecurityExchangeName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d23843d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-11-24_to_2025-11-24",
      "name": "dei:SecurityExchangeName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d23843d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AdrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdrMember",
     "presentation": [
      "http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adr [Member]",
        "terseLabel": "Adr [Member]",
        "documentation": "American Depositary Receipt (or American Depositary Share, ADS)."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "cnta_DocumentAndEntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cnta.com/20251124",
     "localname": "DocumentAndEntityInformationLineItems",
     "presentation": [
      "http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Line Items]",
        "terseLabel": "Document And Entity Information [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "cnta_DocumentAndEntityInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cnta.com/20251124",
     "localname": "DocumentAndEntityInformationTable",
     "presentation": [
      "http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Table]",
        "terseLabel": "Document And Entity Information [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "terseLabel": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasuredAtNetAssetValuePerShareMember",
     "presentation": [
      "http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measured at Net Asset Value Per Share [Member]",
        "terseLabel": "Fair Value Measured at Net Asset Value Per Share [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.cnta.com//20251124/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d-3"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001193125-25-292015-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-292015-xbrl.zip
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MZ"1H^#90NI5CY_HQ)@N?Z(+I3WMQ4N=#F#VVU:E"B1%>/L9_HF#3PYTG/&7
M^1#67-V628)S\1@@7\0!%W=<F'M^-XEJG!.^4I.4AQ,>UN1ZCU2KF+O9Y,XA
M_DW@((_;$QL)P62$+"7HG$A-\@R^+#USN#F,)CIG$?VP6LZHJ-<QQ;A6V\-B
M@-N/^X._K85+N5:'5!X):.QZ+?0Z%8T!ZI2L+T(U66)SEC[E.83:4I%6$=YG
MC3L,]H>[4AB7=)4*-G/A<M^H%4L3'. 'HR4F8:@,R.R?2Q;30;UVL JTV@I5
MEOB>@?XM4"J*BW^F_RK? )T)/L98\YC&;%C0/\!+,^@/?=$?OCCTAZ[H#YM
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MY>W%0-8<LU7H;LFRA*.7(5Q8,R98CC-/>I\PQ7B>+QQ E;0EGU>03<']4#,
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MU+\*7#;^R"99)*ZH\#@XZV70_*?5D[-R91&^TIS <M9G'(PN$_",-J@FE+V
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M04 ]9&+H\8W;2%: <1<*2?W_\Z(G.<E32.Q<_?>&527V9?>;I8AV[)\=*9@
M 4>9"1*L2J[^.0"GT24?0:^[X4YY=S=^A4$%YCHB%# OHCYA8^;$TKO'% @8
M3R8.21XX!O#DLC5IWA<SE-.LS$\_G-K6R;D@DODL&H8!(X$R\D?H*_JQJ^PI
M.+L*]AKY+XOD5S('2F@#ZCY3,JJY^COK9)[4A\]8#+H.P3NZP]D]-WZP(&ZM
MOCLM')^<E+=;%7H%Z?T \@4!@,[!\<0= HKVB=XF")XC4)<1GXHD23[O++UE
MX':WF+6)J,HF.5\(A&V$1A$/09-@*-<+QZ3'_/ !*8>%2-C-8J 6+!4KDKYV
MB#T!TBQ9X +E90C$'\6^I $+8^%/B #N%_V)&L$T"'N ,>WSAWIHGJH,$D,_
MP%7!)"GKASX B>TPW>-AD"5(7C!&?F4!XZ 0KP)H&ZM0E#2*=E%/ZW UT[U[
M:F)S5XE+*[,)99JNG*8R%U.F<RG5K9(&N65IQNJ/Y^LC.F3=-=KN=^Y)(#9&
MO'%@0C?Q;"/="T._1X'0$M@RJQ'?(1W.3JK5\T6%^+A(5<\KPP]DE@7(L[7G
MPF &5X"<++)(%',1(Z^#M+1C8*NJ?6SX'AG>;+OVH.^&(TG>.B'-#VUB5\I%
MJ#@-ZE<%QV]\O@L^[X1JLQ[ \0FT):A,?W],?O(M,_D44="UQM0BAV\T*U:5
M%BP[L2Q384C.'LR(PL;>[&JYJ'L\S/A-;U*S=ZFYXPPM ^[-5_NCT"O@M_W^
M$[SBK:7G]%N6GHVL#!@M.!F4)B*RR:9L(7%NP<[W#G<K<[K/-ZE[3:F[$B)F
M_$5D[^Q-]IXD>Q56J.:=W<J>Z7-KV=MYG)EQ7'5 QSB$A%GL0 U$F99B"S5%
M$N7!='>9)'CIG2@*.V];41Z_.+U%NF7%#!;$X%G+POM8BNWB\6V]<=09$@>/
M">UD1?;)./OJ$,0I2J):#.Y,1E M+W:S:/W=H.C&;'54+,2,<= ;+@(",@!O
MI[IV5N5_+;O(5D;8YGBY9?>4I'PUY_.G_HT-7MTM!QZE?$($5A%') A'\,(G
M]]B4( =6SLO 83:)\#@BUGJT,[2C31BK4&T$3<O8UXAG7#F]Z39>"6^S#A9!
ME[?@C0OZ4'WM*[[Q8K-P/>/NAB6;+J&SA754VT8M)5SZ%U'S(9\H_\+D$;E>
MW$*>^+O_?--2*^_?F"*VDJLW%#C FY<L"H4G40]UC!Y2)H&S"!YP'Q4NK 2X
M))=55V_:ZA'XKO[-E=#\32PKA5H+\<L&E_\D-Z%$C42D9H\CTHLEL+P_P>,>
MP"2!#B[)@R>'*J;TP2U28F%"S)6R!+V0+M18->/B?G=5Y.I7@8O9!$9Z$^*H
MU5KH\0OX=TQMMIU;(O4$@5D #7'0 1GP\ %F[(2C")=-J2 NZWN!/@:CUY?*
MQPD2YA:7X*UU5JF0//+NR;E:8THJ>^H 380':'"A?\O,AMTKI&G\Q3%GTAMZ
M\.KF3A/H,,NQT'\&S+W3J;4<YS_]<&J=5<\W[&M*&O^JVC9UT[VEYNQCDYI[
MMR0UMV=N[J_A3]SZLY39O86M $-@9>:#5 ,K!Z%*(,6"J5J ,+/A *]_\Y3<
MZ_LKE(K L?P)#JZ4 8I% /!!"6?WGH!V(" T<'"MBCIJAQA6QHO@7,I=H;<:
MN&NS5Y4\3;-76;8N;LD-XVX*NCX=NC]66+>(OBKEMLT]&BOWY7Q75W+,;-,Y
M.%@N.&RT(#?X*N/0]AC0"QQ:_X%.1$Z?ICRX&*:^KQ/Z(:_]<*;^SI/Y1.-L
M6M'Q&>7H;PQ5XNY@PUZHW5ZZ<C"_Y/++;?NRU2XT;Z^O&W>=5BWY\BTLN5C6
MEFLNZ\\U7($KA;L<R];Y:;%L;7OFY<77/M:EFO3HM\K3:.')=E$DCUD\>+<+
MFW$;D(6#ZT<$K\UC0E!R!W[:"%R"6&$1]+/OD#QJ7D2^73YOIH;8MJWS0Z($
M0'E H+>!@.J60*9/ [:90!?8)1T\%D@: \Z4/SS3X5Q9VK&R)]<,E&?PA=Q1
M+@/&!?J(Z$*IEJ8P:7%DLG0T P%/()!#*H&GN:3@JLT->41<58>J[;__38,8
M'%:ME^P3A:#*$9I0[+#'Y -$Y<H6-1,_$-XG@&9G=@M"K2+"%5,LDKN,S5/^
MVSQ@V6%&%$QZGX<C(H&FJ@E^FA/8H%89<3WA<(;&#(P_KDTJV 2(,O3$PWB0
M8O0(K+&RQ##IS"#I/F*A( $Q1RA@"!WPDA$HUF1Z@%!L.5+>.^Z0QHX'PLSN
MB,01PO@/^[BL<0GLZ&=V(LZ/N"9HR"+USJ=ZB= 43JF_390^-_A607M112R(
M3KR\5F,4L*/VX:H^3)_SD"'+9.F7V7<V)PX/@!G@+$"ERV;\((KN$1ZVES&0
M)(XB7S<P[#*/PL2C4TZ:2*)/C+DV.OZX)563J5.H-#KM(_V0;AY/ @$<-@,3
M^E%414"HU)@'?!<:KH=HL>_Y4))&B9GH!)&8NG+3,WVSBJ'53)4!%'481!ZH
MM8Q7:"G)W":F:6?0HAO?A$7]I5*I%&PP*A7[\"B9HM$B8(GQIF-'S:3''%P>
M8,#DCCH0$$< DMYE6UQS7<-NW/R-:B+1/J B$FE?SH]*CT"H"]Z[BXW5/N(>
M,O5ZJ3:$6!KR6L?@G^>KA^L#7W5O1**:9\@\4WVJ&Y,Y*>' :$3M#^ 820!!
MP/<08:!\)"!*R*7B18'+,TJ@@.4"=-K])(F1RBV&'*C['/B&FZA7HFM!U8(1
MH!C1*-I[TZW02=6,K.<SIR[@,0+-!LU59Z!%D>[$]T:HM]-SODXLD.- 4T64
M Z(DFCL584$4IX>9LP;$&X&F9(?[9\!N9F!%CPA&3PA$%66,  .UM=Z'^.#'
MA",@+A4JTG,8<PVVE+9&>JQ4GV#1W-5*LTBN CP2X6EKET4-1K,4ZRGN!JTT
MZH$ L11@E=I2 7#*0WUFE!(;1RP03!BH/$Y\-@ NPL@56 5/T\1<^SL+F3#E
M"JE]^H$15!4S4\,D*N:$:%GY&L8VS%L"Z!5$D8XP3DXB<39&M)%_6,?E(PB9
M7I;:GE!@F(,$&J,C^H4IMM;B!)A:H-T:LMV 60-;RI4Q17L/ZF< *C70/IJ<
M9S4EH/BT_2!HA)1Y]B1Q0\S@4Y'H3B6*ZCB-1O(RZ!4@T!:'5C*(#=%'%)@H
M!&,3&]X5&D2)"(FP%^TK)%IS:>?1>F5N>F0<_1)I#(U*Q*@[L3@V"QU@0NP\
M[QUJ.R:7>2A8 Y3E$LF*>_\&QET% ;;/>VG7!I2,Z[:,:QT'/"TUO)(%5&W8
M4NR?77\!VVRR59QIAB4 L3>*1U-*&&ISO-9_?J_42L];AA)$7Q^DP[D+PQ[*
M9*Y73U/O$+&9JKY9QRU3"2!'.7.903<J)24-,!\T&YJQ$L% +>5(D>3I=-9-
M9C0L\.Q#R+_@S!T:@3/M'R5?M(H#O1ESH_.P]L"<\$GNE5!^*%J7%R!@=PE+
M&<=23!UZO040@CS*,6>9>)$.Q+(!/!NI141.+:E9Q)CJX"2/C;>G;VU!/"#R
M*/#Z&9,W0-BF :7OT1[X@@A4]L!EYO7J4R<XB2UR]UG_Z65(@DFT08CS<!F$
ME5ZT5@5H.Z'2P<##:E;P[J^8^C,7A6%D!A'J! U@>KE\(A;]6*F^L5PQRI'R
M-2)U8$U[Z3"$#C)0]G4&&M$W]'J@OJVBI7N&6DVTV@"GN6GP<2'1:>&C_@*S
M2J($=18OE18- ,PQ.ZV7(9/V3\((-)XFSZ]AZ#X *'>@#4";D/SGCX?D^OHN
M8P0AVO6 [].3?ZGI6.6+P6Q[#%E!8SN#Y.,=(KDX7?#<-]YVQA)@$WP_@5N+
M &@&T*Y*"+0!2N,,XTH(?9 GM:G9>KU8>X9BJ@XPJQ,+D3(99BU4;D)'+J#Q
M>LR<X^SCB>_9[OF,EYWI5OF:DYG[A?"=%BSEXJSK[R&,?4R'@6+SZ0-(+GI6
M(=<>=R8- :^,$C"7STP58086Z$)H3$STT%FH%N0H0^OL?=VKSV9GET\.LJL,
M!^3@;:'A;:%AQ4+#V;>]T/ A77E-=Z(DF3>EN\7++S[DW</9T5_G%,)NV/P1
MIQ .#O0Y!/7AELSG-B<'%D\IZ/=GE1<[.? BQP+V<:N+X;17ORGN)BP^8:_]
MEIO<5I)CHZ:[G+KU"U?!&89=(IL+[)'<^@$%I94EX!:A8 ;O<_9KWKVZ#$MJ
M%\G9.40+^R$0C NDH$3_.I=K5TZK%9>-+:LXE".U\73C@FFR0KEDX7;+=<F9
M!=2+$EUU>N%O0.CC%R;TL2'T[18AVM^4,G;EE6C2A&"-Z2SP2IJ8M1R=PS F
M18\.G'3X=R695:[ND6)-4'0<E-: D2NTH52ONEY228FZ=S6/>M!US?*RIQ7?
ME?JQ6H*_5DM<\WL0.A.5S=1,DQ=F);EL'68,W]JS\V_QYC/CS5>]4*US]>M-
MH_NYW>H\)<.D.L1<<"#Q'H'G+>&;A0@=DVVW>UNGJ-NSNW;=V)\0M?[AZAR<
MO@8N6:. V4-!J'.O/3:D?C]9>E1Y&%,!DT@Q+EJJ[H!6PY##Q)Z6:'X6GO!7
M6VJ+?LYW$BM6EX2*\\'A7%)#Q7_;AXNK#IJ?'J?AXIQK_S(V)&/**AL#D_6_
ME;+N4O<M+"XRS J3JXJ^#IN[$4>_3&I[NO<]J?ZXD'G#1N]'JH&2*$$,%'/:
M&\+GD+[Z>>N-],"S8?NF2!8C1^13\;)X1.Z&\/%UHT:=YMPW;II#C_7!;B8W
M]MZJ&WOY,L=NWB.[*/5"=P+/$!+X]?\'4$L#!!0    ( !<[>%M[9J,N5,D
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MN@]_N3X#DW;#P\G&SN"_ZTFFKWI%$,5_@"K(V,6X!-]A?(#!CK[CE'P[3?;
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M,L'F/%5/&V"00?P$ *C4PI\J:09$4H_/,46UX 3 RI>G"F0B=4O]26"ZJ]P
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M0&?X.KI'X)\OLC51BA0QG2"*09ILHLKD.XH45Q^_X&T @SY\8#)A#!"UW',
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M(4WE9>-#XKT QLVZ-.,M6-?+Y?A:7:%)\#S8RQ4"XN^5OD.BI8O+Q/!F&B(
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MT<DX.6GE4BQ.J8;X"I!6)$5^K"8N/P8Y[?5+EOG'4>1S_!"!^:A,E"P(OL'
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MQ7B9,T:<Z_*@UI2%GZ7X%F/%/WR/%3]L3UBBL\#RCD^4EZU;HT(+8C54)T
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M/=G'?V''$Z/Q;:P*R@#EEL=Q;ENOLY*F)2Q35I%Z_0H*%5*-1:Q=N\ "VQH
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M,Q'T)5S:/#W8[DF-,)"/96P@*.FND^KT4MHZROKP[Y'U*XMM=\I#Q &97:C
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MI*%OG5FL<3@%L[J@4J;)4VYR:2L&PF]26V-OOARD6FU\UIY6<M%B%42P/-S
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M7:<:DNS:8=U@/V83CAG74&S&FUE6"B%-P5?CF.03B?"UVO-AAE[UQ(BK"T?
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M\@_/EK<B#<$+EJ59D!^<ZV%L_0/87Q#-W]Q0@T.!$)W@T@(]H5$1#F-;4MJ
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MF2$YR&HJ(</QT#EJDB8QL@.*A6"$R5+W:ZN>]9X,"L+*;*<V_8+/@$TK1\7
M^A;8:@,D;()X">ZC8ZP6Y+#RN(A#*K6PDRR2'KB:':0  <GROP>_[AZ<K6'W
MG^/N'QK#H<HUTJ8KG?M> R[.'#&&?;].?LT*/'%RX:G=TV2@L/W&-0=6'"-
M0$ U)C7;WJMTF^FK+XL>]I:?3C-X@E2 PQ\=CH@A,(@R;I:+;ZOX$>&Y<IJB
M@PL2ZSKH[1P)W ',17H&59$MDL_'5V653?)R5NLZ>?@YZ@TCG40$9S;ETFHP
M5#,5%%\19USSXA#Q@4IU2\3'Z&9BO;?,%6Y9@:X$/$ZL%,P'3NH*(Q;&/CW+
M8+DCRCHX9Q/&I &(1T#)!'8SMSAO%-\+>K]T@X5Z6C7[.[?:+ZMBM\CR/&/)
M2?;$WHP C9A=189KWJXO)C;(L1W*-QM@?O$]P'P?+]C<T27Y>BINE8D[Q/<0
M?5;EYFXP4M0J?WS2-").B+>RR035AC.90O<7F3?1JB1C0)1KRN09UHIF9@PP
MIEM'$BO?\(QH?)ZEO93ST?8\Y-9&#7EMB02D+XP48(M1[]"F[A*G(5LV#-T+
M?LJ:A;N!:![NU))=%Y-K(Q%@BX^0KP\C0K,)5X12]QQ'K0,H18Q+<6.P,>">
MS+#]7CQ3"  *=RNW4+2F!04+XW!XWF7X([+7E\9^A!$$[0'-V'G0CM9:#=CQ
ML!+P=. 8PFPI2TC3!?!4.T2\O*H9VOXVX!@N5-)8)]3F9:4F+7QUS>VR;+L1
M$BFN5'-K$BSE[6=G:UYZ,2BS-"F+<I'6PJ_;XHV4XLV9R2*Y (J(;F= E 1\
M6K->+912F?Q"M8ICTK;>// J':$#E&R/LCFQ'T(0L!;:1R[UNS*76I72/IB%
M!#)7Y64P;/P**#YS(K:584P=4Y5\#PU=\WRB@,<UP=:$^-[<'C!P,:E/BZ,7
MJXP48\JH^74^JO9S+N5;9?QK**_<_:'#RNO=I[\>GGX\^O@N.>[^FG0_'B3G
M1Q\.C4G:/3)_2#Z]3?[R^?2WY/STJ'LLZNTGT'#G[X_.DNZ[T\/##X?@*+SO
M'A\G;PX3>N#A0?+F-WS<_J>/9^>GG\T'1Q^3[O[^I].#[L?]0W/IG;\W#SG<
MW# O/H,7F7^8!>B>'\(_/A[^FOSVZ?07_-ZGS^?)Z>&[[JD9W2?\WLGIT<?]
MHY/C0_RE><?;XZ/]<_P'/*Z3G)T<[A^]/3JD^> ?#KJ_F:>\-;,R#['/WS\Z
M_PV_TTD.N_OODY/NJ?G@_>'IH9G T>GIX5\_[7??'/]&*W*6R@C>?CXV;S]/
M#O_G'.9_<GCZX>C\G.=]<F*&8WYU"*-)S3K06L 2G1Z]>W]N'K*Y@6L*7\<5
MAM4Q7SLVTSPVT_NT?WAX -O2/3TZ@_^%-3"3^'1JYG#</8>/<"3>+IB_PMC.
M3[L?S[K[YT=F[6%QS@\_G)C?F,'1O#IXZ3VZ8_1CQP@Y=J*0B.9?U!5#[H]*
MI\$! :;3RA@299\Z_<UZXX)K\/&TF2-:0Z#'Z\+&ZH[YG2<#RZB!EUQM3O]T
MJEA P@Q#FKPIJ6K2?/@AFUR"US1)?\(E>_.SL"B .STH'.LYEV]<07K=XV(H
MJ+E8HS.>*'CC"=7";>*U[:$%H)LOLABHXKA3,?<+0CYDVX+;]B %MMQ8AZI4
M=6I0]S!3ODN"+Z@/#9?:%I/AZJK*(Z@L;7NS;F2,PP2'K)P8*X)Z<93&$6+[
MAP-0%N9+?-<+GUQ @[$KT*R+Q8E6T,X5VVES7A4?6-><FD*!K;GB#3^G?D#4
M?]LMM(Q,^F4$0X,2.W/GJ7;>+FN7W"9IM^TL""*CGK)(4LH'[E$R-'2B.<)D
M9.SH%@(ZU7^*.PO1TM =JI DD&^7.F+;2\7EI_4Z2I-G"75+8#FTI&)1;/3.
M9:%OLKF[78G]RNR#?1=_2YP(W;P 8 $>=T5$*HRY#?V@ZZ0-<9@:\[[?29-/
M$V-MO&7=<C8U*V9D\NF+>P'/0?DP+*2;[.SM0HVDQF1GLRKK79K_O<RPK@ZC
M.A=\9F("S(MQRA'#$[\]G;?/K3]NJK5Q-H<F(4PM>T6$JRR%E VQ1Q5'YR^Z
M:*[ -6![.=RPU.M3@#57W%AA2#'Q?TA%[;1T9]E34WY8D8)%_I LVZ)'M*A/
M *WR)="QX*H-I/F>3R1LX]:+=L5Y,S:RPQO!H5D)]J#!:OO(2L@*%XWTB# &
M\W>E61#-PD64:M;+'. Q=Q$(=C47SF)@!^-IDO0+"X;OTVUNK*NP=O<%1E7_
M(D1*^T!B->DS&>?1T)(;Z;RYS2PTNFB2N\O77; 8<$B!5G<V!BHRQ9\G;=_,
MS_GM.H_E<T<-RM$HJ^HT%J7$O5Y=^NT56'$*)1<N<:3HL\K2?L5\G1L3-BM<
M)]!=PO&4H3P.9A5'="DQ@YR'2*]NWE.'K%T\,]68CN%$LB9MP W.Q=K*8D"#
MN$0>SM*"0X8%G6'9M9I"#'1F%<US2!(>J9/E?:3@9>%7/PI+&6D-9G#E[*[[
M$K=^#:DC&MU9;R,67! ,];[8%7>@BK"'167DP5NGH?E=>4/=7&TW16\:S<2T
M,\[&MHX<!_8-1V]??H_>WB]Z*R)*-U!;M&J99(VS:)O*=N5R1UUB&=B$\##X
M75W:)P\0&$;,&P(K ,DO.8\#2#U'++EH<HHO-7)#8W3)=@U7JH@MW(:*X"[A
MI"=2 C%PD]"E0_$[ $!_F6!%PH5L+,@%MHBN'GA-%H]9+!G%<. 26-+IQ!AR
M1E2<(Z]ZGKC)N$N(,)0/,8,UV"XO.]R!$\PQ%>Q8&PUSS;$(E1PV"X3<J#9A
M M+#//[DEB/<;317^#@$ZG)$^]*&V.G1FF[_<>?8VTY^+:'^<) /'28BQZ#O
MS B6II/+,-]ASC+$^J7="V*=T;82N-%H1GEG,W.TY('>.5LC+=X-SH^1A1SB
M%LRM^G1:QCXM)O(AS$?] 8^'_AN]!APY@FM 8*6$& ^LT.:&6R(?_20$(9PR
M:W)D9@#E'.6B,L520S.YCUOD$B-_ !9U((O[%1:(-=#F!BR,K)QTT@I66MK8
MR\?F)'E_,8(F?S*S:UO*(@KIZ^5L$#J$@"<1CEE0R(\[\J['%]E\6V,:;386
M=_PB5PD< 2I2%R"T ^COZSAHPP6C1J\,HLLS(ND;(!=P#N!0Z*A6Y:!FR&>O
M9B-5<:&B%V*<7V!I 'R2C2R-\]QN^N9&6P[Z$0;A$$;PO!P(N.$_L15BSBV)
ML>"$$3\#:@1=2G-E8H&G0(0-2 J$)!$< 84NH#MG2:E[@#<!\'6@)H&\NN/9
MB)F&UGB9[U';D!/KIK\%?-ZOG.L\88II<YYKE="(]+IR]HH+/:5&LTC@*8C.
M6;Z?0@"3]:U G@(JEV]XM%2SB6IP ,H#4 2I8X*D?<8<+2)\,0R&/\;X'UX5
MTM9I+.$K[ W*W2Y=;5.$H3*;@D*%-@LJK P9 8"A549B\MSFDJ_L^KKL /W6
M\2#II[3]&N%SRCXXA2/R;.?Y=NIQ=/4PSB:X1-Y"VUW3TKNVO807FY\5F/M"
MF;: )8T1'8Z]UNOZ"/>H5URP5"8M/D5N@Y4CH+SE4_0F!HW0<<&-U_#OI,"7
M#H8[T"[=9CHL;@Q@L"$VP8H=?C)W>Q0&B6ESGS[5K8N%1&W9*+VP*Q5\<>0U
M(A)@%U6.Y0VA++:')9;,&#V]N?$ESZ^P:>ZCZRYJ!]-U>(VWQ6#6+R#VB0D"
MT+27Q97K<&0UED,E-U33W2J([^W'N,,$4H&M%8S%2WDD%YFO$;U)L?A(UU'T
M"Q:T^DZ#U^ 5B"S0U5CXIC<W1OGD I.ZV'IS:-<4HHL#8\>6U9P5(:VO&>WT
M!@:L+P77ZH@Z6]LB!EU^4D_+_A=SPPX ];WEVK!"L]MYPG\P2JQOQ*^@QO.5
MWQ0IX*"[4\-K67#$E4GKMS[K!K]#X4J);E2%@>%;>:V>O);0:CL&!#$LL8T(
M_DM"MZJ3/+<21@!P'5R^=)$E@YGTL]"%#$'P0D>7"0=YNUDY_N[<>XVK$8D0
M+G^CD=IG.]\CM0\=U="R" U<LRN\RB C=)V-9MF4(1V,HE=12/T)ZV_L>59S
MJ16"#(WI4]1?+.1!2,!O?WI?/[Z'WM].)A:6+V<;,'^8'W>==C'H([!BJJY#
MX&<J=3"XA.QWE*3"I]GOJ%HDRAV4I]Q& : O)&;,!#J'@<($*^5FLF0@J+9X
M)%C0YH?M^:GL+1I#IRJ-:V"&L0Z7?^#+JKV?15WC,IA]N<FJ/$PXT!)YFP;?
M,C=L=L%0&T .9<:<HGX_0W\'R,VA! 6T_LFA/2%@:FJQ90<%>B9<76Q[GH?N
MV;)1H2B9JT.E * =5U$3AS+CB^7-^$P]SN!N,;)R7533F>MV)E9$ZFP(N+XO
M,,'H61.:)9P"=VN)\GA7Y1T0'HA#0P?7=NSE_(?O. 7[@#0 %;>.WMQPUI>Y
MTVG) -N-58'\I23X3HM=>-N#K1VBA9*CXL^34K7_V!(CAZJ(*8A"_[T=RHMO
M91'<+E,3(U!?6=G8*B=G$!E( +1@%?@7NF,G17$(915T75-NT7UM4N_!:XCU
M[>UQ(UBDZ]"P F37. /^A&QD'*2Z'%%O5^@]/I8 3[/4PVT^%J;NE\29 A6!
MU"K6++'Q64$2'+0RV]Q02$'"FV1+1I Z.54:S1Z59ETRBBE*#^FEH'0WH0ZR
ML<KBU-KYCC9>*NR@R3J?;(YAV"%1;"8@FQ_P+0V3V]QHG1V2$;9,P-.NP2S,
M4,$+IZ"FBY ;/6.%K='G+6.T<.SO:Q#)N\B4#VI)WKS?3[I&M+KQXNN8!"8M
M KA@C]+D(!]FT 'UE&K!HU7I&GHF%1*#B'*'BSYD4G??GT+C=9O0=G %AK8$
M ^E;R;,/\"6O_5B)X&G>B:\A4H]I(2^C]-GJ;DLPT4B.F;D6'0D77O+QED0I
M40&XFEDLEN*G9.&/H4+*HU;!XVL\7PX:!&"2--G=PWW:[YA'[O[PX^MD]\6S
MW:TOVZ^3K3=VL/Y!D'?! &L=>[#XJ5>J(; \HT_/V-S(O8=D<I?#K H=+F8Z
M_>7CW^^\[9S:\>\]W^N\V#.>W&MJ0AT. ($S7^WMSW[L/,5W4U<INPJ;&\$H
MWIX=?;5!/'VQU^$5V+=[Z)W<U63-CND.0D4C@FG#D/3>[*:P2GNP0C#078S)
MNZ QV=9;!W;@B]6(+XQB>WKMO@0\?D"\7L:6J&<5CA;.GZL)7)8&HX'9/3T'
MRJ+DZ$BD_Z <#)Z\-0_^DOQJU@E@5 !6APPGM7(>) !.F8W-DTZJ<LJ6\.W&
M\.UVSGJV^SU6]: &]5/&.\WP,&;5M(YR6SB+@,@.(,-^4]H*Z;[Z?9I8!R\@
MQY*(Q\1BPJ@0E[OB,==<>4&>5:-\!<+>(N-HR#K,?,<<2Z;V0Y_<#=1-H4=%
MW8K_,;?A9IP<)DA[T+R\CR :3(TKZBVTE&U&42^9/,&2+FYN +>9?5":A(QO
MFBO$7'WJSZ ZL^D,%Y6OFKDSA*0\[O#,B!F>>C/?O9V=G12L%E01BC'M7+O%
MYLODA*@OG,G+*.IQBEFOFIXKSJ'*Q*'_GW<N.L9NO[GI0 4##!?8.Z%_^N8&
M@ZG50AF5.KTL!]8;4)(""$A'4QG!SJA&W#,&LV$-N&-RY "5^17^0=6R@_LR
MI(B"-:;6X; 2O]!GBEP=0;7Z.'.HPG-K3X,$83$?MVDCU\]^/;FPG$'-^$<C
MO!&&1"R52WL.QXHC8#0'QAR$X!55/B!3RF51#9J$8! MH6I\V-<Z'[G$3L']
M*Y<.;EF\AL$4+O."$=/K)N.*JV-?QT83E9#?1ZNQW]UV^)@'#UCX&,W:208+
M]+X=,4;!E1]H\6%TY"E6+5;T&?HWWK:X7/HK_+>QYJ:7CG%5>66,0)51GXPR
MC,0<P-.+'II6SID(GIV<6532&C:JZU..-$FX^&J(+Q4GF0_.%OY=S973N);S
MA%%8/'],37J^CS'>2HS4+68'Q(K45KR+QUIT>/"N>TI]TI;->XC -+"0:YD0
M70R.R\IQ)6KQ(M!'[9PDKA(5I*5U7'@.@R;4$M\X"(3F;IL@# \G&D/$57<"
MK+,+859^5 ##&N)EFWRO9EF8%'=@=P#IO69<^[1XP0@=U[YB4$M= <46*S\[
MLH=>@GAKQS_D\1.)L,?$(G,%F>8VUL>C4KS1_LQJ5:#!@["Z$[O-#0%*CR%&
M54!W$F15KN*WK(7)8;*/<"A$$0*!HRN+1>&44 ,[YT/*9M,:+OF'"V'>QZ<R
M5\[?3C67S0E03!]-N)(9*S?>& 7_Y>](JO#-NHY[WUW'!PU\AU>64620_R)L
M3,W@&/B*#W&( :I\'-/FACG &39&Q:Q:'XE#N3($B"T=VU@O-\8.%Q1G4['T
M4T+W,:=P 38J,@HV7,K,\@\[9L2EXVN>4+5N>^X M)X'+?^XL;SSF+W#C?_I
M'!EI]@^/C\].NOM'']_]OW_;^3?\]TGWX$#^S>+S#*3GS:?3@\-3_)A'19\\
M,2)WW#TY.WPE_[%P7T,A *&BLW%^^C/_QX&\^,?_--KC3^<'[@]_Y:G09)V
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MJT87*HG(?Z,3ZU[UH5K[?Q[CF*EX?=PR,3KHT\%OYL/WYQ^.?_Y?4$L#!!0
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MV>Z]6)7/5K>?P2N#W2NC(;U\8#K%HJ$NU6I$:.4Q/0GR)9R0>#=P!EYV*O-
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M3@J&)H%0]'4*EB-4GGF.U\2H1U-J)N>U3$1?!IR][0E\JQHNGI4YL-P@DV6
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M-:A&$_( ]=Z\?DFY/S;GI^')H>2?>=+'<6<ZL]+!8Z9NE+]VO#=NO6O"+50
M!%9I/"/\0KWFPDVDLWH7_49F4:#\2)+O2Q\4H#I&6/IP:%))=,+<D'4WJOKB
M&S5* S3NT8_",T5DG7.KT5Z"O]'=+YJG%'KKS-'TXR=2/>%]5B*.\=ZAHM<J
M>3^LY%TOH9)7U6%;!'.K1<_GNIEKF=X&6$"G,,?I.*!,:2K[-@EF5:(P&!#B
M7_;A^&CA]0^GM)LEI#3=\/O28B#F8!^JM#\3^4JR*J::Z*X(FA9UUR%]AGR)
M0RI%\S/0<P#6.7SM! [@@@]A+&/R#EVJ[)H2Q)&\/\OL&ZK;VJ.UX1YH8K6J
MP?'A\O.^6WF#K)Z!TRJ/%R#,_-P^-ZME&,(Y!4)7'W4#[0MV@MVU!_-,?1+T
M:Y6Q.6NLQ'9W!J4WY10T@T05A*/:#'.Z;E*4&)^KWC?W#@_B9A&8)Z$N?&$A
MK0]O)JI%^A1BFDL =4\$7^PYX)DF0. MA_I;J?% J?%]":7&M"GKD6]!^WT]
M.%^&<HADB&'T+*0Z(9X#B,9D86RZCEH0!0<1LX A0])(X0,VRR,K/%?JFZ9G
M\[7NK*23ORI]TZ8"Z<(_>'9A<CO#LT!AY6BJ\3!(6ZQ;E\FF1M.9HD1X2OEQ
MAJXILJ6]Q(D$D:^=BF(N6$5$#A9/(!T0J %3W>"1VV;5K6W_5[+M7_\]*D-O
M_EF5H2^.+H\N?ME?DM+03A]FV[_%6B!N(^:V%/0_H8.H=:B8Z)H#]>2R21KN
MZ4=E#B<XUCD;*5+_$LZPDO!(/]  =,K'DJHBM(VPR=_BEAU!\"&[B%#+]MQN
MH!;V@=^:KJ?7253&!0(X9)9AXRXR=1$'0B&^)#,@CJ"N=H>5<ZUR]'-0&ZR&
MP**G@)&N91C15G& /7=[>]@:3C#XK;MSZP5E"D2PAJZ!=;U_9AN/*;H(IQ 8
M!9GV <"#(JA4U],B9]VM,WS5+^B+?4'G^G60!,%>L?C@U#V-J"2A&@&@V<$_
M$9=@K+].G?+/0U!]&*_A0*LC$\Q;S]D)UI]0+(DZM>N"!5FHC44?B]:A/E9F
M&# N"V19<0(:(_8TJ2BZF )Z$AJHF+M->A?$EW3FXU<AZ)E,TN0+)RY6(VY9
M?3+!K['\ICVOB$B>Y7N<P0M4>U6W\O2<WKFUB6?T[:U=.V>ZJH";!>;-;\?K
MT#T7 IJQ\R$P4!!693$8-:"+KTBL>2$GHH&K-2O !GLRHPW2%6[#R+J_#,-K
MJUX%Z^*#LR=<^=Y)W&!$"HD[359<LI8PY.9"M.+-E18E@.AC1.QHL+*MJF%2
M_F?,4GE0?#A==/LQ&3NUREGZH(\NM)THM<^\7KA#TR#U7[-+(E91,=KGH2Z$
MBBWO#=]4M)W!"R&F.4"F<<9K2W[]0QLB6P5Q7A_ZFIZX(U;#9[P%W$IU;'U,
MV#(5>9/0.(U"+Q@>J7Q4U=GJ.4  KR&!FK !KPXV&"<47PDEL"R(^;'21K@)
MS]> 1]SR>S6LUF[;GM/I@85W,I_73S$QVQM+V_W&2[>]^7)!^$VL[A[K4[S;
M67#*^LF:+I*3Q.:<[:OBA@0$GV;.@EQ401-Z7FWE[O/CO6?DT\OS,#?9^306
MB D35J@@5;-&)K2M!F=77ESK>]0*DA7+=/ZR5 %* 9&79)-6CCRQ'%G&Y@?A
MH-ZT&4\NLGM-7EC=]08*-34#K:4VY.+EJ]?$IB]?O9F?XX U\+L=@S7%S6V#
M5$]+<,O84>%F0?MPI]T&JFDMYOB)Z6,9NP\LHH]"?N?C\Y8<C)9 'HE EK&D
M?XZ64V5UL\1HI!D[17X\VZN'+"V@J2ECRS'E= ZID\[?[;@%&W73'^KZB@9?
MAL:P,6D1.,_INXR*UYZ.>!#J&D2Y<;I4F1QN.2("?3FF(>FO%4X8EJE2#'?A
M*1U?@W5JT.<8F5(9#T.?!W-+Q4Q/VS+1$S/1,M;]E\)W6<2D/,C*N62(R;,R
MV.+&ORD=? 4UCM+9=591S2[3*'?,0")<H78^8]&"$+UO,54-'B4W9 QIE#N0
M/+R*7,>54?/,0-G,T >L&U]FAH+5M?5BP0.& V ' 52>9&PPMHKE4Y+T,I;6
M!ZK2'2KZNCQ^7B2)SHISQ:IV_J$IG8=(9P.&W!B!RI6F2:!.\(-UFY +53>*
MLYTLM-2O\EX=^8]Z;)*I<!BC*\4S'%21N&VP2?D=[GV:Z;SI$V-.NP@8NW*2
M%!HG!B< / :<:YS4Y:#!=*=-\OB$Q?J]4A5VG[\_._P5OOQT]?ED[_\!4$L!
M A0#%     @ %CMX6V/1#C/> P  2 \  !$              ( !     &-N
M=&$M,C R-3$Q,C0N>'-D4$L! A0#%     @ %CMX6RMC@H_X!0  XS@  !4
M             ( !#00  &-N=&$M,C R-3$Q,C1?9&5F+GAM;%!+ 0(4 Q0
M   ( !8[>%N4Z#(+-0@   !?   5              "  3@*  !C;G1A+3(P
M,C4Q,3(T7VQA8BYX;6Q02P$"% ,4    "  7.WA;M]BO]+$%   O/0  %0
M            @ &@$@  8VYT82TR,#(U,3$R-%]P<F4N>&UL4$L! A0#%
M  @ %SMX6]*68,^D%0  68,   T              ( !A!@  &0R,S@T,V0X
M:RYH=&U02P$"% ,4    "  7.WA;>V:C+E3)  !)U0, #P
M@ %3+@  9#(S.#0S9&5X,3$N:'1M4$L! A0#%     @ %SMX6[TF6++?(P
M&N8   \              ( !U/<  &0R,S@T,V1E>#4Q+FAT;5!+!08
.!P ' +T!  #@&P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>d23843d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cnta-20251124.xsd" xlink:type="simple"/>
    <context id="duration_2025-11-24_to_2025-11-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847903</identifier>
        </entity>
        <period>
            <startDate>2025-11-24</startDate>
            <endDate>2025-11-24</endDate>
        </period>
    </context>
    <context id="duration_2025-11-24_to_2025-11-24_us-gaap-StatementClassOfStockAxis_us-gaap-FairValueMeasuredAtNetAssetValuePerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847903</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-24</startDate>
            <endDate>2025-11-24</endDate>
        </period>
    </context>
    <context id="duration_2025-11-24_to_2025-11-24_us-gaap-StatementClassOfStockAxis_dei-AdrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847903</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-24</startDate>
            <endDate>2025-11-24</endDate>
        </period>
    </context>
    <dei:SecurityExchangeName
      contextRef="duration_2025-11-24_to_2025-11-24_us-gaap-StatementClassOfStockAxis_us-gaap-FairValueMeasuredAtNetAssetValuePerShareMember"
      id="Hidden_dei_SecurityExchangeName_duration_2025-11-24_to_2025-11-24_us-gaap-StatementClassOfStockAxis_us-gaap-FairValueMeasuredAtNetAssetValuePerShareMember">NASDAQ</dei:SecurityExchangeName>
    <dei:SecurityExchangeName
      contextRef="duration_2025-11-24_to_2025-11-24_us-gaap-StatementClassOfStockAxis_dei-AdrMember"
      id="Hidden_dei_SecurityExchangeName_duration_2025-11-24_to_2025-11-24_us-gaap-StatementClassOfStockAxis_dei-AdrMember">NASDAQ</dei:SecurityExchangeName>
    <dei:AmendmentFlag contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-275">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-11-24_to_2025-11-24"
      id="Hidden_dei_EntityCentralIndexKey">0001847903</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-302">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-303">2025-11-24</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-304">CENTESSA PHARMACEUTICALS PLC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-305">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-306">001-40445</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-307">98-1612294</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-308">3rd Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-309">1 Ashley Road</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-310">Altrincham</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-311">Cheshire</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-312">WA14 2DT</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-313">GB</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-314">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-315">468-5770</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-316">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-317">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-318">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-319">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="duration_2025-11-24_to_2025-11-24_us-gaap-StatementClassOfStockAxis_us-gaap-FairValueMeasuredAtNetAssetValuePerShareMember"
      id="ixv-320">Ordinary shares, nominal value &#xa3;0.002 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2025-11-24_to_2025-11-24_us-gaap-StatementClassOfStockAxis_us-gaap-FairValueMeasuredAtNetAssetValuePerShareMember"
      id="ixv-321">CNTA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-322">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2025-11-24_to_2025-11-24_us-gaap-StatementClassOfStockAxis_dei-AdrMember"
      id="ixv-323">American Depositary Shares, each representing one ordinary share, nominal value &#xa3;0.002 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2025-11-24_to_2025-11-24_us-gaap-StatementClassOfStockAxis_dei-AdrMember"
      id="ixv-324">CNTA</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-325">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2025-11-24_to_2025-11-24" id="ixv-326">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
